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ABSTRACT
Overall cancer mortality rates have risen from about 4% of all deaths in the early 2 0 th
century to about 25% of all deaths by the end of the century in the United States. To assess any
potential hypotheses for this increase required knowledge of the mortality rate changes specific
to each form of cancer, and the time points when these rates had changed. For this purpose,
population and cancer mortality data of the U.S. were collected and organized to create age-
specific mortality rates for each birth decade from the 1800s forward, delineated by the organ of
incidence. Concurrently, cancer survival data were collected so as to correct for any effect of
improved treatment on historical changes in cancer mortality rates.
To analyze these data, a mathematical model for the three-stage process of carcinogenesis
(initiation, promotion, and progression) was developed to estimate for each birth decade cohort
the value of the fraction of the cohort at lifetime risk for that cancer, the value of the growth rate
of the respective precancerous lesion, and the values for the mutation rates of normal and
precancerous cells in the organ of incidence. This methodology permits the analysis of the
potential historical effect of new chemical exposures during the last century on cancer mortality
rates. These chemical exposures represent potential risk factors that determine the fraction of the
population at risk of developing cancer (lifetime, primary risk factor), or that hasten death by
cancer by altering either mutation or cell kinetic rates (accelerating, secondary risk factor.)
COLON CANCER: Application of this model on the colon cancer mortality data resulted
in the estimate that 42% of the population in the U.S. was at risk for developing colon cancer,
independent of gender or race. More importantly, there was no significant historical change in
the calculated fraction at risk for birthyear cohorts from 1860 to 1940, suggesting that the
primary risk factors for colon cancer are not environmental.
Although direct observation of in vivo mutation rates of colonic cells does not yet exist,
the calculated rate for the first initiation mutation in the colon was interestingly found to be
similar to the mutation rate observed for the hprt locus in human peripheral T-cells (-2.1 x 10-7
per cell year) and the spontaneous mutation rate of the hprt locus of human B-cells in culture.
The estimate for initiation mutation rates increased no more than two-fold from the birthyear
cohort of 1860 to the birthyear cohort of 1940, except for European American females for which
calculated initiation mutation rates were historically invariant, but since the accuracy of primary
data for mortality rates and survival rates cannot be ascertained, the apparent small differences
might admittedly arise from unknown biases. Evaluation of the parameter of the growth rate of
precancerous lesions showed no significant historical change on this parameter. Curiously, the
calculated doubling rate of these lesions (-0. 17-0.21) was found to be similar to the growth rate
of children, suggesting that the required initiation events have the net effect of potentially
reactivating pathways involved in child development.
The predominant historical change in the observed mortality rates for colon cancer
occurred only at old ages. fh, the ratio of the number of deaths attributed to colon cancer to the
number of all deaths sharing the risk factors of colon cancer, increased historically. This is
consistent with the hypothesis that treatment for the connected diseases, which share the same
risk factors as colon cancer, has improved more rapidly than treatment for colon cancer.
Alternately, the number of underdiagnosed colon cancer deaths may have decreased historically.
The increased risk of dying and actually being correctly reported of dying of colon cancer within
the elderly population is consistent with the increase in fh. The conclusion is therefore that the
observed changes in colon cancer mortality rates can be predominantly explained by the increase
in the lifespan of the American population.
LUNG CANCER: Data from cohorts born in the early to mid 1800s permitted
observation of age-specific lung cancer mortality within populations not yet affected by cigarette
use, as confirmed by independent nonsmoker lung cancer rates from smaller control studies (Peto
et al, 1988, 1992). Likewise, data for birth year cohorts from 1880 forward permitted observation
of the age-specific lung cancer mortality in populations with historically documented levels of
cigarette use. Based on the mathematical carcinogenesis model, 10% of nonsmokers were
estimated to be at lifetime (primary) risk of death by lung cancer, though less than 1% actually
died of lung cancer due to competing forms of death. On the other hand, 94% of smokers,
essentially all, were estimated to be at lifetime risk of death by lung cancer though less than 10%
actually died of lung cancer. The fraction at lifetime risk for all other birthyear cohorts,
consisting of mixed populations of smokers and nonsmokers, was found to be a simple linear
function of reported cigarette use, independent of gender or race.
The mathematical carcinogenesis model predicted that the marked increase on lung
cancer mortality rates among smokers was due to an elevated growth rate of their precancerous
lesions. Growth rates of preneoplastic colonies of both genders and ethnic groups were found to
be 0.17 and 0.32 doublings per year for nonsmokers and smokers respectively. However, with
regard to the rates of events such as genetic alterations necessary for initiation or promotion, the
analyses suggest that there were no differences among smokers and nonsmokers of either gender
or ethnic group, assuming that the number, but not necessarily the kind, of rare events needed for
initiation or promotion was the same for smokers and nonsmokers at risk.
Furthermore, if the growth rate of a precancerous lesion initiated during the period that an
individual smoked is reduced from the estimate of 0.32 doublings per year while smoking to 0.17
after smoking cessation, the mathematical model accurately predicted the incidence data reported
among former smokers (data from Peto et al, 2000). These results could not be replicated by
alternately reducing mutation rates after smoking cessation. These findings support the
conclusion that cigarette smoking causes lung cancer by stimulating the growth of preneoplastic
lesions in all smokers, and that the data of age-specific lung cancer mortality rates are
inconsistent with the widely held but untested assumption that cigarette use increases the rate of
genetic change in human lung epithelial cells.
5Any data and mathematical tools mentioned herein can be acquired either at the MIT
Center for Environmental Health Science (CEHS) database webpage (http://cehs4.mit.edu), or by
contacting Pablo Herrero Jimenez at pherrero@alum.mit.edu, or Prof. William Thilly at
thilly@mit.edu. The offices of the MIT CEHS are located in Room 16-743, and can be reached
at the phone number, (617) 253-6220.
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1. INTRODUCTION
With the advent of new treatments, better personal health care, and an improved
sanitation infrastructure, (i.e. antibiotics, insulin, vitamin supplements, clean water systems),
mortality rates by infectious diseases and metabolic disorders, as well as mortality rates among
infants, consequently dropped throughout the 2 0 th century in the United States. Whereas more
than 25% of Americans died of infectious diseases at the beginning of the 2 0 th century, less than
3% did so in the 1990s (U.S. Bureau of the Census, 1900-1936; U.S. Department of Health and
Human Services, 1937-1997). Concurrently, the percentage of deaths in the United States caused
by cancer has steadily increased from about 4% at the beginning of the 2 0 th century to about 25%
in the 1990s (U.S. Bureau of the Census, 1900-1936; U.S. Department of Health and Human
Services, 1937-1997).
This increase in U.S. cancer mortality rates has been postulated to be a result of
environmental exposures from new industries and technologies of this century. Chemicals in the
environment are hypothesized to induce genetic alterations (mutations) of DNA through the
formation of chemical-DNA adducts, which consequently are misrepaired or misreplicated by
the cell, thereby altering the 'normal' DNA sequence of that cell (Loechler, 1989). Since cancer
is a result of the accumulation of genetic alterations in tumor suppressor and/or oncogenes of a
cell (Knudson, 1971), this led to the hypothesis that chemical exposures induce the necessary
genetic alterations for cancer, and thereby are the direct cause of the observed increase in cancer
mortality rates of this century.
However, there is yet little in vivo evidence to demonstrate the effect of chemical
exposure on human DNA. As direct experimental exposure studies on humans are logically not
feasible, researchers rely on either animal studies or cell culture studies to postulate the potential
effects of chemicals on humans. Mutagenicity studies have shown that exposure to a chemical
creates a unique mutational spectrum on the studied DNA sequence (Benzer and Freese, 1958;
Coulondre and Miller, 1977; Cariello et al, 1990; Keohavong and Thilly, 1992). The
determination of the mutational spectrum of a suspected carcinogen can then be compared to the
mutational spectrum observed in tumor samples of individuals known to have been exposed to
the suspected carcinogen. In the case that these mutational spectra match, it is then argued that
this is evidence of a direct etiology of the cancer by the chemical.
For example, there is little doubt that smoking cigarettes increase an individual's risk of
developing lung cancer, as suggested by the preponderance of cigarette smokers among lung
cancer victims of the 1940s and 50s (Wynder and Graham, 1950; Doll and Hill, 1952; Hammond
and Horn, 1958) and subsequent epidemiological studies. Denissenko et al (1996) determined the
mutational spectrum of the TP53 gene caused by benzo[a]pyrene, a suspected carcinogen found
in cigarette smoke, showing that the induced mutational hotspots were identical to those seen in
lung tumor samples taken from smokers. The initial conclusion was therefore that
benzo[a]pyrene is a cause of lung cancer in smokers.
However, more recent studies of the mutational spectrum of the TP53 gene among a
larger number of smokers and nonsmokers with lung cancer have shown that these same
mutational hotspots are observed independent of smoking status (Rodin and Rodin, 2000).
Furthermore, the tumor suppressor gene(s) involved in the initiation of lung cancer are not yet
known, and the loss of function of the TP53 gene has not been shown to be a necessary event for
lung carcinogenesis. Lastly, TP53 does not appear to be a part of the initiation or promotion
processes as mutations appear to arise in sectors, but not the totality, of tumors in which they are
measured.
Current research (unpublished) by Dr. Xiao-Cheng Li-Sucholeiki, Dr. Luisa Marcelino,
Amanda Gruhl, and Hiroko Sudo, of the Thilly lab at the MIT Center for Environmental Health
Science has sought to determine in vivo mutant fractions in normal lung epithelial cells of
smokers and nonsmokers. With emphasis on the mutational hotspots of the TP53 gene, their
preliminary results reveal no significant differences in the mutant fraction and thereby mutation
rate, of bronchial epithelial tissue samples taken from smokers and nonsmokers of similar age (as
of this date, three and two lungs of each respectively). This is insofar consistent with previous
research that noted no significant differences in the mutant fraction of mitochondrial DNA of
normal bronchial epithelial cells taken from smokers and nonsmokers (Coller et al, 1998).
Additionally, indirect effects of external stimuli must be considered seriously before one
can conclude that a chemical induces cancer through the induction of genetic alterations. For
example, rats treated with methylnitrosourea (MNU) develop mammary tumors. However, MNU
was shown to select previously occurring mutants in the H-ras gene rather than inducing the
specific G--A transitions as had been previously assumed (Cha et al, 1994). The selection of
cells containing independently generated mutations might occur as a result of chemical contact
with the affected cells or a more general effect on all cells by releasing growth signals, by
mimicking these growth signals, or by suppressing a body's ability to eliminate precancerous
cells.
In the case of human colon cancer, a conclusive cause is yet unknown. The loss of
function of the APC gene is associated with the initiation of most cases of sporadic colorectal
cancer (Powell et al, 1992). Brindha Muniappan of the Thilly lab has sought to assess the
possibility that APC hotspot mutations were induced through DNA misreplication. So far she has
identified 6 mutational hotspots induced through in vitro replication of APC by DNA polymerase
p (unpublished). Of these 6 hotspot mutations, 3 were found to be concordant with the APC
mutational spectrum of cells taken from colon cancer samples (accounting for more than 50% of
the APC mutations, by frequency, observed in colon cancer patients). This work suggests that
endogenous processes rather than chemical exposures may be involved in the early stage of
colon carcinogenesis.
Barring further experimental evidence, it cannot yet be concluded whether or not new
chemical exposures during this century have led to the dramatic increase in human cancer
mortality in the U.S. The hypotheses behind this increase are that chemical exposures directly
induce the necessary DNA mutations for carcinogenesis, permit the selective growth of specific
mutant cell populations, or accelerate the onset of a cancer independently induced by
endogenous processes. Alternately, the overall shift in U.S. cancer mortality rates could simply
be a consequence of the increase in the lifespan of the American population due to the improved
treatment and prevention of other formerly prevalent forms of death.
In seeking an alternate method to determine the reasons for the increased risk of
developing cancer seen among Americans, all available cancer mortality data in the U.S. were
collected starting with the reporting year of 1900. Based on previous analytical models of
carcinogenesis (Nordling, 1953; Armitage and Doll, 1954, 1957; Knudson, 1971; Moolgavkar et
al, 1979, 1981, 1988, 1990a, 1990b, 1992; Dewanji et al, 1989, 1991), a mathematical model was
derived for the three-stage carcinogenesis process of initiation, promotion, and progression,
which further accounts for the possibility that only a fraction of each birthyear cohort is at risk of
developing cancer, defined by the interaction between inherited traits and environmental risk
factors.
Previous analytical models have been used to determine such factors as mutation rates of
normal and precancerous cells, the number of such necessary events, and the growth rates of
precancerous lesions, but only among individuals of the same birthyear cohort. As an extension,
application of the quantitative model to existing U.S. mortality data for multiple birthyear
cohorts allows the determination of the historical changes, if any, in mutation rates of normal and
precancerous cells, and growth rates of precancerous lesions for individuals who died of cancer.
Historical changes in any of these parameters consequently permit inferences regarding the
mechanisms by which new environmental exposures may have affected the mortality rates of
these cancers in this century. Likewise, the calculation of the fraction at risk for a given cancer as
a function of an individual's birthyear can serve as a marker of the changes in the suspected
fraction of the population exposed to any necessary environmental risk factor.
Special emphasis has been placed on assessing colon cancer and lung cancer mortality
rates. Tested herein is the hypothesis that risk for colon cancer is not environmental, as suggested
by the preliminary result that the majority of APC hotspot mutations, by frequency, are induced
endogenously; the expectation of the analyses is of a historically invariant fraction at risk.
Additionally, tested herein is the hypothesis that the increased risk in developing lung cancer
among smokers is consistent with Denissenko et al's (1996) observation that chemicals found in
cigarette smoke induce genetic alterations, or alternately that mutation rates in smokers and
nonsmokers are similar (Coller et al, 1998; Li-Sucholeiki et al, unpublished), but cells containing
previously occurring mutations selectively grow when exposed to cigarette smoke.
2. LITERATURE REVIEW
2.1 MATHEMATICAL MODELING OF CARCINOGENESIS
2.1.1 Mortality Data - Birthyear-specific vs. Cross-sectional
Kermack et al (1934) first reported that mortality trends in England and Wales, Scotland,
and Sweden were best described as a function of age times a function of the date of birth.
Conceptually, the argument is that environmental exposures throughout life are the determining
factors of both the expected age at which death will occur as well as the potential causes of
death. Given that individuals born in the 1800s would have experienced considerably different
environmental exposures early in their lives than, for example, individuals born in the 1900s, the
age-specific function of mortality would be predicted to vary by birthyear cohort.
Were one to instead consider mortality rates for individuals who were alive during, for
example, the 1970s (Cross-sectional mortality data), each age group of this cohort consists of
individuals born during different historical periods. For example, the existing population of 90-
year olds alive in the 1970s would have been born in the 1880s. Smoking prevalence among U.S.
women born in the 1880s was less than 3% (Harris, 1983). In contrast, the existing population of
50-years olds alive in the 1970s would have been born in the 1920s. Smoking prevalence among
U.S. women born in the 1920s was 40% (Harris, 1983). As there is an increased risk of dying of
lung cancer among smokers (Wynder and Graham, 1950; Doll and Hill, 1952; Hammond and
Horn, 1958), the average 90-year old and the average 50-year old who were alive in 1970 would
have had a different experience in their exposure to cigarette smoke, and thereby a different
likelihood of dying of lung cancer during the year 1970, a likelihood which is not solely
dependent on differences in age.
Furthermore, female smokers born in the 1880s began smoking on average at age 31,
whereas female smokers born in the 1920s began smoking at age 21 (Harris, 1983). The age-
specific onset of lung cancer disease due to smoking cigarettes would therefore be expected to
occur 10 years later in the life of a female smoker born in the 1880s than in the life of a female
smoker born in the 1920s. In other words, one expects the lung cancer mortality rate of a 50-
year old female smoker born in the 1880s to be the same as for a 40-year old female smoker born
in the 1920s, and so forth. Only by correcting for the differences in smoking prevalence and age
of smoking initiation can one truly compare lung cancer mortality rates among different age
groups using cross-sectional mortality data.
However, for other forms of cancer, such as colon cancer, one cannot similarly correct
for differences of exposure to an environmental risk factor, as the predominant cause of most
cancers are not as well known or as well documented. Therefore, as Kermack et al (1934)
suggested, it is simply best to consider individuals by their date of birth to reduce the potential
confounding factors of a historically variant environmental exposure to an unknown cancer risk
factor.
Additionally, Kermack et al (1934) reported the self-evident need to incorporate the
probability of still being alive at any age when modeling hazard (death or incidence) functions,
since mortality/incidence rates are reported as the ratio of the number of deaths vs. the number of
people still alive. Obviously, an individual can only die once. If only a fraction of a cohort is at
risk of dying of a particular form of death, one must thereby consider the relative probability that
an individual at risk of death is still alive versus that of an individual not at risk, who is therefore
at an overall reduced risk of dying.
Fitting mortality data for all forms of death, Kermack et al (1934) ascertained that the age
dependent driving function for all deaths followed a simple Makeham-Gompertz relationship
(exponentially increasing). This model fit the English and Scottish males' experience, but not the
females'. Likewise, the model did not fit the male or female Swedish data. The significance that
the rise in mortality as function of age may be exponential was however not explored.
Figure 1 demonstrates the application of the Makeham-Gompertz model to the U.S.
mortality data of individuals born in the 1880s, who are more than 40 years of age (See Materials
and Methods, Section 3, for description of the collection of data). As was the case for the English
and Scottish mortality data among males, the U.S. mortality data does show a Makeham-
Gompertz relationship, except for infant mortality rates and mortality rates among 10-40 year
olds. These early deaths primarily represent deaths by infectious diseases (as many of these
deaths occurred before the discovery of antibiotics), as well as familial forms of cancer, violent
forms of death, and other diseases that would predispose an individual to an early death. The
early mortality data sets analyzed by Kermack et al (1934) would have also primarily included
deaths due to infectious diseases.
However, these forms of death at early age do not necessarily follow a similar age-
specific trend as the predominant forms of death among older adults (i.e. cardiovascular disease
and cancer). Figure 2 demonstrates that in the U.S., the mortality rates among adults by
cardiovascular disease do resemble a Makeham-Gompertz relationship, monotonically increasing
for all ages, as had the mortality rates among the elderly from any and all forms of death (Figure
1). However, mortality rates by infectious and parasitic diseases reveal a peak mortality during
infancy and a peak mortality throughout adulthood. This illustrates the necessity of analyzing
mortality data by each form of death independently.
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Fig. 1: Age-specific mortality rate by all forms of death
Mortality rates by all forms of death among European American males (EAM) and European
American females (EAF) born in the 1880s and 1890s.
Included is a fit to the 1880s data assuming that the age-specificity of death follows a Makeham-
Gompertz relationship as suggested by Kermack et al (1934).
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Fig. 2: Age-specific mortality rates by infectious diseases and by cardiovascular disease
Mortality rates by infectious/parasitic diseases, and by cardiovascular disease among European
American males (EAM) for all birthyear cohorts between the 1800s and the 1980s.
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Figure 2 also reveals that mortality rates by infectious/parasitic diseases has decreased
throughout the century, as one would expect with the advent of antibiotics. Curiously one notes
that in the more recent birthyear cohorts, there has been an observed increase in mortality by
infectious/parasitic diseases among the elderly.
2.1.2 Cancer Mortality Data (Nordling, 1953)
Kennaway (1947) noted that penile cancer development was dependent on the age at
circumcision; the earlier the circumcision, the lower the chance of developing cancer. This
suggested that unknown events increasing with age could create preneoplastic conditions which
were prevented by the act of circumcision. Indeed, mortality rates for all cancers rise
monotonically as a function of age, similarly to cardiovascular mortality rates (Figure 2).
Adapting this concept to the general case of all cancers, Nordling (1953) described the
first preliminary model of cancer, a process by which a single cell within a cell population of
constant size accumulates a series of independent 'changes', now more commonly referred to as
genetic alterations, either through mutation or epigenetic effects. After the accumulation of all
these events, the cell acquires the capability to create an expanding colony of cells, a tumor. The
role envisaged for exogenous agents was to accelerate this chain of events by increasing the
likelihood of some, if not all, genetic alterations.
The probability that a cell has acquired the final event necessary for carcinogenesis
would directly depend on the probability that there already exists a cell in that individual which
has acquired all the other necessary events. Likewise, the probability of acquiring the second to
last necessary event for carcinogenesis is itself dependent on the probability that there already
exists a cell in that individual which has acquired all but two of the necessary events. This logic
can be carried further to all other previous events. As this allows an individual to acquire cells
which have accumulated an incomplete set of necessary events for carcinogenesis, Nordling
(1953) deduced that cancer incidence would increase with age as older people are more likely to
have cells already containing some but not all necessary events. Quantitatively, mortality could
be described as a function of tn- l where 't' is the age at death (or incidence) and 'n' is the number
of events required for carcinogenesis (Figure 3). If cardiovascular disease were a process similar
to cancer, requiring a certain number of events to occur for an individual to develop the disease,
it would explain why the overall mortality rates observed by Kermack et al (1934) among adults
appeared to have an exponential (Makeham-Gompertz) relationship.
Nordling concluded that his carcinogenesis model would be incorrect if mortality rates
were seen to decrease at higher ages. At the time, some countries did appear to report decreases
in mortality by cancer in the older age groups, a trend which he attributed to deaths among older
people being designated as "senility" and "other and unknown causes", a trend not seen in the
more developed countries. "If, on the other hand, the frequency of cancer actually ceases to
increase after a certain age, the hypothesis must be rejected." Nordling did not examine mortality
rates past the age of 75 for any country, but did find the best correlation for all cancer data when
plotted against time to the sixth power, suggesting 7 mutations were required to get cancer.
Figure 4 represents our own organization of the cancer mortality data in the U.S. as
reported since 1900. Cancer mortality rates do in fact rise monotonically to about age 85 as had
rates for cardiovascular disease (Figure 2). Contrarily, cancer mortality rates eventually reach a
maximum and drop among the elderly. This phenomenon is further explored below in Section
2.1.7. Analysis of our own data set by the Nordling model predicts that 6 events are necessary for
carcinogenesis in males, and 5 events are necessary for carcinogenesis in females (Figure 5).
Fig. 3: Nordling (1953) model of carcinogenesis.
Cancer is modeled as the accumulation of 'n' independent events in a single cell, transforming an
otherwise normal cell into a cancerous one. The terms ri, rj, ... represent the rate of each of these
events, where each stage is represented by the number of events already having occurred in the
cell. Rate ri represents the rate at which the first potential event occurs, which can be any one of
the 'n' necessary events, assuming that order is not important in carcinogenesis. The 'j'th, or
second event, represents any of the remaining 'n-l' necessary events, and so on.
S..............................................
rk, rl, ...
0 Phenotypically normal cell
Number of accumulated mutations
SCancerous cell
Mortality rate as a function of age = Constant x agen-1 = K tn-l
where the constant KI is proportional to the product of the rates of all 'n' necessary events for
carcinogenesis (ri, rj, ....) and the number of cells at risk
Fig. 4: Age-specific mortality rate by all cancers
Cancer mortality rates among European American males for birthyear cohorts since the 1800s. If
one considers mortality rates for all ages up to 75, birthyear-specific mortality curves appear to
monotonically rise for all ages as predicted by the Nordling (1953) carcinogenesis model in
which a set of 'n' necessary events must be accumulated by a single cell in order to convert a
normal cell into a cancerous one. Inclusion of data past age 75 however reveals that mortality
rates not only reach a maximum, but also gradually begin to decrease among the most elderly.
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Fig. 5: Application of the Nordling (1953) model on U.S. cancer mortality
Cancer mortality rates for European American males (EAM) and females (EAF). The slope of
the log-log fit to the cancer mortality rates for ages 35 to 75 predicts that 5 + 1 = 6 events are
required for carcinogenesis in males, and 4 + 1 = 5 events are required in females.
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2.1.3 Cancer Mortality Data (Armitage and Doll, 1954)
Just as the evaluation of overall mortality rates by Kermack et al (1934) revealed the
necessity of evaluating each form of death independently, Armitage and Doll (1954) opted to
apply Nordling's hypothesis to individual types of cancers, as well as separating mortality by
gender. By doing so, they estimated that the number of mutations required for individual cancers
fell within the 6 to 7 range for gastrointestinal cancers, as Nordling had predicted for all cancers.
Deviation from the Nordling model below age 30 was attributed to a more susceptible
subpopulation that died off early (i.e. people with polyposis coli). Deviation above age 75 was
attributed to inaccuracy of the data set. No data above age 85 were apparently available.
Furthermore, for gender-specific cancers, such as breast cancer and testicular cancer, Armitage
and Doll (1954) found that the Nordling model did not accurately predict the cancer experience
assuming any number of necessary events for carcinogenesis.
Figure 6 demonstrates the application of the Nordling model to the U.S. cancer mortality
data set for all birthyear cohorts since the 1800s (intestinal cancer among European American
males, and breast cancer among European American females). The same conclusions are reached
as in Armitage and Doll (1954), of 6 to 7 necessary events for intestinal cancer, and the failure of
the Nordling model to accurately predict breast cancer mortality rates, unless it is assumed that
two independent subpopulations are at risk for breast cancer. By the Nordling model, 3 times as
many events are expected to be required for early breast cancer than for late onset breast cancer,
meaning that these events would need to occur more than three time as fast as the 3 to 4 events
predicted to be necessary for late onset breast cancer.
Fig. 6: Application of the Nordling (1953) model on intestinal and breast
Intestinal cancer mortality rates among European American males (EAM) and breast cancer
mortality rates among European American females (EAF). The slope of the log-log fit to the
cancer mortality rates for ages 35 to 75 predicts that 5.4 + 1 = (6 or 7) events are required for
intestinal carcinogenesis (Armitage and Doll, 1954). Contrarily, the Nordling model fails to
predict breast cancer mortality rates among females, unless breast cancer with early onset
represents a subset of the population that dies off faster than the remaining population. In this
case, the Nordling model would predict 8 + 1 = 9 necessary events for the early onset form of
breast cancer, but 2.2 + 1 = (3 or 4) necessary events for the late onset form of breast cancer.
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2.1.4 Precancerous growth (Platt, 1955)
In response to Armitage and Doll's (1954) analysis of cancer mortality curves, Platt
(1955) suggested that the capability of a cell to create an expanding colony is not necessarily
unique to a cell in a cancerous state, but could theoretically be observed in cells that have
accumulated some, but not all of the necessary events of carcinogenesis. These cells would be
considered to compose precancerous lesions which like cancerous lesions grow, albeit at a
slower rate. Platt further expounded upon the possibility that cigarette smoke increases the
kinetic rates of lung epithelial cells. The suggestion permits for two potential explanations as to
why cigarette smoke increases the likelihood of developing cancer, either by increasing the
turnover rate of normal and/or precancerous lesions, or by increasing the rate of genetic
alterations if the time a cell has to repair damaged DNA is diminished by more rapid division.
2.1.5 Cancer Mortality Data (Armitage and Doll, 1957)
At Platt's (1955) suggestion that a cell having undergone a single mutational event may
proliferate at a faster rate than a normal cell, Armitage and Doll (1957) reformulated the
Nordling model to accommodate two necessary stages, the first creating a proliferating colony
(initiation) and the second permitting an inexorable conversion (promotion) to a lethal tumor.
They noted that an intermediate, growing colony would not require as high a mutation rate per
cell, such that only one event might be needed to reach each stage. However, as with their
application of the Nordling model, Armitage and Doll were able to fit the gastrointestinal
mortality data well, while other cancers were believed to still be dependent on additional age-r
dependent factors. They further estimated that the exponential growth rate of precancerous
proliferating lesions is about 0.12, which translates to a doubling rate of about 0.18.
Figure 7 summarizes the Armitage and Doll (1957) model for the general case of 'n'
necessary initiation events, which create a proliferating precancerous colony, and 'm' subsequent
promotion events which create the first cancerous cell. This produces the interesting condition
that the precancerous lesion is expected to comprise of a mixed population of growing cells that
have acquired all 'n' necessary mutations, but only some of the 'm' necessary promotion
mutations. The precancerous lesion will comprise of a growing colony of cells with the 'n'
initiation mutations, a growing colony of cells with the 'n' initiation mutations plus one
promotion mutation, and so on. This explains the observation of the loss of function of genes,
necessary or not, in some but not all cells of lesions. Additionally, the proliferating rate of a
precancerous cell may be dependent on the number of promotion events already accumulated.
2.1.6 Cancer Mortality Data (Peto et al, 1975, 1977)
Peto (1977) however pointed out the complications with Nordling's base model. Peto
argued that any model, where incidence is proportional to tn-1 and 'n' is large, could be fit to
mortality data for many different values of 'n', suggesting that there was no easy way to
determine which model was most plausible. His recommendation was that knowledge of cell
kinetics and in vivo carcinogenesis would be required to ascertain the most appropriate model.
Peto et al (1975) did however argue that the increase in mortality rates with age is likely due to
the accumulation of mutations, rather than an increasing mutation rate with age (Section 2.2.4).
2.1.7 Cancer Mortality Data among the Elderly (Cook et al, 1969)
The apparent maximum in cancer mortality rates in old age was initially recognized but
dismissed as an error of diagnosis and/or reporting in the elderly. In an attempt to address the
Fig. 7: Armitage and Doll (1957) model of carcinogenesis
Cancer is modeled as the accumulation of 'n' independent events in a single cell,
transforming an otherwise normal cell into a precancerous one which can itself create a
proliferating colony (initiation). Within this expanding colony, a cell acquires 'm' further events,
creating the first cancerous cell (promotion). The terms ri, rj, ... represent the rate of each of the
initiation events, while the terms rA, rB, .... represent the rate of each of the promotion events.
The doubling rate of a cell in the precancerous lesion is represented by the difference between
the potential division rate of the cell, a, and the potential death rate of the cell, P. The subscript
in (a - P)x represents the last promotion mutation acquired.
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problem of modeling cancers that did not conform to Nordling's model with or without Platt's
modification, Cook et al (1969) were the first to postulate that the recognized downward trend in
older patients should not be attributed entirely to misdiagnosis in the elderly. "One explanation
of a decreasing rate of increase in old age is that it is an artefact of progressive under-estimation
of incidence as age advances...Visual inspection of the graphs show that when curvature is
present, it usually occurs throughout the whole range of ages examined, and no relationship was
found between the amount of downward curvature and the difficulty of diagnosis, as assessed
independently by two colleagues."
They attributed this downward trend to three possibilities. Firstly, they specifically
reasoned that a true maximum in the age-dependent mortality and incidence rate would be
expected if there were a distinct subpopulation at risk. By virtue of cancer risk, such a
subpopulation would have a higher overall death rate than the remaining population which had
no risk of cancer. As a birth year cohort aged, there would be a smaller remaining fraction at risk
and thus the observed cancer mortality rate in the surviving population could reach a maximum
and decline. The mortality and incidence rate of cancer within the subpopulation at risk must
therefore eventually decrease back down to zero, as soon as all members at risk have developed
that cancer or have died. Cook et al (1969) however does not consider the possibility that these
individuals within the subpopulation at risk are not only placed at risk for the cancer of interest,
but may also be placed at risk for diseases that share common risk factors with that cancer. This
possibility is further explored in Section 3.5.2.2.
Secondly, Cook et al (1969) suggested that incidence could be dependent on the time of
first exposure such that the curvature of the mortality curves is representative of the distribution
of the age at which an individual was exposed to the necessary environmental risk factor. There
would be a small percentage of the population that is not exposed until late in life and who
therefore die at lower rates later in life. It is important to point out that in their analysis Cook et
al studied cross-sectional data. For the cohort they studied, individuals living in the 1960s, those
who died of lung cancer in their 90's (equivalent to 1870s birthyears) were less likely to have
been smokers than those who died in their 70's as smoking prevalence was higher among the
later birthyear cohorts (Harris, 1983); as a result, cross-sectional mortality would seem to
decrease at the higher ages.
Thirdly, Cook et al (1969) suggested that there may be varying amounts of exposure
within the same population, so that people dying at later ages were exposed to less of the
carcinogen and thereby develop cancer at a slower rate.
2.1.8. Cancer Mortality Data (Knudson, 1971) and beyond
During the 1970s, Knudson and Moolgavkar, first separately and then in collaboration,
made the most extensive attempts to model cancer mortality in terms of the number of required
mutations and cell kinetics. Knudson (1971) deduced that children born with a germinal mutation
in one of the alleles of the later to be named Rb gene, developed multiple, bilateral
retinoblastomas. These were mainly observed in families with retinoblastoma history. Non-
familial retinoblastomas were most often detected as single and unilateral. Based on these
observations, Knudson formulated a two-mutation model much like Armitage and Doll's (1957),
in which the second mutation must occur in a rapidly dividing cell (as retinoblasts are highly
proliferative).
Moolgavkar et al (1979, 1981, 1988, 1990a, 1990b, 1992) and Dewanji et al (1989, 1991)
further extended this model. They assumed that any cell could either divide and make two new
cells with rate a or could die or terminally differentiate irreversibly at rate P. In the event that
this cell had not yet acquired the first (and only) initiation mutation, then a = f$ while in an
"initiated" cell, a > fi An initiated cell would then either become stochastically extinct with
probability (1 - -) or grow to form a preneoplastic colony in which all cells have an equal
probability of experiencing a second mutation and giving rise to a lethal carcinoma. The concept
of stochastic extinction permits us to make the prediction that when multiple precancerous
lesions are observed in an individual, their average growth rate, (a - 3), is higher than the
average growth rate of a lesion in an individual of the same age who only had a single lesion.
Furthermore, the average size of these precancerous lesions is inversely proportional to the
growth rate, if one were able to detect the lesions after no more than a few years since initiation.
Moolgavkar's two-mutation model adequately described birth-year dependent but not
cross-sectional mortality rates for several cancers, restoring the ideas of Kermack et al (1934) to
cancer modeling. Analyses of mortality and incidence data were additionally limited to ages less
than 85.
1.2 GENETICS OF CARCINOGENESIS
1.2.1 Initiation of Colon Cancer
Vogelstein's group (1992, 1994a, 1994b) has discovered that loss of both alleles of the
tumor suppressor gene, APC, is required for most sporadic colon cancers as well as tumors in
familial adenomatous polyposis coli (FAP). (Not all forms of colon tumors exhibit loss of APC,
vis. HNPCC patients). Vogelstein proposed that colon carcinogenesis consists of a normal --
adenoma -4 carcinoma sequence for which loss of both APC alleles is required to obtain an
adenoma.
In Moolgavkar's and Knudson's single initiation mutation models, the first APC mutation
would have theoretically led to preferential growth of a cell and form an adenoma. However,
FAP patients and normal individuals with APC+/- crypts do not exhibit adenomas in such crypts.
FAP patients do exhibit increased occurrences of hyperplastic polyps, but these are distinct from
adenomas as they are nondysplastic (Jen et al, 1994). To further support the contention that loss
of both APC alleles are required to produce a proliferating precancerous colon adenoma,
Vogelstein observed that in FAP patients, who are born with a germinal mutation of APC, 80%
of their colon adenomas show loss of the inherited wildtype APC copy. After examining the
smallest of preneoplastic lesions, 19 of which 24 had mutations in both APC alleles, they
concluded that these "... results support the idea that complete inactivation of the APC gene is a
critical step for colorectal tumor initiation... Moreover, inactivation was observed in the earliest
recognizable phase of tumors, including some lesions as few as two dysplastic crypts." Since
their techniques did not detect mutations in the promoter or intron regions and did not detect
large deletions, it could not be ascertained whether all adenomas or tumors actually contained a
second APC mutation.
Therefore, it was reasonable to suggest that two initiation mutations and at least a single
promotion mutation are required to induce neoplastic growth, an assumption justified by the
quantitative analyses herein (Section 4.1.1). Moolgavkar and Luebeck (1992) have recognized
this point, "Compared with the two-mutation model, the three-mutation model was more
consistent with the number of mutations reported to date in colon cancer and with mutation rates
measured in the laboratory." Based on their analysis of British colon cancer incidence, they
furthermore concluded that there was no growth advantage in a cell containing the first of two
APC mutations.
2.2.2 Promotion of Colon Cancer
Little is yet known as to the number of necessary promotion events for colon cancer.
Early colon carcinomas and adenomas do demonstrate marked loss of heterozygosity (LOH) for
informative loci on all chromosomes, on average 22% (Vogelstein et al, 1988, 1989; Garcia-
Patifio et al, 1998; Resta et al, 1998; Uhrhammer et al, 1999; Ragnarsson et al, 1999).
Additionally, in a single study, loss of genomic imprinting (LOI) in colorectal carcinomas for a
single marker was found to be 44% (Cui et al, 1998). Assuming that promotion entails the loss of
heterozygosity or imprinting of 'm' genes, mathematical models could theoretically predict the
number of necessary events. For each modeled number 'm', one can estimate an average
promotion mutation rate which can then be compared to the equivalent mutation rate that would
give rise to the reported levels of LOH/LOI.
2.2.3 Genetic Alterations Observed in Other Cancers
For several other human organs it appears that independent losses of both alleles in
certain tumor suppressor genes constitute initiation, i.e. n = 2. The genes and the organs in which
their loss appears to represent the only events of initiation are Rb (retinoblastoma, others) VHL
(kidney), P16 (melanoma), PTCH(skin), NFl,,and NF2 (central nervous system) (Friend et al,
1987; Gnarra et al, 1994; Kamb et al, 1994; Gailani et al, 1996; Rouleau et al, 1993). Others
genes involved in initiation of many cancer types are being pursued vigorously by the cancer
genetics community. No gene has yet been found to play this role for lung cancer, nor has any
gene been found to play a role in promotion for any cancer.
The apparent role of the loss of heterozygosity (LOH) in carcinogenesis is suggested by
high LOH levels distributed across the genome in most tumors of epithelial origin. Loss of
heterozygosity by chromatin loss or recombination was not detected in normal bronchial
epithelium of nonsmokers (Wistuba et al, 1997; Kohno et al, 1999), while half of 200-800 cell
biopsies taken from cigarette smokers were reported to exhibit marked LOH levels (Wistuba et al
1997, 1999a; Kohno et al, 1999). Allelic loss in severely dysplastic colonies averaged 30%
among multiple loci. In lung tumors, allelic loss levels vary among chromosomal regions
averaging perhaps 60% over all loci analyzed (Wistuba et al, 1997, 1999a, 1999b).
However, we are not able to verify that the reported analytical procedure could account
for certain technical difficulties expected in the analysis of small cell isolates in which stochastic
sampling errors would become critically important. Whereas Wistuba et al (1997) reported
mutant clusters containing as many as 90,000 mutant cells, results from Coller et al (1998) and
Li-Sucholeiki et al (unpublished) suggested that mutant clusters are far smaller, 16 to 32 cells.
Any conclusion with regard to LOH in bronchial epithelia of smokers and nonsmokers is held in
abeyance until these technical concerns are addressed. Additionally, to date, no demonstration
has been made that any particular LOH event is required during promotion.
Curiously, many mutations recorded in malignant tumors, such as in the ras proto-
oncogenes or the TP53 gene, do not appear to be a part of the initiation or promotion processes
as they appear to arise in sectors, but not the totality, of tumors in which they are measured. The
absence of these mutations in every carcinoma cell suggests that they are not among the rate-
limiting steps in normal tissue cells or precancerous cells which define the age-specific mortality
rates. These post-neoplastic mutations may be considered important steps in tumor progression
(death from a cancerous tumor) which is considered a relatively rapid process of less than three
years duration for most cancers (Axtell et al, 1976).
2.2.4 Somatic Mutation Rates in Normal Tissues
Dr. Aoy Tomita-Mitchell compiled all published reports of the age-specific mutant
fraction at the hprt locus in human peripheral T cells (Bigbee et al, 1998; Branda et al, 1993;
Davies et al, 1992; Finette et al, 1994; Henderson et al, 1986; Hirai et al, 1995; Hou et al, 1995;
Huttner et al, 1995; Liu et al, 1997; McGinniss et al, 1990; Tates et al, 1991). Figure 8 shows
these mutant fractions as a function of age. These data show a similar distribution around the
mean for all age groups, 0-9, 10-19, etc. up to age 75 after which the number of persons with
relatively high mutant fractions appears to decline markedly. Using all of the data from ages 0-
75, one calculates a constant rate of hprt loss of 2.1 x 10-7 mutations per cell year. Additionally,
the overall estimated mutation rate for hprt in T-lymphocytes from these studies did not show
any changes due to an individual's smoking status, but this could be due to human T-
lymphocytes not being the primary target of cigarette smoke mutagenicity in vivo.
In human B-cell cultures, the observed spontaneous rates of mutation at the hprt locus
ranges from 0.5 to 2.5 x 10 mutations per cell division (Gennett and Thilly, 1988; Oller and
Thilly, 1992; Chen and Thilly, 1996). These in vivo and in vitro estimates are in reasonable
agreement and represent loss of an active gene copy by point mutations and large deletions but
not by recombination.
Two estimates of LOH rates in humans differ significantly. Grist et al (1992) reported
that the sum of all pathways for loss of heterozygosity of the HLA-A locus in peripheral T-cells
was bou 6.6x 1-7
was about 6.6 x 107 events per cell year. However, Fuller et al (1990) and Jass et al (1994)
report observations of colon unicryptal LOH (loss of O-acetylate transferase activity) of about 2
x 10-5 per cell year, 30 times higher than LOH rates seen in blood cells.
Fig. 8: Mutant fraction of the hprt locus of peripheral T-cells
Illustrated as a function of age (n = 740); the slope of the line is 2.1 x 10-7 hprt mutations per
cell year.
Compiled by Dr. Aoy Tomita-Mitchell
(Bigbee, 1998; Branda, 1993; Davies, 1992; Finette, 1994; Henderson, 1986; Hirai, 1995; Hou,
1995; Huttner, 1995; Liu et al, 1997; McGinniss et al, 1990; Tates et al, 1991)
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2.3 RISK FACTORS FOR CANCER
2.3.1 Cigarettes - Lung Cancer
The role of cigarette smoke in lung cancer causation was discovered by noting the
general rise in lung cancer deaths and the preponderance of cigarette smokers among lung cancer
victims in the late 1940s and 1950s. (Wynder and Graham, 1950; Doll and Hill, 1952; Hammond
and Horn, 1958) The epidemiological evidence, though clear, did not indicate by what means
cigarette smoking acted on lung cells. Cigarette smoke contains small amounts of chemicals such
as polycyclic aromatic hydrocarbons, nitrosamines and other substances that mutated cells in
culture and also induced tumors in experimental animals. It was thus inferred that cigarette
smoking induced tumors by inducing point mutations (Dennisenko et al, 1996; Nesnow et al,
1995; Cloutier et al, 1999; Peterson et al, 1991).
For example, the mutational spectrum of the TP53 gene caused by benzo[a]pyrene
included the mutational hotspots seen in lung tumor samples taken from smokers. The initial
conclusion was therefore that benzo[a]pyrene, found in cigarette smoke, is a cause of lung cancer
in smokers (Denissenko et al, 1996). Rodin and Rodin (2000) have reanalyzed the kinds of
nuclear TP53 point mutations occurring in cells of established lung tumors and concluded that
these do not differ between smokers and nonsmokers in marked contradistinction to earlier
interpretations (Hernandez-Boussard et al, 1998). They concluded that cigarette smoke
alternately elevates the risk of lung cancer through the selection of specific mutant cell
populations, which are at risk for undergoing further promotion to cancer.
Coller et al (1998) examined the mutational spectra of a 100bp sequence of mitochondrial
DNA in bronchial epithelial samples taken from smokers and nonsmokers, including three
monozygotic twin pairs, discordant for smoking. Coller et al (1998) concluded that the mtDNA
mutant hotspots found in smokers' samples did not differ from the mtDNA mutant hotspots
found in nonsmokers' samplers. Furthermore they did not find a statistically significant elevated
mutant fraction among smokers.
Adapting the methodology by Coller et al (1998) to nuclear DNA mutations, Dr. Xiao-
Cheng Li-Sucholeiki, Dr. Luisa Marcelino, Amanda Gruhl, and Hiroko Sudo of the Thilly lab at
the MIT Center for Environmental Health Science determined in vivo mutant frequencies of
bronchial epithelial cells of smokers and nonsmokers (unpublished). Given the results by
Denissenko et al (1996), they were interested primarily on the hotspots of the TP53 gene.
Preliminary results revealed no significant differences in the mutant frequency of bronchial cells
of three smokers and two nonsmokers of similar age. The mutant fraction of the hotspot at base
pair 746 was found to be on average 4.0 x 10-5 among nonsmokers and 4.7 x 10-5 among
smokers, with the highest mutant fraction actually observed in one of the nonsmokers.
Alternately, the mutant fraction of the hotspot at base pair 747 was found to be 2.5 times higher
in smokers. However, this was not found to be significantly different as the variance of mutant
fractions between smokers and nonsmokers was about the same as the variance of mutant
fractions within the smoker and within the nonsmoker groups themselves. This leads to the
preliminary conclusion that cigarettes elevate the risk of developing lung cancer by means other
than a direct mutagenic effect on bronchial DNA.
2.3.2 Methylnitrosourea - Breast Cancer (rats)
When treated with methylnitrosourea (MNU), rats develop mammary tumors. Cha et al
(1994) demonstrated that MNU did not actually induce the G--A transitions of the H-ras gene
found in all tumor cells of about 85% of these mammary tumors. Alternately, these mutations
were found to arise in preexisting clusters of 100-200 cells. MNU was revealed to select for
those cells already containing independently generated mutations. The cause for this selection is
yet unknown; possibilities include the induction of the release of normal growth signals in these
mutant cells, the mimicking of those signals, or the suppression of internal mechanisms which
may help eliminate precancerous cells from the body.
This example in rats provides an alternate hypothesis for how smoking may elevate the
risk of developing lung cancer. Cigarette smoke could likewise select for specific mutants in the
bronchial epithelium, permitting the proliferation of certain cells that can then undergo
promotion. Indeed, Auerbach et al (1957) has described the replacement of the normal lung
epithelial architecture due to smoking cigarettes. Smokers' upper bronchi contained frequent
areas of epithelial thickenings composed of multiple layers of basal cells, rather than the normal
nonsmokers' epithelium which is composed of a layer of basal cells and a layer of ciliated cells.
These thickenings may represent the selected growth of metaplastic and/or dysplastic cells.
Furthermore, these changes can be effectively reversed by smoking cessation (Auerbach et al,
1962).
Therefore, any potential indirect effect of an external stimulus must be considered
seriously before one can conclude that a chemical induces cancer through the induction of
genetic alterations.
2.3.3 DNA Misreplication - Colon Cancer?
Unlike lung cancer, a conclusive cause for colon cancer is yet unknown. It has been
shown that caloric and dietary intake affects the risk for colon cancer (Giovannucci and Goldin,
1997), but Kinzler and Vogelstein (1996) have suggested that dietary factors might not be
mutagens, but rather behave as irritants that initiate tissue regeneration. An increase in the
turnover rate of normal or even precancerous tissue would therefore increase the risk of colon
cancer without the need of an exogenous induction of the mutations necessary for colon
carcinogenesis.
Research in the Thilly lab by Brindha Muniappan (unpublished) has determined that 3 of
the 6 so far identified mutant hotspots of the APC gene induced by DNA polymerase P in vitro
replication are concordant with the mutant hotspots of the APC of cells taken from colon cancer
samples. These 3 mutants comprise more than 50%, by frequency, of all APC mutants observed
in colon cancer patients. As initiation of most colon cancer involves the loss of function of the
APC gene (Powell et al, 1992), the conclusion is that endogenous processes rather than chemical
exposure might be involved in the initiation of colon carcinogenesis.
This does not exclude the possibility of a potential effect of chemical exposure on colon
carcinogenesis. Chemical exposures (i.e. diet) may still play a role in smaller subpopulations by
accelerating the onset of colon cancer in those individuals, by affecting the error rate of
endogenous mechanisms, or by altering cell kinetic rates of preexisting mutant cells. However,
these risk factors would not be considered primary, essential risk factors for colon cancer
development.
3. MATERIALS AND METHODS
3.1 BIOLOGICAL ASSUMPTIONS
3.1.1 Turnover Unit
Dr. E.E. Furth (University of Pennsylvania Medical School) has observed that in the
colon: 1) cells undergoing apoptosis can be found near or at the top of a crypt, or lie within the
colonic mucosa where they are being degraded by macrophages, 2) mitoses can be detected all
the way along the crypt wall, suggesting that as cells within the crypt divide, new cells are
pushed upwards towards the lumen of the colon, replacing those which have been lost through
apoptosis, and 3) the stem cell population at the bottom of the crypt helps conserve the overall
population of cells within each crypt. It is yet unknown whether each crypt in a human contains a
single stem cell or more, but each stem cell is assumed to repopulate an independent portion of
the colonic tissue; this portion of a tissue defines a turnover unit.
The architecture of the turnover unit in other tissues is not as well understood. In the case
of the lung, pluripotent stem cells are assumed to reside in the basal layer of the epithelium, as
these comprise the dividing cell population of the normal lung tissue. However, transition cells,
non-stem cells which have not yet differentiated into ciliated cells, might also be found in this
dividing compartment. As is the case in the colon, stem cells in the lung theoretically regenerate
lung tissue by generating transition cells, which themselves can generate other transition cells or
fully differentiated cells.
Figure 9 illustrates a basic representation of how a fully-developed turnover unit might
undergo tissue renewal. As cells in the terminal layer undergo apoptosis, cells from the previous
layers, composed of transition cells, divide and replace those cells which had been lost. As more
transition cells divide to replenish the terminal layer, these transition levels themselves must also
Fig. 9: Hypothetical turnover Unit
Illustration of hypothetical model by which a tissue regenerates itself (illustrated for a single
turnover unit of the tissue; actual size may vary).
a. Two cells from the terminal layer undergo apoptosis (not necessarily concurrently)
b. A transition cell from the previous layer divides and replaces the two cells lost in step a.
(symmetric division)
c. Two more terminal cells undergo apoptosis (not necessarily concurrently)
d. Again, a transition cell from the previous layer divides and replaces lost cells from terminal
layer (symmetric division)
e. Since two cells from this last transition layer have now been lost due to migration and
differentiation into the terminal layer, a cell from the previous transition layer now divides
and replaces these two 'lost' transition cells (symmetric division)
f. As more terminal cells are lost, transition cells continue dividing to replenish both the
terminal layer and each transition layer. Eventually, the transition cell which is the direct
descendant of a stem cell division itself divides to replenish the second transition layer
(symmetric division)
g. Stem cell divides; one cell remains as pluripotent cell; other replaces lost cell in the first
transition layer (asymmetric division). This allows for the turnover unit to be renewed while
maintaining its stem cell.
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be replenished. Transition cells from previous layers must thus eventually divide to help
conserve total cell population within the tissue (Figure 9e). Eventually, the first transition cell,
the daughter cell from a stem cell division, must renew the next layer, such that now the stem
cell itself must divide to complete the full renewal of the tissue (Figure 9g). The stem cell itself
does not migrate to the first transition cell layer; it simply divides to replace the lost first
transition cell, thus permanently maintaining a stable cell population in the tissue (asymmetric
division). With this final division, this portion of the tissue has undergone full regeneration.
Naturally, tissue may not renew itself in as orderly a fashion as illustrated in Figure 9, but
the key point is that the stem cell does not undergo symmetric division. Migration of the stem
cell into the transition layer would otherwise lead to loss of the turnover unit, with its eventual
differentiation. Furthermore, all other cells would eventually become differentiated and sloughed
off through apoptosis.
In this model, transition cells move up one transition layer at a time after each tissue
turnover, until it and its daughter cells reach the terminal layer. Within the next turnover, these
cells are lost after undergoing apoptosis. If either a transition or terminal cell has acquired one of
the necessary mutations required for initiation of a tumor, that mutation would eventually be lost
due to normal tissue turnover, unless that particular cell loses the remaining initiation mutations
before termination (Figure 10a-e). On the other hand, a mutation acquired by a stem cell would
not only never be lost since stem cells do not undergo apoptosis, but also a mutation in the stem
cell would eventually lead to the transformation of the previously normal turnover unit into a
turnover unit whose all cells contain that mutation (Figure 10f-j).
Fig. 10: Redistribution of mutant cells through normal cell turnover
Upper panel; Loss of mutant cells through normal cell turnover
a. Two cells from the terminal layer undergo apoptosis (not necessarily concurrently)
b. A transition cell, which has acquired a mutation, located on the previous layer divides and
replaces the two cells lost in step a. (symmetric division)
c. Another two cells from the terminal layer undergo apoptosis (not necessarily concurrently)
d. Rest of turnover unit undergoes further tissue renewal with no more accumulation of single-
mutant cells since all other transitional cells are normal
e. Within the next round of turnover, the two mutant cells now in the terminal layer, are
replaced by two wildtype cells from previous transition layer. Loss of mutant cells within the
turnover unit has occurred. (This occurs regardless of which cell first acquired the mutation,
except in the case of the stem cell; See below.)
Lower panel; Transformation of normal turnover unit into a mutant turnover unit through normal
cell turnover:
f. Stem cell acquires mutation during a previous division.
g. In the next turnover, the first transition cell (normal) replaces the next layer of transition cells
with equally normal cells. Stem cell divides asymmetrically such that the new first transition
cell now also carries the same mutation as the stem cell.
h. In the next turnover, the first transition cell (now mutant) replaces the next layer of transition
cells with equally mutant cells.
i. Further turnovers subsequently replace transition layers previously normal with cells that
carry the same mutation as the stem cell.
j. Eventually, terminal layer is replaced entirely by mutant cells; with a mutant stem cell, this
turnover unit cannot reverse to wildtype since the stem cell assures that all transition layers
will maintain the mutation found in the stem cell.
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If the stem cell has acquired one of the initiation mutations (Figure 10, lower panel), the
whole turnover unit is now a target for a second initiation mutation. By the same logic that the
first initiation mutation must occur in the stem cell, so must other necessary initiation mutations,
as any subsequent mutation in a transition cell or differentiated cell would eventually be lost
after normal tissue renewal. The exception is the very last initiation mutation which could
theoretically occur in any of the cells. Once a cell has acquired the 'n'th and final initiation
mutation, it acquires the capability to produce a proliferating colony, a precancerous lesion,
whose kinetics are assumed to be independent of the mechanisms involved in normal cell
turnover. All cells in an organ are assumed to be at potential risk for conversion to a
precancerous cell. (In the event that a differentiated cell that has accumulated all necessary
initiation mutations cannot reversibly continue to divide, then the number of cells at potential
risk for initiation is half of all cells in an organ).
Dysplastic colonies of the colon, small adenomas, in fact arise at various positions along
the crypt wall, particularly above the area associated with highest mitotic activity, suggesting
that the origin of a precancerous lesion is not restricted to the stem cell population, but may
include any cells of the transition or terminal layers.
Based on the two initiation mutation model suggested by the genetics of carcinogenesis
(Section 2.2), the first initiation mutation would arise in a stem cell, while the second initiation
mutation would more likely arise in one of the other cells in the turnover unit. These cells
inherited the first mutation as a result of normal tissue renewal within a turnover unit containing
a mutant stem cell.
3.1.2 Initiation ('n' events)
As Peto (1977) first pointed out, the first carcinogenesis models (Nordling, 1953;
Armitage and Doll, 1954) can accurately fit cancer incidence/mortality data for a large range of
number of necessary initiation events, n. It was thereby recommended by Peto that one cannot
use mortality curves to determine the number of necessary events, but instead one should rely on
in vivo observations of carcinogenesis. The following observations can be of use:
1. Small adenomas (precancerous lesions of the colon) already contain loss of normal
APC expression. (Powell et al, 1992)
2. FAP patients born heterozygous to the APC mutation have an increased risk of polyp
formation; APC ÷/ " crypts are histologically normal (Bjerknes et al, 1997) suggesting
that loss of the normal APC allele alone in FAP patients is required for tumor
development, but that loss of both APC alleles is needed for tumor development in a
normal patient.
3. Mutations in APC result in apoptosis which "...could alter the precise homeostatic
balance required in renewing cell populations." (Kinzler and Vogelstein, 1996) Dr.
E.E. Furth (University of Pennsylvania Medical School) determined that
adenomatous cells show both an elevated rate of cell division and cell death with a
slightly higher rate for cell division leading to an overall growth rate for the adenoma;
carcinomatous cells show further elevation of cell division rates.
Based on observations 1 and 2, two mutations (loss of APC expression) are required for the
initiation of most colon tumors within the non-FAP population.
3.1.3 Growth of Precancerous Lesions + Promotion ('m' events)
Carcinogenesis must include at least one further event (promotion) as suggested by the
observation that cancerous cells divide faster than precancerous cells. Figure 11 illustrates our
adaptation of Armitage and Doll's multistage model (1957) and the theoretical work of Knudson
and Moolgavkar (Knudson, 1971; Moolgavkar et al, 1979, 1981, 1988, 1990a, 1990b, 1992;
Dewanji et al, 1989, 1991), using three necessary events for the development of the first
cancerous cell (2 initiation + 1 promotion event).
In this model, a stem cell acquires the first initiation mutation in a tumor suppressor gene
at a rate ri. After several rounds of normal turnover (assumed to be completed in negligible time),
the turnover unit for that stem cell will be repopulated with single mutant cells, each of which
can undergo loss of the second copy of the tumor suppressor gene at a rate rj. A cell that has
undergone both mutations is said to be initiated (precancerous) and now has an elevated division
rate, a, and death rate, P.
If the series of divisions and deaths by these precancerous cells is approximately random,
then a small precancerous colony could undergo stochastic extinction, as previously described by
Moolgavkar (1990b). Assuming that the precancerous colony has grown to a size large enough
that extinction no longer is significantly probable (stochastic survival), then the colony
undergoes further growth at a deterministic doubling rate of (a - D. Each of these cells can
lastly accumulate a third mutational event at rate rA (promotion). Accumulation of the promotion
event (assuming one) leads to an elevated growth rate of those cells, the initial phenotype of a
carcinoma.
Fig. 11: Three-mutation (2 initiation, 1 promotion) model of carcinogenesis
1. A stem cell acquires the first of two initiation mutations at rate ri.
2. After several rounds of normal cell turnover, stem cell repopulates turnover unit with
transition and differentiated cells containing the first initiation mutation.
3. One of the cells in the turnover unit acquires the second initiation mutation at rate rj,
becoming an initiated precancerous cell.
2. Initiated cell either undergoes a division with probability a+x(a+p) or dies with probability
13+(cxa+), where a represents the average division rate of cells of the precancerous lesion,
and p represents the average death rate of cells of the precancerous lesion.
5. Any surviving cell in the precancerous lesion can undergo further division or death by the
same process as in 4.
6. If precancerous lesion becomes large enough, complete stochastic extinction becomes
significantly improbable, such that the lesion appears to grow at a doubling rate of(a - 3).
7. Cell in the precancerous lesion acquires a promotion mutation at rate rA. Assuming only one
promotion mutation is needed for carcinogenesis, cell becomes cancerous.
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3.1.4 Progression
In the three-stage carcinogenesis model, progression consists of a cancerous cell
acquiring any further mutations or events needed to lead to the death of the cancer patient (i.e.
bringing about metastasis). If subsequent mutations are necessary for death, the elevated growth
rate of a carcinoma predictably suggests that these mutations are acquired fast and should not
affect the overall model. This third stage occurs rapidly and can be effectively modeled as
occurring in zero years. (Axtell et al, 1976)
3.2 PRIMARY DATA SETS
3.2.1. Mortality Data
Annual age-specific mortality data for the U.S. population were obtained from the U.S.
Bureau of the Census (Mortality Statistics, 1900-1936) and the U.S. Department of Health and
Human Services (Vital Statistics of the United States, 1937-1992). Care was taken to maintain
computer records using the same structure as the original sources.
For each reporting year, we created a Microsoft ExcelTM spreadsheet listing the year of
death, the cause of death, its corresponding International Classification of Disease number, and
the number of deaths broken down by age, gender, and race. Figure 12 illustrates an example of
one of these spreadsheets for the reporting year 1990. This is an exact replica of the original
source, representing our raw data set. The data for White Male/Female represents mortality
among European American males/females (including Hispanics), and the sum of the data for
Black Male/Female and Other Male/Female (primarily of Asian descent) represents mortality
among Non-European American males/females.
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Figure 12: Mortality spreadsheet for the reporting year of 1990 in the U.S.
Reproduced from (U.S. Department of Health and Human Services, Vital Statistics of the United
States, 1990).
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Figure 13: Mortality spreadsheet for the reporting year of 1990 in the U.S. w/ formulae
Reproduced from (U.S. Department of Health and Human Services, Vital Statistics of the United
States, 1990)
Shows incorporated methodology for quality assurance of the raw data set. One can compare
calculated vertical and horizontal row totals with reported totals.
For example:
Cell C5: = SUM(D5:AD5)-I5
SUM of all deaths for White Males (Row 5) for all ages from under 1 year (Column D) to 100+
years (Column AC, not shown) + deaths for individuals of unknown age (Column AD, not
shown)
Cell I5 (as can be confirmed in Figure 12) is subtracted as it represents the sum of deaths for
under 5 years, which were already included when summing cells D5 through H5.
Alternately, Cell C5 could have been set to =SUM(I5:AD5)
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Ages are reported by the number of years since birth. While one typically refers to a
newborn as being one year of age, for the purpose of mortality, these children are reported to be
under 1 year of age, and so forth. The ages for which data were available were as follows: under
1 year, 1 year, 2 years, 3 years, 4 years, under 5 years, 5-9 years, 10-14 years, 15-19 years, 20-
24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 years, 50-54 years, 55-59
years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 80-84 years, 85-89 years, 90-94 years,
95-99 years, 100+ years, and unknown age. For the reporting years of 1900-1909 the category
for 100+ years was not available, but 95+ was used instead.' Although not used herein, mortality
rates were reported for the years 1880 and 1890 in their respective Census reports, but no
intercensus data is available.
Mistakes are inevitable when transcribing so many numbers from one source to another.
For quality assurance, the values listed in the TOTAL columns were not actually transcribed.
Instead, the Microsoft ExcelTM spreadsheets were directed to sum up each of the rows,
representing the independent gender and race cohorts. This only assures that the total of the
numbers transcribed were correct. To assure that the correct number was placed in the correct
cell, column totals were also summed by the spreadsheet. In doing so, one can catch transcribing
errors if numbers were accidentally shifted within a row. (This was a predominant problem for
diseases with many blank cells). Figure 13 demonstrates how to calculate these totals (Cell
references: letter represents column, and number represents the row of the cell).
For the reporting years of 1900-1913, race was not delineated. In 1914, 95.5% of the population of the states and
counties with death registries was reported to be of White descent, so the 1900-1913 data is used herein as an
estimate for European American mortality. For the years 1914-1932, no distinction was made between Black
Americans and Other Americans.
In 1972, the final mortality numbers were not released. The U.S. Department of Health and Human
Services opted to report numbers for half of the death records and multiplying the results by two. In 1962 and 1963,
mortality data was published without values for New Jersey, which were added only after publication. Corrected
mortality for these years were available only for the 5-year age groups of 0-4 years to 80-84-years (U.S. Department
of Health and Human Services, 1982b).
The diseases for which data were collected are as follows (ICD-9 Number):
All causes
I. Infectious and parasitic diseases (001-139)
Intestinal infectious diseases (001-009)
Intestinal infections due to other specified organisms (007-008)
Ill-defined infections (009)
Viral hepatitis (070)
II. Neoplasms (140-239)
Malignant neoplasms, including neoplasms of lymphatic and
hematopoietic tissues (140-208)
Malignant neoplasms of lip, oral cavity and pharynx (140-149)
Of lip (140)
Of tongue (141)
Of pharynx (146-149.0)
Of other and ill-defined sites within the lip, oral cavity,
and pharynx (142-145, 149.1-149.9)
Malignant neoplasms of digestive organs and peritoneum (150-159)
Of esophagus (150)
Of stomach (151)
Of small intestine, including duodenum (152)
Of colon (153)
Hepatic and splenic flexures and transverse colon
(153.0-153.1, 153.7)
Descending colon (153.2)
Sigmoid colon (153.3)
Cecum, appendix, and ascending colon (153.4-153.6)
Other and colon, unspecified (153.8-153.9)
Of rectum, rectosigmoid junction, and anus (154)
Of liver and intrahepatic bile ducts (155)
Liver, primary (155.0)
Intrahepatic bile ducts (155.1)
Liver, not specified as primary or secondary (155.2)
Of gallbladder and extrahepatic bile ducts (156)
Of pancreas (157)
Of retroperitoneum, peritoneum, and other and ill-defined
sites within the digestive organs and peritoneum (158-159)
Malignant neoplasms of respiratory and intrathoracic organs (160-165)
Of larynx (161)
Of trachea, bronchus, and lung (162)
Of all other and ill-defined sites within the respiratory
system and intrathoracic organs (160, 163-165)
Malignant neoplasms of bone, connective tissue, skin, and breast
(170-175)
Of bone and articular cartilage (170)
Of connective and other soft tissue (171)
Melanoma of skin (172)
Other malignant neoplasms of skin (173)
Of female breast (174)
Of male breast (175)
Malignant neoplasms of genital organs (179-187)
Of cervix uteri (180)
Of other parts of uterus (179, 181-182)
Of ovary and other uterine adnexa (183)
Of other and unspecified female genital organs (184)
Of prostate (185)
Of testis (186)
Of penis and other male genital organs (187)
Malignant neoplasms of urinary organs (188-189)
Of bladder (188)
Of kidney and other and unspecified urinary organs (189)
Malignant neoplasms of other and unspecified sites (190-199)
Of eye (190)
Of brain (191)
Of other and unspecified parts of nervous system (192)
Of thyroid gland and other endocrine glands and related
structures (193-194)
Of all other and unspecified sites (195-199)
Malignant neoplasms of lymphatic and hematopoietic tissues (200-208)
Lymphosarcoma and reticulosarcoma (200)
Hodgkin's disease (201)
Other malignant neoplasms of lymphoid and histiocytic tissue
(202)
Multiple myeloma and immunoproliferative neoplasms (203)
Leukemia (204-208)
Lymphoid leukemia (204)
Myeloid leukemia (205)
Monocytic leukemia (206)
Other and unspecified leukemia (207-208)
Benign neoplasms, carcinoma in situ, and neoplasms of uncertain behavior and of
unspecified nature (210-239)
Benign neoplasms (210-229)
Of female genital organs (218-221)
Of eye, brain and other parts of nervous system (224-225)
Of all other and unspecified sites (210-217, 222-223, 226-229)
Carcinoma in situ (230-234)
Of breast and genitourinary system (233)
Of all other and unspecified sites (230-232, 234)
Neoplasms of uncertain behavior (235-238)
Neoplasms of unspecified nature (239)
III. Endocrine, nutritional, and metabolic diseases and immunity disorders (240-279)
Disorders of thyroid gland (240-246)
Diabetes mellitus (250)
Cystic fibrosis (277.0)
IV. Diseases of blood and blood-forming organs (280-289)
V. Mental disorders (290-319)
Senile and presenile organic psychotic conditions (290)
VI. Diseases of the nervous system and sense organs (320-389)
Multiple sclerosis (340)
VII. Diseases of the circulatory system (390-459)
Hypertensive disease (401-404)
Ischemic heart disease (410-414)
Cerebrovascular diseases (430-438)
Atherosclerosis (440)
VIII. Diseases of the respiratory system (460-519)
Acute bronchitis and bronchiolitis (466)
Influenza (487)
Chronic obstructive pulmonary diseases and allied conditions (490-496)
Bronchitis, chronic and unspecified, emphysema, and asthma (490-493)
Bronchitis, not specified as acute or chronic (490)
Chronic bronchitis (491)
Emphysema (492)
Asthma (493)
Bronchiectasis and extrinsic allergic alveolitis (494-495)
Chronic airways obstruction, not elsewhere classified (496)
IX. Diseases of the digestive system (520-579)
Ulcer of stomach and duodenum (531-533)
Chronic liver disease and cirrhosis (571)
X. Diseases of the genitourinary system (580-629)
XII. Diseases of the skin and subcutaneous tissue (680-709)
XIII. Diseases of the musculoskeletal system and connective tissue (710-739)
XIV. Congenital anomalies (740-759)
XV. Certain conditions originating in the perinatal period (760-779)
XVI. Symptoms, signs, and ill-defined conditions (780-799)
Senility without mention of psychosis (797)
Accidents and adverse effects (E800-E949)
Suicide (E950-E959)
Homicide and legal intervention (E960-E978)
Injury undetermined whether accidentally or purposely inflicted (E980-E989)
Injury resulting from operatirons of war (E990-E999)
Files for each disease can be retrieved at our website (See end of ABSTRACT for instructions.)
3.2.2 Population Data
Population values were provided by the Duke Center for Demographic Studies for the
years 1950 to 1992. For previous years, population estimates were derived directly from census
counts for those states and counties reporting to the national death registries. The states with
death registries are reported at the beginning of the mortality data books (U.S. Bureau of the
Census, 1900-1933; Texas was the last existing state to be added to U.S. mortality results in
1933; Hawaii and Alaska were added later when they became states).
Population values are available for the same age groups as in the mortality data sets for
reporting years 1950-1992. Prior to 1950, population values for children are only available for
the age groups: under 1 year, and 1-4 year olds.
3.2.3 Mortality Rate Data
Combining mortality and population data sets permit calculation of the age-specific
mortality rate for each birth year, "h", designated OBS(h,t) for the "OBServed" form of death
mortality rate at age "t".
(Eq. 1)
OBS(h,t) = recorded deaths from the form of death of interest for birth cohort h at age t
recorded population size from birth cohort h at age t
An individual who is listed as being X years old will turn (X + 1) years old during the
year. Yearly mortality data lists individuals by their age at the time of death, such that this
individual may be listed as dying at age (X + 1) in the mortality data set, but is listed as being X
years old in the population data set, since the population estimates were for the beginning of the
year.
To correct for this confounding factor, the mortality values of, for example, reporting
year 1950, are linked with the population values of the year 1951. These population values
would represent the number of individuals who survived during the year 1950, to which is added
the number of deaths during the year 1950. For example, OBS(1900,50) would be derived by
determining the number of people who died in 1950 at age of 50 from the form of death of
interest, and dividing that by the number of 51 year olds alive at the beginning of 1951 plus the
number of all 50-year olds who died in 1950. The 51-year olds alive in 1951 and the number of
50-year olds who died in 1950, represent the individuals who could have potentially or actually
died at age 50 during 1950.
With this correction, any individual who was 50 years of age at the beginning of the year,
turns 51 and dies, would be included in the number of deaths occurring at age 51, and he/she is
included under the population of 51 year-olds, thereby guaranteeing that both numerator and
denominator of the calculated OBServed mortality rates consist of the same pool of individuals.
To convert our extensive database of raw mortality numbers into mortality rates required
the construction of a template spreadsheet to more rapidly do all calculations. The template that
has been built has been extended to the reporting year of 2050. This template was used by Jose
Marquez, MS, when putting together the mortality data for Japan for the reporting years of 1950-
1995. (See end of ABSTRACT for instructions on acquiring this and any other file of interest).
As new mortality and population values are collected, they need only be added to the template
file which will automatically convert these values into rates, grouped by birth-year and decade
cohorts. Furthermore, all relevant graphs are generated by this template.
Figures 14 through 20 demonstrate how to construct such a template (Some knowledge of
Microsoft ExcelM or the spreadsheet program of choice is needed). A template file is made up of
multiple worksheets presenting data and making calculations in the desired methods. To travel
from one worksheet to another, one need only click on the name of the worksheet as listed on the
lower left comer of the template file. For example, Figure 14 shows that the Raw Data (EAM),
Raw Data (EAF), Raw Data (NEAM), and Raw Data (NEAF) worksheets are available. To look
at any other existing worksheets not listed one would click on the arrows on the lower left corner
of the active window.
The first four worksheets of the template file (Figure 14) consist of the raw numbers of
deaths as already typed into the raw data spreadsheet shown in Figure 13, using the sum of the
numbers for Black and Other Americans to calculate the number of deaths for non-European
Americans. (One could conceivably construct 6 separate worksheets to represent each gender
and race combination).
Each row of these worksheets consists of the numbers of deaths for each reporting year
for the form of death of interest; each column represents the number of deaths for each age group
(as listed in the original raw data file). Scrolling down in the active window will reveal the rows
for the reporting year of interest for which data needs to be transcribed as data becomes available
for more years.
It is advisable to place any cautionary notes in these files. For example, Figure 14 reveals
that for the reporting years of 1900-1909, leukemia was not included as a cancerous form of
death. During these years, leukemia had been listed under the form of death, "Anemias and
leukemias". Mortality data for the next year, 1910, revealed that more than 90% of the sum of
deaths by "Anemias and leukemias", were in fact anemias. For larger accuracy, leukemia values
were excluded prior to 1910.
The next four worksheets (Figure 15) provide the equivalent population values for each
reporting mortality year. Population values in these worksheets have already been adjusted as
mentioned at the beginning of Section 3.2.3. In the Population (NEAM) and Population (NEAF)
worksheets there is a note to remind the user that populations for Non-European Americans were
combined with European Americans for the years 1900-1913, as mortality numbers were not
delineated by race for these years.
The next four worksheets (Figures 16, 17) calculate the mortality rate for each birthyear
cohort and each age group. Ages are listed by the midpoint of the age groups (i.e. 9-14 years
becomes 12.5). Figure 16 provides the calculated rates, and Figure 17 provides the equations
used to do so.2 For example, the calculated cancer mortality rate of 0.5 year old (under 1 year)
European American males born in 1900 is equal (=) to the number of deaths in this age group
during the year 1901 (cell reference: 'Raw Data (EAM)'!C4 as shown in Figure 14) divided (/)
by the equivalent population in 1901 (cell reference: 'Population (EAM)'!C4 as shown in Figure
15). Representation of mortality/incidence rates per 100,000 requires further multiplication (*
10A5).
The next two worksheets (Figures 18, 19) recalculate the mortality rates, but now as birth
decade cohorts. 1800s represents individuals born in 1800-1809 and so forth. The formulas used
to calculate these rates are similar to those for individual birthyears (as shown in Figure 17), with
the addition of the SUM function for use with 10 reporting years' worth of data. The number of
2 NOTE: As can be observed, at the time that this template was generated, we made the decision to transpose the
data such that the mortality rate for each age group is now listed by row instead of by column (compare Figure 15
with Figure 16). Anyone familiar with the formula filling features of Microsoft ExcelTM knows that this template
could have been generated far more easily without having done so.
cancer deaths among 0.5 year olds born in the 1900s would have occurred in the reporting years
1901-1910 (cell references: SUM('Raw Data (EAM)'!C4:C13) as shown in Figure 14).
Note that it is more appropriate to calculate birthyear decade mortality rates by dividing
the sum of the number of deaths during 10 years by the sum of the populations during these 10
years. It is not accurate to alternately take a 10-year average of single birthyear mortality rates.
The following worksheets (Figures 20-22) contain pregenerated graphs for the mortality
rates calculated in the previous worksheets. These graphs are automatically updated when new
data is introduced to the raw data worksheets. Figure 20 illustrates mortality curves by birth
decade cohort for all age groups. Figure 21 shows mortality curves, but only up to age 35, to
facilitate the observation of childhood cancer rates. The template file also contains pregenerated
graphs that break down these mortality curves into the age ranges of 35-80 and 80 to above, not
shown.
Figure 22 shows an alternate way by which to plot mortality rates for each individual age
group as a function of the birthyear cohort. This is relatively useful when assessing any potential
unknown changes in disease classification or treatment. The template contains such plots for the
following age groups (0.5, 3, 12.5, 22.5, 32.5, 42.5, 52.5, 62.5, 72.5, 82.5, 92.5, and 102.5).
For example, mortality by diabetes mellitus among 52.5 year old European Americans
suddenly dropped for the birthyear cohort of 1877 (Figure 23). The exact time point of this drop
corresponds to the year 1877 + 52 = 1949. This drop is actually not due to the advent of insulin,
but is actually a change in the classification of death by diabetes. Prior to 1949, deaths by heart
disease among the diabetic were reported as being due to diabetes. Since 1949, deaths by heart
disease among the diabetic are reported as being due to heart disease instead.
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Fig. 14: MORTALITY TEMPLATE: Raw mortality data
Number of deaths by all forms of neoplasms, reported by year of death and age at death. Age at
death corresponds to the years since birth.
Mortality by all under y 2 under 5-
NeoLsTotl one year ar 2 r years 4 s years 5-9
excludes leukemia 1900-1909
1900 7,451 20 15 14 12 8 69 31
1901 7,857 20 10 16 13 14 73 29
1902 7,921 21 8 16 15 8 68 31
1903 8,574 18 13 13 15 10 69 33
1904 8.994 26 9 9 17 11 72 29
1905 9,326 23 9 12 10 13 87 33
1906 11,281 27 11 14 20 13 85 43
1907 11,940 21 19 22 15 7 84 29
1908 13,163 20 14 23 16 11 84 31
1909 15.046 31 12 20 20 18 101 45
1910 17,057 45 28 49 24 30 174 73
1911 18,189 47 37 28 33 20 165 73
1912 19,175 49 39 30 46 38 200 108
1913 20,771 38 38 44 43 31 194 103
1914 21,515 42 32 50 41 28 193 108
1915 22,716 56 45 58 36 42 235 123
1918 24,185 50 55 35 48 39 227 117
1917 25,470 66 50 42 40 35 233 140
1918 26,705 62 62 55 41 38 258 108
1919 28,551 46 52 44 58 42 242 129
1920 30,457 59 67 44 49 44 263 141
1921 32,246 72 49 61 63 51 298 139
1922 34,780 55 72 86 53 55 301 140
1923 37,546 76 72 68 63 48 327 178
1924 39,410 87 64 79 85 60 335 226
1925 41,267 57 75 82 85 57 358 209
1926 43.590 60 81 87 81 54 363 220
1927 44.911 75 66 88 89 66 364 228
1928 48,364 77 74 90 83 66 390 255
1929 49,395 64 61 93 81 78 377 248
1930 52,590 76 70 94 109 100 449 322
1931 53,797 72 72 107 103 95 449 314
1932 58,107 78 88 103 92 89 430 335
1933 59,939 76 78 93 106 106 459 336
1934 62,807 94 100 85 112 108 499 364
1935 64,515 74 86 109 105 87 461 331
1936 67,223 90 88 84 110 92 484 382
1937 68,993 95 93 124 91 122 525 383
1938 71,506 88 114 121 118 106 547 358
1939 72,603 107 108 122 101 84 522 329
1940 75,674 126 100 130 132 114 602 372
1941 76.583 122 120 156 141 116 655 371
1942 78,026 86 104 132 146 99 567 340
1943 79,744 106 120 148 148 114 636 371
1944 82,270 105 147 158 149 98 653 401
1945 85,725 106 127 168 161 134 696 401
1946 88,518 126 128 158 194 139 745 405
1947 933276 126 130 182 178 176 792 457
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Fig. 15: MORTALITY TEMPLATE: Raw population data
Population values are estimated as in the following example.
Number of (5-9) years olds during the year 1900 = Number of (5-9) year olds alive at the
beginning of 1901 plus the number of (5-9) year olds who died during 1900.
under ~ne10-14:
Allages indr " 14years 5-9 yearsyear years
Agc-
Year 'I
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1817
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
10.460,870
10,665,737
10,878,683
11,101,311
11,33 1.93 1
11.544,247
18.003,611
18,390,526
20.569,525
23,441,331
25,257,297
28,552,932
28,980,075
30.522,033
30.407,088
30,824,47 1
32,387,588
33.778,300
38,510,413
39,668,929
41,056.604
41,726,529
43,689.132
45,682,432
46,742.009
48,189,643
49,113,238
50.531,264
53.338,0 13
54,331,625
54,812.075
54,904,077
55, 196.733
57,941,007
58,326,8 12
58,691,560
59.089,274
59,436.86 1
59.756,78 1
287.058
282,744
286,992
289,733
296,890
302,024
459,898
465,091
511,843
570,773
612,104
680,630
683,660
722,358
708,339
708,772
751,595
781,908
876,431
882,985
800,193
891,656
918,611
942,020
944,833
961,916
963,507
970,783
1,017,317
1,0 16,389
1,004,826
989.703
975,360
1.0 10,709
1,006,574
996,520
988,752
979,024
864.149
873,499
887,406
899.797
913,632
926,504
1,459,915
1,483,490
1,653,526
1,875,114
2,032,574
2,333,125
2,371,144
2,523,915
2,531,764
2,568,193
2,740,991
2.876,930
3,277,669
3,383,178
3,444,806
3,439,60 1
3,555,738
3,655,681
3,684,900
3.755,489
3,768,758
3,826,665
4,004,606
4,019,419
3.976.044
3,933,968
3,891,387
4,036,474
3,999,671
3,960.380
3.922,8 15
3.884,276
1,026,670
1,037,319
1,047,972
1,058,326
1,068,475
1,673,780
1,692,439
1,885,327
2, 127,683
2,316.035
2.679, 178
2,732.320
2,922,057
2,938.011
2,990,802
3,196,401
3,370,799
3,853,010
4,014,675
4,143.446
4,201,012
4,404,056
4,583,457
4,881,407
4,831.932
4,906,733
5,053,207
5,351,101
5.435,995
5,341.675
5,247,745
5,153,275
5.304.291
5,212,729
5. 120.795
5,028,650
4,935.999
969,298 3,845,835 4.843,149 5,281,014 5,487,781 5,089,172
931,529
946,249
960,987
976,354
991,520
1,006,181
1,572,832
1,596,436
1,788,456
2,029,548
2,199,245
2,535,302
2,577,040
2,746,011
2,753.247
2.795.934
2,976,141
3,133,014
3,574,694
3,722,422
3,858.337
3,927,333
4,134,500
4,320,789
4,429,046
4,578,456
4,663,583
4,816,412
5,109,435
5,202,772
5,181,809
5,160,981
5,140,168
5,360,516
5,345,115
5,329.82 1
5,313,984
5,297,687
15-19
years
910,184
931,251
952,435
974,149
995.695
1,016,781
1,597,082
1,631,674
1,835,225
2,099,450
2.235.926
2,527,375
2,532,031
2,650,155
2,616,888
2,821,253
2,740,348
2,840,241
3,207,291
3.283.407
3,432,117
3,520,054
3,729,818
3,931,657
4,057,976
4,219,664
4,327,546
4.497.054
4,804,729
4,924,914
4,957,311
4,990,418
5,022,606
5,296,955
5,335,696
5,374,288
5,413,137
5.45 1,101
20-24
years
951,874
976,991
1,002,038
1,027,616
1,053,043
1,078,124
1,706,471
1,751,100
1,972,997
2,253,682
2,397,635
2,657,156
2,653,275
2,749,560
2,683,965
2,677.832
2,766,649
2,838,869
3,193,806
3,240,993
3,363.783
3,427,614
3,599,427
3,770,520
3,867.911
3,993,125
4,076,399
4,205.383
4,461,822
4,554,467
4,587,550
4,620,327
4,652,830
4,907,445
4,944,'722
4,981,643
5,018,874
5,054,650
84
Fig. 16: MORTALITY TEMPLATE: Calculated age-specific cancer mortality rates by year of
birth.
(Reported per 100,000)
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Fig. 17: MORTALITY TEMPLATE: Calculated age-specific cancer mortality rates by year of
birth w/ formulae
(Reported per 100,000)
Example: Calculated cancer mortality rate of 0.5 year old (under 1 year) European American
males born in 1900 is equal (=) to number of deaths in this age group during the year 1901 (cell
reference: 'Raw Data (EAM)'!C4 as shown in Figure 14) divided (/) by the equivalent
population in 1901 (cell reference: 'Population (EAM)'!C4 as shown in Figure 15) reported per
100,000 (*10^5).
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Fig. 18: MORTALITY TEMPLATE: Calculated age-specific cancer mortality rates by decade of
birth.
(Reported per 100,000)
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Fig. 19: MORTALITY TEMPLATE: Calculated age-specific cancer mortality rates by decade of
birth w/ formulae
(Reported per 100,000)
Example: Calculated cancer mortality rate of 0.5 year old (under 1 year) European American
males born in the 1900s is equal (=) to the sum of all deaths among 0.5 year olds born in the
occurring in the reporting years 1901-1910 (cell references: SUM('Raw Data (EAM)' !C4:C13)
as shown in Figure 14) divided (/) by the equivalent population in 1901-1910 (cell references:
SUM('Population (EAM)'!C4:C13) as shown in Figure 15) reported per 100,000 (*10A5).
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Fig. 20: MORTALITY TEMPLATE: Age-specific mortality curves by decade of birth.
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Fig. 21: MORTALITY TEMPLATE: Age-specific cancer mortality curves by decade of birth
(up to age 35).
Reveals occurrence of childhood cancers.
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Fig. 22: MORTALITY TEMPLATE: Cancer mortality trends for 52.5, 62.5, and 72.5 year olds
as a function of birthyear cohort.
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Fig. 23: Mortality trends for 52.5, 62.5, and 72.5 year olds as a function of birthyear cohort for
diabetes
Plot reveals drop-off in mortality rates by diabetes corresponding to the reporting year of 1949.
Deaths by heart disease among diabetics were reported to be due to diabetes prior to 1949, but
due to heart disease since 1949.
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Fig. 24: Mortality trends for age groups > 50 years as a function of birthyear cohort for infectious
and parasitic diseases
Plots reveal: drop-off in mortality rates by infectious diseases corresponding to improving
sanitation methods during the last two centuries, drop-off in mortality rates by infectious diseases
after the advent of antibiotics (drop after mortality rates had reached a plateau), and the increase
in mortality among the elderly during the more recent years.
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Alternately, mortality data by infectious diseases plotted in this method (Figure 24) reveals
the time point of the advent of antibiotics (the decrease in mortality after mortality rates had
appeared to plateau). Furthermore, it reveals that prior to the advent of antibiotics, mortality by
infectious diseases had dramatically decreased, presumably due to improvements in sanitation
systems. Curiously, they also reveal that mortality by infectious diseases has actually increased
among the elderly in the last decade, due to unknown reasons.
3.2.3.1 Colon Cancer Mortality Rates
Figures 25 and 26 summarize the age-specific intestinal cancer mortality records for the
birth years between 1840 and 1930 for European and Non-European-Americans respectively.
Intestinal cancer records are available since 1930, as opposed to 1958 for colon cancer when
specific diagnoses became available. Intestinal cancer data is used herein to approximate colon
cancer deaths; deaths by cancer of the small intestine represented only 3% of the total number of
deaths from intestinal cancer in the period during which colon cancer was specifically recorded
(U.S. Department of Health and Human Services (Vital Statistics of the United States. 1958-
1992).
3.2.3.2 Lung Cancer Mortality Rates
Figures 27 and 28 summarize the age-specific intestinal cancer mortality records for the
birth years between 1820 and 1990 for European and Non-European-Americans respectively.
One notes that there are no apparent differences between populations of European or non-
European, predominantly African, ancestry with regard to the historical record of age-specific
lung cancer mortality rates.
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Fig. 25: Intestinal cancer age- and birthyear- specific mortality curves
(EAM - European-American males, EAF - European-American females)
(Data recorded 1930-1992)
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Fig. 26: Intestinal cancer age- and birthyear- specific mortality curves
(NEAM - Non-European-American males, NEAF - Non-European-American females;
primarily of African-American descent)
(Data recorded 1930-1992)
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Fig. 27: Lung cancer age- and birthyear- specific mortality curves
(EAM - European American males, EAF - European American females)
Date recorded (1930-1992)
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Fig. 28: Lung cancer age- and birthyear- specific mortality curves
(NEAM -Non-European American males, NEAF -Non-European American females;
primarily of African descent)
Data recorded (1930-1992)
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3.2.4 Survival Rate Data (Cancer)
For each birth year cohort h and each age t there is an associated relative 5-year survival
rate for cancer, S(h,t). S(h,t) represents the probability of surviving those causes linked to that
cancer. (Eq.2)
S(h,t) = (recorded cancer survivors at age t+5, diagnosed at age t)
(recorded diagnoses of cancer at age t) x (survival rate for all forms of death, age t + 5)
Relative survival rates correct for the fraction of individuals diagnosed with cancer who may
have died of an unrelated form of death within the 5-year period after diagnosis.
Eisenberg et al (1968) have summarized the age-specific relative survival cancer rates for
1935 to 1959 within the state of Connecticut for both males and females up to ages 65-74, and
for ages greater than 75. The NCI Monograph No. 6 (1961) summarized similar relative survival
rates for 1950 to 1957 for both males and females, including both a larger set of hospital
registries, and relative survival rates for untreated individuals. The Cancer Patient Survival
Report Number 5 (1976) extended this work to the period of 1950 to 1972, including survival
rates for patients of both European and African descent. Ries et al (1983) similarly reports the
relative survival rates for the period of 1973 to 1975 by age, gender, and race. Last, the SEER
Cancer Statistics Reviews (1993, 1997, 1999) have recorded the 5-year relative survival rates for
1983 through 1991.
Reported survival rates do not account for those deaths of individuals first diagnosed with
cancer at the time of death. The percentage of 'incidences at autopsy' is 1-2% for the 1990s
[personal, communication, L.A.G. Ries, SEER]. For diagnostic years 1935-79 the percentage of
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'incidences at autopsy' for the state of Connecticut was generally 1-3%, but was shown to
increase as a function of age (Heston et al, 1986).
3.2.4.1 Survival Data - Colon Cancer
Aside from the survival rate reports listed in Section 3.2.4, Beart et al (1995) have
reported the age-specific relative survival rates for 1983, although gender and race were not
specified. Beart's overall survival estimates for the early 1980s were about 10% lower than as
reported by SEER (1999). Consequently for the 1980s, SEER's reported survival rates were
decreased by 5% to represent the average reported survival rates of SEER and Beart et al (1995).
Colon cancer survival rates are approximately constant between ages 40 and 75 in recent
decades (Ries et al, 1983; SEER 1993, 1997, 1999). However, Beart et al (1995) extended the
survival data to 80 years and found survival rates decreased significantly from 70-79 and >80
years of age. Survival rates appear to decrease even further in extreme old age when colon
cancer is more often detected in an advanced stage. In persons over 80 years of age, only 2.4% of
all colon tumors were treated by surgery and chemotherapy, compared to 26.3% for persons less
than 50 year olds (Beart et al, 1995). As an estimate, survival rate for untreated tumors of 75+
year olds were used to estimate survival rate of centenarians, 3-4% (NCI Monograph No. 6,
1961).
Figure 29 illustrates survival rates for European-American females born between the
1840s and 1930s. The data recorded by year of diagnosis in Figure 29 are converted into age-
specific relative survival values by year of birth. Where values were unknown, estimates were
interpolated. Survival rates reported for the age ranges "under 45" and "above 75", are plotted at
ages 40 and 80, respectively, as these are approximately the average ages of individuals dying of
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Fig. 29: Survival rates - Colon Cancer
Age-specific relative survival rates for colon cancer among European-American females
(a) by year of diagnosis and (b) by year of birth.
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colon cancer in these age groups. S(h,t) increases steadily with historical time which creates a
steady age-specific increase in -S(h,t) for any particular birth year cohort, but which still
decreases markedly in extreme old age.
Table 1 summarizes the relative survival rates by year of diagnosis, using averages for
those years for which more than one value was available. Averages were weighted according to
the number of patients examined in each study. To estimate relative survival rates for Non-
European-Americans, we used reports for African-American survival rate data set for the 1950s
through the 1990s, as African-Americans comprised more than 75% of the Non-European
population. Estimates for the 1940s and 1930s cohorts of Non-Europeans were interpolated
assuming that the change in the survival rate for European-Americans was proportional to the
change in the survival rate of Non-European-Americans during this period. No estimates were
allowed to drop below the reported survival rates for untreated individuals.
1: Summary of the relative survival rates
Ages: 0-44 45-54
0.58 0.62
0.59 0.65
4 0.51 0.54
0.55 0.53
Ages: 0-44 45-54
0.49 0.59
0.58 0.56
4 0.44 0.49
0.52 0.54
Ages: 0-44 45-54
0.47 0.48
0.58 0.50
10.42 0.46
0.53 0.50
by year of diagnosis
55-64 65-74
0.65 0.66
0.62 0.64
0.55 0.52
0.56 0.53
55-64 65-74
0.59 0.60
0.56 0.57
0.49 0.47
0.53 0.43
55-64 65-74
0.48 0.48
0.50 0.48
0.45 0.38
0.45 0.50
Table
1990s
EAM
EAF
NEAM
NEAF
1980s
EAM
EAF
NEAMV
NEAF
1970s
EAM
EAF
NEAM
NEAF
75+
0.59
0.60
0.45
0.46
75+
0.57
0.55
0.37
0.41
75+
0.44
0.46
0.32
0.37
100+
0.03
0.04
0.03
0.04
100+
0.03
0.04
0.03
0.04
100+
0.03
0.04
0.03
0.04
1960s A
EAM
EAF
NEAM
NEAF
1950s A
EAM.
EAF
NEAM
NEAF
1940s A
EAM
EAF
NEAM
NEAF
1930s A
EAM
EAF
NEAM
NEAF
Untreated*
Males
Females
,ges:
ges:
0-44
0.50
0.50
0.29
0.36
0-44
0.42
0.46
0.28
0.44
0-44
0.27
0.34
0.18
0.30
0-44
0.30
0.25
,ges:
Lges:
0.20
0.22
Ages: 0-44
0.00
0.11
* Reported as Other and Untreated (NCI Monograph No. 6, 1961).
3.2.4.2 Survival Data - Lung Cancer
Survival of lung cancer approaches 5% at fifteen years after diagnosis, with a 15%
probability at five years. Survival is pro tempore approximated as zero.
3.2.5 Estimates of Error in Reported Data
It is obvious that the numerator defining OBS(h,t) in Equation 1 will be affected by the
probability that an actual cancer mortality is recorded as such. It is equally obvious that there are
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no records of inadequate diagnosis per se. Improved estimates can be made by accounting for the
number of deaths in a cohort without any adequate diagnosis as a function of age, which
represents a relative marker of the potential accuracy of the data as a function of the reporting
year and age group. For instance, in centenarians the percentage of deaths with vague diagnoses
was about 20% in the 1930s for European-American males, decreasing to less than 5% by the
1950s.
Inspection of the historical record for the number of deaths with vague or unrecorded
diagnoses for all ages, genders, and ethnic groups, for each birth year cohort analyzed, creates a
matrix for each demographic group defining an estimate of the probability of accurately
recording the cause of death as the function R(h,t).
(Eq. 3)
R(h,t) = recorded deaths from specified causes from birth cohort h at age t
all recorded deaths from birth cohort h at age t
Figure 30 shows the percentage of all deaths with vague diagnoses plotted as a function of the
birth year for several age groups of European-American males. The assumption here is that the
proportion of cancer deaths among all deaths with unrecorded diagnoses is about the same as the
proportion of cancers among all deaths with recorded diagnoses.
Application of this assumption still underestimates the true cancer mortality fraction.
Since about 50% of present deaths are recorded as due to cardiovascular or cerebrovascular
causes, small overestimates in these diagnoses would lead to large underestimates of mortality
from any other specific disease.
Furthermore, a diagnosis of cancer may be in error, particularly if a detected mass were a
secondary tumor from another organ. This kind of error has been addressed in a number of
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Fig. 30: Percentage of all deaths with vague diagnoses
European-American males, ages 50-54, 75-79, and 90-94 as a function of their year of birth.
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studies in which pathological samples were reviewed. Colon cancer was actually found to be
somewhat over-reported in death certificates primarily because of inclusion of a portion of rectal
tumors (U.S. Department of Health and Human Services, 1982b). Lung cancer mortality rates
were reported to be "fairly accurate" as tumors had both high detection and confirmation rates.
3.2.6 Mortality Data Adjusted for Historical and Age-Specific Survival Probability and
Reporting Error - Colon and Lung Cancer
Combining available mortality data, survival data, and vague diagnoses data improve
upon the estimates of actual occurrence rates of colon cancer. The amended data set is of
sufficient accuracy to permit application of mathematical analyses, but exploration of the effect
of errors in survival or reporting data on the estimation of parameters (Section 4.1.3) will be
considered.
Figures 31 and 32 recast the data of Figures 27 and 28 using all of the estimates of S(h,t)
and R(h,t) with OBS(h,t) to define a new function OBS*(h,t).
(Eq. 4) OBS*(h,t) = OBS(h,t) + [R(h,t) (1 - S(h,t))]
These figures are estimates of what colon cancer mortality rates would have been in a
world with accurate diagnosis and recording but no therapy of any kind. In a sense it is a
reconstruction of "incidence" data in a world with accurate diagnosis but without effective
therapy.
In the case of lung cancer, since R(h,t) is approximately 1 for the years of death reported
and S(h,t) is approximately zero, OBS*(h,t) - OBS(h,t).
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Fig. 31: Colon cancer age- and birthyear- specific mortality curves adjusted for historical
changes in underreporting and survival rates (European-Americans)
OBS*(h,t) = OBS(h,t) + [R(h,t) (1 - S(h,t))]
122
EAM
0b
U,
av
300
200
100
0
80 90 100 110
EAF
------ 1840s
------- 1860s
-- X 1880s
--- 0-- 1900s
--- A-- 1920s
- 1850s
--- 1870s
- -- 1890s
-- 4-- 1910s
--- A-- 1930s
0 10 20 30 40 50
Age
60 70(years) 80 90 100 110
oc
400
Birth Year
------ 1840s 4 1850sO
Ul)
0 10 20 30 40 50 60 70
Age (years)
3J'JV
300
250
200
150
100
50
0
rnn
v
m
123
Fig. 32: Colon cancer age- and birth year- specific mortality curves adjusted for historical
changes in underreporting and survival rates (Non-European Americans)
OBS*(h,t) = OBS(h,t) + [R(h,t) (1 - S(h,t))]
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The importance of accounting for survival and reporting errors is illustrated by
comparing the function OBS(1880s,t) for the EAM cohort of Figure 25 to the function
OBS*(1880s,t) for the same cohort in Figure 31. In the former, OBS(h,t) 'appears' to reach a
stable maximum plateau by age 90, but in the latter, OBS*(h,t) shows a clear maximum
declining through age 102.5. A similar effect may be noted by comparing the NEAF cohort of
OBS(1870s,t) to OBS*(1870s,t).
3.2.7 Prevalence of Cigarette Use.
Prior to the 1880s, tobacco was predominantly chewed or smoked in pipes. Cigarettes
became inexpensive and widely available after the 1880s with the invention of the automatic
cigarette roller by Albert Bonsack (http://www.tobacco.org/History/Tobacco_History.html, "A
Capsule History of Tobacco.")
Figure 33 shows the maximum cigarette-smoking fraction and the average age at which
smoking started for each birth decade cohort since 1881-1890 as collected and organized by
Harris (1983). Some smokers within each cohort began smoking very late in life or ceased
smoking in middle age. Thus this maximum value is perforce an overestimate of the
continuously smoking population. For those birth cohorts that began smoking in adolescence,
lung cancer death rates rose rapidly at about age 50 (Figure 27), increased approximately linearly
into old age, reached a distinct maximum and declined in extreme old age. In earlier birth cohorts
that did not start using cigarettes until later in adulthood, lung cancer death rates also show a
marked rise, but considerably later in life as may be seen by inspecting Figures 27 and 28.
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Fig. 33: Smoking prevalence in the U.S.
Maximum US cigarette smoking fraction (circles) and average age at which smoking habit was
adopted (triangles), organized by birth decade cohort. Male and female values are represented by
closed and open markers respectively. The fraction of lifetime smokers is perforce somewhat
lower than the maximum values.
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3.2.8 Histopathology of Lung Tumors.
Zheng et al (1994) and Thun et al (1997) have independently examined the historical
changes in lung cancer incidence by histologic type in the state of Connecticut. Age and gender-
specific mortality rates for each of the three predominant histopathologic forms of lung cancer,
squamous cell carcinoma, small cell carcinoma and adenocarcinoma are summarized in Figure
34. These data are reproduced from an earlier publication (Thun et al, 1997) and from additional
data kindly put together and supplied by Dr. Thun. Additionally, bronchioloalveolar
adenocarcinomas rates were shown to remain relatively constant (Zheng et al, 1994).
About 75% of all lung cancer cases of specified histology were squamous cell
carcinomas for the earliest male cohort studied (birth year cohort - 1880s) but this fraction has
decreased considerably in ensuing birth decade cohorts. Among females, who as a group showed
an increase in smoking prevalence since the birthyear cohort of the 1910s, squamous cell
carcinoma was never greater than 50% of all reported lung tumors and this fraction declined
from a maximum in the birth cohort of the 1910s to the most recent cohort analyzed. Since only
2-3% of women born in the 1880s smoked (Harris, 1983), most lung cancer cases in this female
cohort would have been expected to have occurred among the nonsmoking fraction. From these
data and others it has been established lung cancer cases among nonsmokers are predominantly
adenocarcinomas. (Wynder and Berg, 1967; Cooper et al, 1968; Vincent et al, 1965; Ernster,
1994) While the literature clearly defines the histopathologic spectrum of lung cancers, the
position of tumors recorded with regard to position in the lung is not as well defined. Tumors of
"mixed" histopathology are noted but we have not been able to ascertain, for instance, the
fraction of adenocarcinomas or tumors of mixed histopathology that arise in the tracheal
bronchial epithelium as opposed to the peripheral bronchiolar epithelium. Assuming that
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Figure 34. Age-specific lung cancer incidence rates organized by birth decade cohorts and
histopathologic form of cancer
(Connecticut rates, Thun et al, 1997)
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adenocarcinomas are all in the peripheral bronchiolar epithelium appears to be unjustified. Risk
parameters for these two epithelial cell populations will be calculated using a range of estimates
of the fraction of lethal lung tumors arising in the two lung regions.
3.2.9 Smoking Cessation - Lung Cancer Incidence in Former Smokers
Peto et al (2000) have collected and organized incidence data for lung cancer as a
function of time after smoking cessation (Section 4.2.9). The data suggest that while smoking
cessation reduced the lifetime risk of developing lung cancer in former smokers, incidence rates
did not decrease to levels observed for nonsmokers. The lifetime risk for lung cancer in a former
smoker is thus revealed to be not only a function of the time since smoking was ceased, but also
a function of the duration that individuals smoked. Analysis of Peto et al's data by the three-
stage carcinogenesis model can test the hypothesis that smoking cessation returns the individual
to the lifetime risk and physiological parameters of nonsmokers soon after smoking cessation
and that residual elevated risk has been created by establishment of preneoplastic colonies during
the period of cigarette use.
3.3 KNOWN PHYSIOLOGICAL PARAMETERS
3.3.1 Number of cells at risk
3.3.1.1 Number of cells at risk - Growth of child
The volume of an organ is assumed to increase proportionally to the mass of an average
individual. Since the colon is approximately a cylindrical tube and the lung is approximately a
series of tubes, the number of colonic and bronchial epithelial cells is thereby proportional to
body mass to the two-thirds power.
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Figures 35a and 35b below show the masses of average males and females respectively as
a function of age. For both males and females, body mass increases exponentially from age 1.5
years to 14.5 years in females and 16.5 years in males. A higher constant rate is obtained for
growth between birth.and age 1.5 years.
From Figures 35a and 35b, the growth rates of males and females can be estimated from
the slope of the log2 of the mass of average individuals for the age intervals 0-1.5 and 1.5-14.5
for females and 1.5 to 16.5 for males. These estimated growth rates for mass were then
multiplied by 2/3 to obtain estimates for the growth rates of colonic and lung epithelial cells,
representing these organs as tubular.
Ages Growth rate (mass) Growth rate (colonic, lung cells)
Males
Females
0-1.5
1.5-16.5
0-1.5
1.5-16.5
1.23
0.159
1.17
0.167
0.82
0.106
0.78
0.111
The number of colon and lung epithelial cells as a function of age, Na, can therefore be written as
a function relative to the number of colonic epithelial cells in an adult, Nmax. For males, the
number of cells as a function of age is:
(Eq. 5)
Na, males
Nmax = cells in adult organ
0.106(16.5-a)
= Nmax + 2
0.106(15) + 0.82(1.5 - a)
max + 2
a > 16.5
1.5 < a 5 16.5
0 < a 5 1.5
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Fig. 35: Mass of males (a) and females (b) as a function of age
(Hamill et al, 1979)
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The number of cells in a female follows by similar reasoning.
One should also account for the fact that the weight of an average female is about 80%
that of a male at age 18 (Hamill et al, 1979).
3.3.1.2 Number of Cells at Risk - Colon
The number of cells in an adult colon can be calculated as follows. On average, the cross-
sectional count of the number of cells is 262 along the 'V-shaped' crypt. The number of cells
along the circumference of the top of the crypt is approximately 40-60 cells. Assuming a crypt
has a cone-like shape, then the number of cells per crypt is:
262 6550 cells
~ 50 --
2 crypt
where the size of a cone is about half of that of a cylindrical tube. Additionally, the number of
crypts in any direction is about 100 crypts per cm. leading to:
crypts _ 100 crypts 100 crypts 104 crypts
2area cm cm cm
The colon can be approximated to be a cylinder of 130 cm in length and 10 cm in circumference
leading to a surface area of 1300 cm 2. Therefore the total number of cells in the colon is:
cells crypts x surface area = 6550 .104 -1300 = 8.5 x 1010 cells
crypt area
Correcting for the different sizes of males and females leads to an estimate of 9.1 x 1010 colonic
cells in an adult male colon and 7.9 x 1010 in an adult female.
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3.3.1.3 Number of cells at risk - Lung
The number of total epithelial cells down to the sixth bronchial bifurcation estimated
from post mortem dissections is about 2.4 x 108 cells. (Dr. Xiao-Cheng Li-Sucholeiki,
unpublished) Most squamous cell carcinomas and small cell carcinomas are reported to arise in
this region (Berg, 1970; Walter and Pryce, 1955a, 1955b). By calculations from histological
preparations and the anatomy of the bronchial-alveolar region of the lung some 2.8 x 1010
epithelial cells line the bronchial tree from the sixth to the approximately 24t h bifurcation for the
most extensive "trees" before the alveolar ducts and alveoli (Kuhn, 1995; Prodi and Mularoni,
1984). These numbers are employed in the models of carcinogenesis in the tracheal bronchial
and bronchiolar regions of the lung respectively. The number of epithelial cells in the alveolar
ducts and alveoli approaches 8 x 1011 but the low number of reports of tumors of alveolar origin
indicates that these cells are at negligible risk of giving rise to tumors (Zheng et al, 1994).
3.3.2 Cell Kinetic Rates
Expression of mutation rates per cell division further requires knowledge of in vivo cell
kinetic parameters.
3.3.2.1 Cell Kinetics - Colon
To count the number of mitotic events and cells undergoing apoptosis in normal tissue,
precancerous lesions, and carcinomas from a long series of observations from many patients,
slides can be prepared in either of two ways. For observation of mitotic figures, tissues are
stained with eosin and hematoxylin. Mitotic figures can then be observed with a trained eye
under a high-powered microscope. Apoptotic figures are observed after in situ labeling, a process
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which identifies DNA with nuclear fragmentation, a feature characteristic of early apoptosis.
First, microscope slides containing slices of paraffin-embedded tissue are heated to remove the
surrounding wax. The tissue slices are then treated with Proteinase K to digest cellular proteins.
Biotin-labeled deoxycytosine and deoxyadenosine triphosphates are combined with unlabelled
deoxythymidine and deoxyguanosine triphosphates and added to the slides along with
polymerase I Klenow fragment. The polymerase uses the dNTPs to fill in gaps in the DNA
"ladder" that is a hallmark of apoptosis. After a short incubation period in a buffer (containing
Tris-HC1, magnesium chloride, bovine serum albumin and mercaptoethanol), hydrogen peroxide
and methanol are added to block endogenous peroxidase. Horseradish peroxidase conjugated to
streptavidin is then applied to the slides and binds to incorporated biotin-labeled dNTPs. A
chromogen, diaminobenzidine (DAB), is then applied to turn the horseradish peroxidase a color
(brown) in order to visualize the conjugated and incorporated nucleotides. Under a high-powered
microscope, apoptotic bodies can simply be counted by observing the morphologically small,
brown pigmented cells.
Apoptotic and mitotic cell counts were done by Dr. E.E. Furth and P. Belair of the
University of Pennsylvania Medicine School. The observations, expressed as events per 100 cells
observed in the crypts, adenomas or carcinomas, are summarized in Figure 36. Apoptotic and
mitotic counts allow estimation of division and death rates by the following transform:
(Eq .6)
rate = (mitotic or apoptotic count) / (mitotic or apoptotic time expressed in years) x
2 if normal tissue
.025 mito. 1 24 hr. 365 days 2 = 2  mito.i.e., normal a = -.2 =.2.92
100 1.5 hr. 1 day 1 yr. yr.
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Fig. 36: Apoptotic and mitotic cell counts of colonic tissue
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Therefore,
Division Death
Normal tissue (T): 2.92 2.92
Adenoma (c, 1): 8.92 -8.92
Carcinoma (ac, 3c): 29.2 -8.92
Mitotic times were estimated from Wright et al (1973) who reported that the duration of
mitosis for the small intestine is 1 - 1.5 hours in vivo. Likewise, Weinstein et al (1973) found
that the mitotic time for the human jejunum is 1.4 to 2.2 hours in vivo. (No data were found for
normal colon). The lengths of mitosis and apoptosis may additionally differ among normal
transition cells, adenoma and carcinoma cells. Treatment herein assumes they are in fact the
same for these three cases. In normal tissue, only half of the cells can undergo division, since one
half are non-dividing terminal cells. The turnover rate of normal colon epithelial cells was
therefore additionally adjusted by a two-fold factor.
Adenomas have higher death and division rates, both about 9 per year. Adenomas grow
slowly so the precision of such observations is not sufficient to detect a small difference between
division and death rates. Small carcinomas show an identical death rate to adenomas, but the
division rate is increased to about 30 per year. A difference between division and death rates of
about 20 yr-1 implies a doubling time of about 18 days, a rapidly growing tumor.
3.3.2.2 Cell Kinetics - Lung
Several groups have reported mitotic and apoptotic indices in normal bronchial epithelial
tissue, in presumptive preneoplastic colonies identified as "dysplastic or carcinomas in situ," and
in macroscopic lung tumors.
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For normal bronchial epithelium, Dr. Elena Gostjeva (Kiev Biotechnology Institute,
personal communication) observed a mitotic index of about approximately 0.05% in cells
sampled from the tracheal bronchial epithelium. This value leads to an estimate of 5.7 cell
divisions per year among stem or transitional cells assuming a duration of mitosis of 1.5 hours in
the lung. 5.7 represents the maintenance turnover rate, deaths and divisions per year, designated
as "4" in the equations describing mutation initiation rates per cell year.
Reports by Tormanen et al (1999) and Cemerikic-Martinovic et al (1998) provide
apoptotic indices of dysplastic lesions, carcinomas in situ, and carcinomas of the lung. These
data coupled with assumptions about the length of observable mitoses and apoptoses (Staunton,
1995) leads to an estimate of the rate of cell divisions and deaths of approximately 13 events per
cell year for potentially preneoplastic lesions. This serves as the approximate value of both "a"
and "3", respectively the division and death rates in the equations describing survival
probabilities and growth rates in preneoplastic lesions. Apoptotic indices for early Grade I
tumors lead to the estimate of a death rate of 28 and a division rate of 42.2 per cell year. These
values are used as the estimates of the rate of cell division "ac", the division rate, and "Pe", the
death rate, in lung tumors. From these, the estimated fractions of newly initiated cells which
survive to form preneoplastic colonies and promoted cells which survive to form tumors,
respectively [(a - 3) / a] and [(ac - fc) / a0 ], are derived (Moolgavkar, 1990b).
3.4 MATHEMATICAL DEFINITIONS
3.4.1 Primary (Lifetime) Risk Factors vs. Secondary (Accelerating) Risk Factors
Here the term "primary risk" requires careful definition. Supposing that there are persons
who by virtue of their genetic inheritance and environmental experience are at risk of cancer,
142
a subpopulation at primary risk for cancer would thereby exist. It is possible that the entire
population has the same genetic risk but not the same environmental experience. Conversely, it is
possible that a common environmental experience is shared by all persons, but only a fraction
carry an inherited risk factor. The key postulate is that persons who do not inherit and experience
these primary risk factors cannot develop cancer in a full lifetime of up to, say, 125 years.
Primary genetic and environmental risk factors for sporadic colon cancer have not yet been
identified and are, therefore, hypothetical. (The primary genetic risk factors for two forms of
familial colon cancer, FAPC and Lynch syndrome (HNPCC), are an inactive allele of the APC
gene or of a mismatch repair gene respectively) (Kinzler et al, 1991; Leach et al, 1993).
Furthermore it is not clear whether cigarette smoke acts as a primary risk factor, essential in the
development of lung cancer, or rather accelerates the onset of lung cancer among individuals
already independently at primary risk for cancer, or possibly both.
Within each subpopulation at primary risk, variations in mutation rates and cell kinetic
rates are to be expected. When an inherited condition or environmental experience lowers the
expected age of death relative to all persons at primary risk, it describes a secondary risk factor,
accelerating the process by which an individual can die of cancer. For instance, persons with
mutation rates only twofold higher than average would be expected to develop cancers much
earlier in life than persons with average mutation rates within the subpopulation sharing the same
primary risk factors, as they would accumulate all of the necessary initiation and/or promotion
events at a faster rate. Inherited or environmental factors affecting mutation rates or precancerous
growth rate would, by this definition, be secondary risk factors.
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3.4.2 Subpopulations at risk
The data of Figures 25 through 28 comprise all recorded deaths from intestinal cancers
and lung cancers. For the case of intestinal cancer, when survival and underreporting are
accounted, Figures 31 and 32, it is clear by inspection that these functions reach a maximum in
old age. This repeated observation is consistent with expectation for a population in which only
some fraction is at lifetime risk of cancer. While recognizing that other explanations for such a
maximum may be devised, the analysis herein is built on the validity of the subpopulation at risk
assumption and the certain knowledge that human populations display a high degree of genetic
heterogeneity.
These data do not, however, separate deaths in families with familial adenomatous
polyposis coli (FAPC) from deaths in families with hereditary nonpolyposis colon cancer
(HNPCC or Lynch syndrome) or from deaths by "sporadic" colon cancer. "Sporadic" cancers
themselves are undifferentiated with regard to the possibility that there are independent pathways
of genetic changes leading to several different kinds of "sporadic" cancer. Also by example, the
lung cancer mortality data of Figures 27 and 28 do not separate by squamous cell lung
carcinomas, small cell lung carcinomas, and adenocarcinomas.
There could be multiple pathways to cancer in any particular organ. The potential for and
rate of transit of these pathways would be determined by unknown but ascertainable alleles of
tumor suppressor genes and genes which effect the rates of genetic changes and cell kinetic rates
in normal tissues and preneoplastic colonies. These alleles would be distributed throughout the
entire population.
There are cancers of organs for which such a treatment assuming multiple pathways is
obviously required. Figure 37 shows OBS(h,t) for death by testicular cancer in which two
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populations are clearly evident, one with all deaths occurring between ages 15 and 40 and a
second group in which deaths begin to be observed after age 50. Mortality data lump the deaths
from multiple independent pathways together perforce.
Even if many possible pathways exist to mortal cancer inherent in a particular individual,
death can be caused by only one. Thus the number of cancer deaths must be the sum of the
deaths caused by each of the potentially multiple pathways:
(Eq. 7) OBS(h,t) = OBS 1(h,t) + OBS 2(h,t) + OBS3(h,t) + .....
In the case of colon cancer, mortality from FAPC and HNPCC families is numerically
small and occurs earlier in life than the "sporadic" form(s) of the disease. For the time being their
real but numerically small contribution to total colon cancer mortality is neglected. Some 80% of
colorectal adenomas in FAPC individuals have been found to lack an operative APC allele. It
appears, therefore, that "sporadic" colon cancers have a single, common initiation pathway, loss
of the two inherited operative alleles of the tumor suppressor gene APC (Powell, 1992). It is also
tempting to assume that the genetic change(s) needed in the promotion of a "sporadic"
precancerous cell to a carcinoma cell would be the same for all individuals, but this assumption
is without any evidentiary support and unnecessary for the analyses attempted below.
These points being noted, colon mortality data can be initially modeled as if there were
one and only one pathway to colon cancer. If there are multiple pathways to "sporadic" cancer,
the derived parameters such as the number of mutations required in initiation and promotion,
their rates and the growth rate of adenomas are, perforce, a weighted average among the multiple
pathways.
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Fig. 37: Testicular cancer age- and birthyear-specific mortality, EAM.
Evidence of independent populations at risk for cancer, or independent pathways of
carcinogenesis: one between the ages 15 and 40, and the other later in life after age 60
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Independent pathways to cancer could also represent independent causes. For example, in
the case of lung cancer, deaths could be subdivided into at least two groups: deaths caused by
smoking cigarettes, and deaths caused by all other potential risk factors. Perforce the possibility
that there exist two separate, but not necessarily mutually exclusive subpopulations at risk for
lung cancer must be considered.
3.4.3 Definition of Primary Risk Fraction
The age-specific cancer mortality for any birth year cohort, OBS(h,t), can be expressed as
a function of the primary and secondary risk factors. The fraction of the population at primary
risk within a birth year cohort, F(h,t), where "h" is the historical birth year and "t" is age, is
defined by the interaction of inherited and environmental primary risk factors:
(Eq. 8) F(h,t) = F(h,t)genetic x F(h,t)environmental
This is an important abstraction: the fraction of the cohort that would die of cancer if there were
no other causes of death. [F(h,t) is not the fraction of the cohort observed to die of cancer which
is much smaller].
Assuming that there is little historical variation in the fraction of the population inheriting
primary genetic risk factors of the nearly 100 years for which data was acquired, F(h,t)genetic
G is a constant. Thus, any real change in F(h,t) with "h" would be ascribed to historical changes
in the environmental primary risk factor, F(h,t)environmental.
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Since historical changes in environmental factors would rarely reach all of the population
simultaneously, primary environmental factors can vary significantly within the lifetimes of
some birth year cohorts, e.g. the cohorts for whom manufactured cigarettes were not available
until middle age. At. this stage of model development, however, F(h,t), will be modeled as
invariant within a birthyear cohort in the case of colon cancer, such that:
(Eq. 9) F(h,t) = Fh = G x Eh
The idea of a fraction of the population with both inherited and environmental risk factors for
cancer is logically straightforward. That fraction is represented as G Eh. But it follows that there
also exist three other distinct subpopulations: those that have neither risk factor, (1 - G) (1-Eh),
those that have the environmental but not the inherited risk, (1 - G) Eh, and those that have the
inherited but not the environmental risk, G (1-Eh). This point is illustrated in a Venn diagram
(Figure 38). Each of these subfractions would have potentially different age-specific death rates.
3.4.4 Definition of Causes of Death Given Inheritance and/or Exposure to a Primary Risk Factor
The total number of deaths within an age interval in any historical year is the sum of the
number of deaths from all possible causes. Thus, the total recorded mortality rate, TOT(h,t), is
the sum of the rate of deaths by the cancer of interest, OBS(h,t), the rate of deaths from
connected causes sharing the same primary genetic and/or environmental risk factors as that
cancer, CON(h,t), and the rate of deaths from causes independent of the primary genetic or
environmental causes of that cancer, IND(h,t). Algebraically:
(Eq. 10) TOT(h,t) = OBS(h,t) + CON(h,t) + IND(h,t)
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Fig. 38: Venn diagram of the population at primary risk as defined by genetic and environmental
risk factors.
Representation of population at risk, F(h,t), as the intersection of the population at genetic
primary risk (G) and the population at environmental primary risk (Eh)
G = F(h,t)genetic
Eh = F(h,t)environmental
G = (1 - G) = not in F(h,t)genetic
Eh = (1 - Eh) = not in F(h,t)environmental
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The historical record defines estimates of TOT(h,t) and OBS(h,t) whereas the values of CON(h,t)
and IND(h,t) are unknown.
For each of these categories of mortality there is a related age-dependent hazard function.
These probabilities are abstract, age-dependent functions:
PoBss(h,t) = probability that a person born in year 'h' having both the primary genetic and
environmental risk for the cancer of interest would die of that cancer at age 't' given no
treatment and no competing forms of death. (population at risk: G * Eh, Figure 38).
Unreported colon cancer deaths are included in this category.
PcoN(h,t) = probability that a person born in year 'h' having either primary genetic and/or
environmental risk of the cancer of interest would die by any form of death connected to
either or both of these risks other than the cancer of observation at age 't', given no
treatment and no competing independent forms of death. (populations at risk: G * Eh, G *
Eh, and G * Eh, Figure 38)
Pum(h,t) = probability that a person born in year 'h' having neither a primary genetic nor
environmental risk of colon cancer would die of any other cause at age 't'. (all
populations at equal risk: Figure 38)
OBS*(h,t) = OBS(h,t) + [R(h,t) (1 - S(h,t))] therefore represents the observed recorded cancer
mortality rate for individuals born in year 'h' who were still alive at age 't' in an abstract world
without therapeutic treatment, while PoBs(h,t) is the expected cancer mortality rate for an
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individual belonging to the group Fh who is still alive at age 't', given no medical intervention.
OBS*(h,t) will suffer from errors in reporting and diagnosis not accounted by our use of R(h,t),
but Poss(h,t), the derived mortality probability for persons in the subpopulation G * Eh,
represents all deaths by the cancer of interest whether they are diagnosed and/or reported
accurately or not in an abstract world where S(h,t) = 0.
The term for the actual probability of death from colon cancer for a person at risk of birth
year cohort h and age t would be the probability of dying of colon cancer in the absence of
treatment, Poss(h,t), multiplied by the probability that treatment has not been successful (1 -
S(h,t)). Similar arguments can be introduced for the connected and independent forms of
mortality so that the probability of not surviving a 'connected' disease would be (1 - ScoN(h,t))
and of an 'independent' form of death, (1 - SIND(h,t)).
3.5 ALGEBRAIC EXPRESSIONS
3.5.1 Probability of Still Being Alive at Age 't'
We assume that a person at primary risk of the cancer of interest can die of that cancer, a
'connected' disease caused by either the inherited and/or environmental risk factors, or a cause
independent of the primary risk factors for that cancer. This permits the writing of the explicit
statement for the probability, PNOT(h,t), that a person within the risk group Fh has not yet died
from any cause at any age between birth and age 't'.
(Eq. 11)
t
-f[PoBS(h,t) (1-S(h,t)) + PCON(h,t) (1-SCON(h,t)) + PiND(h,t) (l-SIND(h,t))] dt
PNoT(h,t) = e 0
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This expression is important because in considering the probability of death by cancer at
age 't', one required physical condition is that the individual not be already dead. In the
terminology of probability and analysis, we are writing equations for the conditional probability
of colon cancer given the fact that the individual is not dead. In considering the diminution of the
subpopulation Fh = G * Eh, we are using a probability model of sampling without replacement.
3.5.2 Observed Mortality Rate at Age 't', OBS(h,t)
3.5.2.1 Fraction at Primary Risk
As described in Section 3.4.3, a cohort is comprised of 4 subpopulations, the fraction at
risk for the cancer of interest, the fraction at risk of dying of the forms of death sharing primary
genetic, but not environmental, risk factors with that cancer, the fraction at risk of dying of the
forms of death sharing primary environmental, but not genetic, risk factors with that cancer, and
the fraction at risk of dying of only forms of death independent of all risk factors of that cancer.
The forms of death by which each subpopulation of Figure 38 is at risk are:
GEh GEh GEh GEh
OBS
CON CON1* CON2*
IND IND IND IND
* All forms of death in either CON1 or CON2 are included in the entire set of connected
forms of death, CON.
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Accounting for the effects of survival, S(h,t), underreporting error, R(h,t), and the four
distinct populations introduced above, the complete equation for the observed mortality of the
desired disease, OBS(h,t), may be written as follows
(Eq. 12)
OBS(h,t) Bh (G Eh) (1 - S(h,t)) • R(h,t) - POBS(h,t) - PNOT(h,t)
Bh [G • Eh PNOT(h,t)
t
-J[PCONl(h,t) (1 - SCONl(h,t)) + PIND(h,t) (1 - SIND(h,t))] dt
+ (1- G) Eh
. 
e
t
-J[PcoN 2 (h,t) (1 - SCON2 (h,t)) + PIND(h,t) (1 - SIND(h,t))] d t
+ G (1 - Eh), e
t
-fP (h,t) (1 - SND(h,t)) dt
0
+ (1 - G) (1 - Eh) e ]
OBS(h,t) equals the number of persons within a birth cohort 'h' who are recorded as dying of the
cancer of interest at age 't' divided by the number of all persons in the cohort still alive at that
'age.
The numerator, the number of deaths from the cancer of interest at age 't', is the product
of the number of persons in the cohort at birth, Bh, the fraction at primary risk, (G x Eh), the
fraction of individuals who develop that cancer and do not survive, (1 - S(h,t)), the estimated
fraction of these cancer deaths accurately recorded, R(h,t), the fraction expected to die of that
cancer in the absence of treatment, PoBs(h,t), and the fraction of (G x Eh) not already dead from
any cause, PNOT(h,t).
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The denominator, the number of persons still alive at age 't', is the product of the
number of persons in the cohort at birth, Bh, and the sum of the fractions of all subpopulations
still alive, adjusted by each subpopulation's specific probability of not being already dead.
Since the terms for number of persons born to a cohort, Bh, and the term accounting for
JP (ht) (1 - S (h,t)) dtsurvival from causes unrelated to the cancer risk factors, e IND IND , are present
as factors in the numerator and all terms of the denominator, they cancel out. The algebraic
elimination of the term for the probability of independent forms of death is extremely important
since there is no satisfactory way of determining its value from public mortality records. By next
dividing the numerator and denominator by e [POBs (h t) (1 - S(h,t) + PCON(h,t) (1 - SCON(h,t)) ] dt
we convert this equation into a more manageable form.
(Eq. 13)
OBS(h,t) =
(G Eh ) . (1 - S(h,t)) - R(h,t) POBS (h,t)
G .Eh
t
f[P (h,I (1 - S(h, t)) + PCON (h,t) (1 - S (h, t)) - P I (h, t) (I - SCON (h, t))] dtOBS CON CON CONI CONI
0
+(1-G)-Eh. e
t
f[P (h,t) (1 - S(h,t)) + P (h,t) (1 - S (h, t)) - P (h, t) (I - S (h,t))] dtOBS CON CON CON2 CON2
0
+ G(1 -Eh). e
t
foP (h,t) (1 - S(h,t)) + P (h,t) (1 - S (h,t))] dt
OBS CON CON
0
+ (1 - G) (1-Eh) e
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3.5.2.2 Accounting for Deaths by Causes Connected to Primary Risk Factors
"Connected" diseases are unknown and therefore there is no way of describing what
PcoN(h,t), PcoNl(h,t), PCON2(h,t), ScoN(h,t), ScoNl(h,t) or SCON2(h,t) might be. To move beyond
this clear absence of data requires an algebraic approximation.
We define the term f(h,t) as the ratio of deaths by the cancer of interest to all deaths
actually caused by either the inherited or environmental risk factors for that cancer of interest.
This fraction, f(h,t), is assumed to be constant for all ages within a birth year cohort but may vary
among birth year cohorts, such that f(h,t) = fh. Assuming an age-independent ratio is not
necessarily grossly improper, as CON1 and CON2 may include other forms of cancer which
might therefore have an age dependence and survival probability similar to that of the cancer of
interest. In balance: the relative age dependence of cancer mortality is not greatly different from
the major causes of human mortality (Figure 1), vascular disease (Figure 2) and any other cancer
(See http://cehs4.mit.edu).
(Eq. 14)
t
f( ,t)POBS(ht) (1 - S(h,t)) dt
(1 -G Eh). e 0
t
E [POBS (h,t) (1 - S(h,t)) + PCON(h,t) (1 - SCON(h,t)) - PCONI(h,t) (1 - SCONl(h,t))] dt
(1 - G) Eh* e
t
f[IPOBS (h,t) (1 - S(h,t)) + PCON(h,t) (1 - SCON(h,t)) - PCON2 (h,t) (1 - SCON 2 (h,t))] dt
+ G (1 - Eh) e
t
.[POBS(h,t) (1 - S(h,t)) + PCoN(ht) (1 - SCON(h,t))] dt
0
+ (1 - G) - (1 -
Eh) - e
i
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Equation 14 defines the approximation using f(h,t) in the context of Equation 13,
distributing the effects of differential death rates among the three populations not at risk for the
OBServed cancer.
It is helpful to recall that the sum of all four subpopulation fractions is equal to one:
(Eq. 15)
[(1 - G) x Eh] + [G x (1 - Eh)] + [(1 - G) x (1 - Eh)] = 1 - (G x Eh) = (1 - Fh)
Combining Equations 13-15 creates the relatively simple expression:
(Eq. 16)
F (1 -S(h,t)) R(h,t) - P (h,t)
OBS(h,t) =h 
OBS
t
f1 (h,t) (1- S(h,t)) dt
o OBS
h hO
for which all values are known save for Fh, fh and Poss(h,t) shown in bold face. Sections 3.5.4
and 3.5.5 demonstrate how to explicitly solve for these parameters.
3.5.3 Observed lung cancer mortality rate at age t, OBS(h,t), of a mixed population of smokers
and nonsmokers
Real populations consist of smokers and nonsmokers. Three groups are at potential risk
for lung cancer:
(a) smokers at risk only because of smoking
(b) nonsmokers at risk because of unknown factors unrelated to smoking
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(c) smokers at risk because of smoking and unknown factors unrelated to smoking
The observed mortality rate, OBS(h,t), can thus be written as a function of each of the
three subpopulations .(subscripts: NS - nonsmoker, and S - smoker):
(Eq. 17)
FhNS (1- Fh,S), POBSNS(h~t).
FhS (1- FhNS). POBS,S(h,t). t
Fh,NS F, (PoBsNs(h,t) + P0
- 5 0ss,NS (h, t) at
fh,Ns
e +
I OBSS (h, t) at
fh,S+
1 1
-f fI OSN (h, t)±$-Pos S (h, t)) at
-. - fh,Ns fh,S
Bs,NS(P,t)) e
OBS(h,t) =
Fh,NS . (1- Fh,S). e
Sf Pos,Ns (h, t) at
fh,NS
-f POBS,S (h, t) at
fh,FSFhs• (1- Fh,NS) ehS +
1 1
- ( POBS,NS (h, t)+-IPoBsS (h, t)) at
fh,NS fh,s
Fh,NS * Fh,S• e
(1- Fh,NS- Fh, S)
This "semi-hairy" expression is easily calculated using parametric values for nonsmokers
derived from birth year cohorts which had not yet adopted the cigarette habit and those for
populations in which the overwhelming fraction at risk was defined by smokers.
?
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3.5.4 Explicit Terms for Primary Risk Factors, Fh and fb, for a Given Number of Initiation
Mutations, 'n'
The first tactic is to introduce a simple function for Poss(h,t). Following the original
logic of Nordling (1953) who noted that the age dependence of phenomena requiring 'n'
mutations in the same cell in a cell population of constant size would rise as a function of age to
the power of (n-1):
(Eq. 18)
Nordling POBS(h,t) = Kh tn-'
Here, Kh is a constant proportional to the product of the 'n' mutational rates and the number of
cells at risk. It is, in fact, the rate of initiation, a fact useful later in deriving estimates of initiation
mutation rates.
Nordling's model however does not permit for the proliferative capacity of a
precancerous cell. The simplest way to incorporate the effect of promotion on cancer mortality
curves is to modify the Nordling (1953) model with a time delay, Ah, representing the average
latency time between initiation of a normal cell and the promotion of any precancerous cell into a
malignant form. The modified model becomes:
(Eq. 19)
Modified Nordling POBS(h,t) = Kh (t - Ah)n-1 (t > Ah)
Substituting Equation 19 into Equation 16, for a given value of 'n', there are four
unknown parameters: Kh, Ah, Fh, and fh-
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(Eq. 20)
OBS(h,t) =
n-I
F -(1 -S(h,t)) R(h,t) K . (t -A )
t
r"n-1
fJK (t-A )0 h h (1- S(h,t)) dt
Fh +(1-F ).e
To explicitly solve for any or all of these four unknown terms, four independent equations are
needed.
3.5.4.1 Parameters determined by inspection: (Fh Kh) and Ah.
Ab and (Fh Kh) are determined for each birth year cohort by inspection of the mortality
data corrected for survival and under-reporting, OBS* (h,t), as illustrated in Figures 27 and 28
for lung cancer, and Figures 31 and 32 for colon cancer. To accomplish these estimations
OBS*(h,t) for values up to the age tmx when OBS*(h,t) reaches a maximum is suitably
approximated for any number of initiation mutations, n, as:
OBS*(h,t) = Fh POBS(h,t) = Fh Kh (t - Ah)n- (t max > t >Ah)
This formulation is essentially that first suggested by Nordling (1953) who did not have data for
extreme old age and thus could not have recognized the maximum.
(t > 4h)
(Eq. 21)
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Its application is straightforward. For example, in the case of n = 2, the approximation of
OBS*(h,t) would have a 'value' of zero up to t = Ab and then rise linearly with slope (Fh Kh).
The x-intercept of the line is Ah. As OBS*(h,t) approaches its maximum at tmax, the
approximation fails. Figure 39 shows the derivation of (Fh Kh) for colon cancer mortality rates
among European-American males born in the 1870s.
Ah and (Fh,Kh) can be similarly determined by inspection for all other values of n by
simply plotting OBS*(h,t) versus tn-i. For the general model with 'n' initiation mutations, Ah is
simply the x-intercept and (Fh,Kh) is the slope of the linear portion of the plot of OBS*(h,t)
n-I
versus t
3.5.4.2 Use of the Area Under OBSR(h,t) to Define Fh in Terms of fb.
Explicit solution of the two remaining unknowns, Fh and fh requires two additional
independent equations. The first is supplied by the integral of the equation OBS (h,t) vs. t from
t = 0 to infinity, where OBSR(h,t) is defined as the expected mortality rate if all deaths from the
cancer of interest were accurately reported.
(Eq. 22) OBSR(h,t) = OBS(h,t) + R(h,t)
The integral of Equation 22 must equal the area observed under the curve OBSR(h,t) vs. t as
illustrated in Figure 40.
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Fig. 39: Estimation of parameters (Fh,Kh) and Ah from linear portion of OBS*(h,t) vs. tn-
(Data illustrated: colon cancer, 1870s EAM)
x - intercept of a line drawn through the linear region of the mortality curve = Ah
slope of the linear region of the mortality curve - (Fh,Kh)
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Fig. 40: Estimation of the integral of OBSR(h,t) = OBS(h,t) + R(h,t).
Open symbols represent extrapolation of the data used for the approximation.
(Data illustrated: colon cancer, 1870s EAM)
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Intuitively, this area, Ah, must be a function of the population at risk of developing the
cancer of interest, Fh, and the fraction of this population at risk which would die from that
cancer, fh, if an individual at risk for that cancer could only die of but those forms of deaths
sharing the same risk factors as the cancer of interest. This area would be independent of factors
which would affect the age at which deaths are expected, such as survival rates, mutation rates
and cell kinetics rates, as well as the number of events required for initiation or promotion.
The algebraic relationship between the area under OBSR(h,t) and Fh and fh is derived as:
RAh = OBS (h,t)at -
0 0
Fh - (1 - S(h,t)) - POBS(h,t)
f f (1 - S(h,t)) ' POBS (h,t) at
Fh 0
Fh + (1 - Fh)- e
00
f Fh - (1 - S(h,t)) -PoBs(h,t) -e
0 t#
Fh - e
t
_- (1 - S(h,t)) -POBS (h,t) at
hO
- I (1 - S(h,t)) POBS (h,t) at
h0
+ (1 - Fh)
In order to permit integration, we introduce the variable v such that:
t
- 1  - S(ht)) POBS(h,t) dt
v fh
v= e
- Lf(1 - S(h,t)) POBS(h,t) dtfhdv 1= - (1 - S(h,t)) POBS(h,t) efh
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thus creating a simpler expression allowing solution of the definite integral:
(Eq. 23)
oo0 1
Ah f OBS(ht) dt f Fhh =f Fh h dv
SF h  v+(- F h v+(l-Fh)
1fh In(F v +(1 -Fh )) fh In(Fh + (1 -Fh))- fh In(1 -Fh)h h h 0
= -fh In(l- Fh)
Note that by first dividing R(h,t) from OBS(h,t) avoids the need to characterize R(h,t), which is
itself not explicitly integrable.
The simplicity of this result provides a practical definition of Fh as an explicit function of
fh and the observed parameter Ah for any cohorts studied and, for that matter, any form of cancer
or other mortal disease.
Equations 21 and 23 alone do not yet define all three terms, Kh, Fh and fh. There are
three unknowns and only two independent equations. For the last necessary equation, one can
take advantage of the feature that the mortality function OBS*(h,t) reaches a clear maximum in
old age. The derivative of a continuous function equals zero at a maximum. By taking the
derivative of OBS*(h,t) and setting it equal to zero at t = tmax,, Fh can be written in terms of the
other unknowns for any value of 'n'. Derivation of this general solution is shown as Equation 24,
using a temporary function 1(t) to represent the terms in the exponential of the probability of still
being alive.
OB S (h,t) - Fh l"h
t
i j(1
fh OFh + (1 - Fh) - e
Fh ' K h. (t - Ah ) n-l
Fh + (1 - Fh) - e
Evaluating the derivative at age t = tmax, where the derivative of OBS*(h,t) equals 0:
dOBS (h,t)
dt I
max
(n - 1) Fh Kh - (tmax - A h
.n -2) S(Fh + (1 l(tmax)-Fh). )
(Fh + (1 -Fh). e l(tmax) 2
n - d(t) (tmax)Fh . Kh - (tmax - Ah) (1 - Fh)
max
(Fh + (1 - Fh) ' e l(tmax) 2
Eliminating common terms this simplifies to:
l(tmax)+ (1 
- Fh)) d 1(t)
- (tmax - A h )  d (t)dt
Evaluating the derivative of 1(t):
(n 
- 1) - fh ( h Se -tmax) + (1 - Fh)) - (1 - S(h,tmax)) - K h
Iax
max
• (1 -Fh)= 0
(tmax -Ah) (1 -Fh)=O
Solving for the fraction at risk, Fh, creates Equation 24:
Fh - [(n - 1) fh (1
(n - 1) - f - (1
-l(tmax))
- S(h,tmax)) Kh
- S(h,tmax)) 
" K h
• (tmax - Ah ) n
n(a
- (tmax - A h) ]
(n - 1) - fh - (1 - S(h,tmax)) • K h
-l(tmax) ()-(1
n
(tmax - Ah)
- S(h,tmax)) • K h
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S(t- A h )n
- S(h,t)) 
- K h S(t- Ah )n-1 at
l(t)
(n - 1) (Fh e
Fh
(n- 1)-f h -(1 -e S(tmax - Ah )
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(Eq. 24)
n
(n- 1) fh - (1 - S(h,tmax))Kh (tmax -Ah)
hmax n-1
a x (1 - S(h,t)) Kh (t- Ah) dtfh 0 n
(n- 1). fh (1 - e ) - (1 S(h,tmax)) K h (tmax- Ah)
This provides four independent equations using three separate features of the mortality curves,
plus the direct observation of Ah:
1. the slope of the (n-1)th root of OBS*(h,t) for Equation 21,
2. the x-intercept of the (n-1)th root OBS*(h,t), direct estimation of Ah,
3. the area under OBSR(h,t) for Equation 23 and
4. the maximum of OBS*(h,t)) for Equation 24.
Together these equations allow the explicit determination of the two desired population
risk parameters, Fh and fh for any birth cohort for which these four features were defined by the
data, which allows one to chart the health effects of environmental changes in populations. Fh is
also the minimum value for G or Eh for any birth year cohort since when Eh = 1, G = Fh and vice
versa. Both of these properties are of clear value in exploring the genetic and environmental
interactions which lead to cancer.
The fh approximation algebraically provides a solution for the limitation created by the
ignorance of the causes of death that share primary risk factors with the OBServed cancer. The
practical 'importance of fh itself is however not entirely clear because it includes both historical
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shifts in the accuracy of cancer diagnoses and in the probabilities of death by unknown
connected diseases.
Furthermore, these equations explicitly derive a value for the physiological parameter Kh
which can be used to estimate initiation mutation rates for any value of 'n' as shown in the
following section.
3.5.5 Explicit Terms for Secondary Risk Parameters
3.5.5.1 The Product of Initiation Mutation Rates, (ri rj rk ... rn).
Initiation with n>l required events is modeled as per Armitage and Doll (1957) in which
'n' events in any cell would create the first cell of a precancerous lesion, extended to account the
cell turnover in normal tissues and the organization of tissues as turnover units of constant and
equal size containing N, total cells at age 'a'.
The Na total cells comprise terminal cells, transition cells and stem cells. The stem cell
and each transition cell undergo t divisions and no deaths per year. The terminal cells each "die"
"r times per year and do not divide. The most probable pathway of initiation is therefore the
accumulation of all but one of the 'n' mutations in the stem cell. The stem cell then repopulates
its respective turnover unit with cells carrying the (n - 1) mutations, such that the nth mutation
could now occur in any of these cells.
The rates of the required initiation mutations are represented as ri rj rk ... r., such that the
expression describing the number of newly initiated cells in year 'a' is simply:
(Eq. 25)
Initiated cells during the year 'a' = n "n (ri rj rk... r.) N, a (Armitage and Doll, 1954)
assuming that the order of the initiation mutations is not important.
3.5.5.2 Difference in Division and Death rates in Precancerous Lesions, (a-0) ,and Stochastic
Extinction of Newly Initiated Cells.
As recognized and algebraically treated by Moolgavkar (1990b), each initiated cell could
die before it divides. Even small colonies have a high probability that all cells will die; only a
few would be expected to survive if the probability of cell division is only marginally greater
than the probability of cell death. Given a cell division rate of a cell divisions per year and a
death rate, 0, for an initiated cell, the probability of non-extinction or survival is (a-3)/a
(Moolgavkar, 1990b).
The origin of this solution comes from the Gambler's Ruin problem. A gambler starting
with 1 dollar (1 cell) makes 1 dollar bids and wins two dollars with probability a/(a+3) (cell
division) or loses the dollar with probability 3/(a+1) (cell death). The probability that the
gambler eventually loses all the money (stochastic extinction) is 1 minus the survival, or 1/a.
Thus the number of newly arising and surviving precancerous lesions in year 'a' would
be:
(Eq. 26)
Surviving initiated precancerous lesions (a) (a - n ' (ri ri rk... r.) Na an"'
All surviving precancerous lesions then have the property of inexorably giving rise to a lethal
carcinoma via net growth and mutation.
The combination of the data of OBS*(h,t) and Equations 21, 23 and 24 allowed explicit
determination of the unknown parameter Kh for any cohort studied. Kh is Nordling's annual rate
of initiation per person modified to include Moolgavkar's necessary term for surviving stochastic
extinction. For the case after Na has reached a maximum, Nma,,x, in young adults.
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(Eq. 27)
Kh- = n T ( ri rj rk... rn ) Nmax
Cell division and 'death' rates can be acquired from actual tissue samples: T in normal tissue, and
a and 0 in precancerous lesions. However, a value for the growth rate of the lesion, (a - P1 is
small and accurate independent estimates for the division and deaths rates in vivo are not
plausible so as to properly estimate this difference from tissue samples.
One can make use of an interesting property of OBS*(h,t) to explicitly define ((a-1) and
then estimate the value of (ri rj rk ... re). For this, Nordling's model for the expected mortality
from the OBServed disease, Poss(h,t), needs to be extended to account for the growth rate of a
precancerous lesion.
3.5.5.3 Probability of Promotion at Age 't' Given Initiation at Age 'a', m = 1
Assuming that the third stage of carcinogenesis, progression, occurs rapidly and can be
effectively modeled as occurring in zero years, the expected mortality from the OBServed form
of cancer simply equals the probability of initiation at age 'a' (Equation 26) times the probability
of promotion occurring at a later age 't'. The model for the second stage of the three-stage
carcinogenesis model, promotion, is again based on Armitage and Doll (1957) in which 'm'
particular events in any cell of the precancerous lesion would create the first cell of a carcinoma.
Since the number of promotion events needed for cancer is yet unknown, the simplest case to
consider is that a single genetic event could turn an adenoma cell into a carcinoma cell.
Based on the Exponential distribution, the probability of at least one cell undergoing
promotion at age 't' in an adenoma that was initiated at age 'a' is:
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(Eq. 28)
(-rA [•2 (  (-)(t-a) _ -C
d(1 - e In 2 c  )
d(t -a)
The product in the exponential represents the expected number of cancerous cells in the
precancerous lesion that have been promoted (t - a) years after initiation and survival of
stochastic extinction.
Here, rA represents the promotion mutation rate per cell division, and (ac - O)+oac
represents the probability of a promoted cell colony surviving stochastic extinction, given cell
division and death rates per year of a, and Pe respectively. The remaining terms in Equation 28
describe the total number of cell divisions, or chances for promotion, occurring within the
precancerous lesion, derived as follows:
The initial number of cells in a lesion that has survived stochastic extinction, is not one,
but a/(a - 3) (This is because of the stochastic redistribution of surviving cells among all
initiated lesions into the surviving precancerous lesions, since stochastic processes cannot
increase or decrease the total number of initiated cells in a population. This phenomenon has the
effect of reducing the age-specific fraction of persons with an initiated colony but also
considerably shortens the period expected to "promote" one cell in an initiated colony into a
neoplastic cell for any number of required promotional events). The colony then grows at a
doubling rate of (a - 0) per year, such that the number of cells in the precancerous lesion after (t
- a) years, the time since initiation, is:
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S.2(t-a) (a- P)
Since the division and death rates of a precancerous lesion are approximately equal, a
year can be divided into a periods, the chances per year for a precancerous cell to divide or die.
The number of cells in the adenoma can be expressed as a function of the number of these
periods that have elapsed, 8:
.2 [a(t' a)(a -) ( -( 8  )
.2 a _ 2 a
The number of total cell divisions having occurred in the adenoma can then be related to
the number of cells. In order to have a colony of a certain size, Nprec, we recognize that there
must have been (Nprc + 2) divisions within the last period of possible division:
8 (x -3)
2 c x
a 2
a-B 2
Consequently, the total number of cell divisions is the sum of the number of divisions needed to
give each of the intermediate sizes of the precancerous lesion up to the last period, 6:
1 1 - - - -Sa a - (a- a) a
S 2 a 2
i=1 - 2 i a-13 2
This summation can be solved explicitly as:
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-3/ca (2 (-f)(t-a) - 1)
2 -1
Taking the integral instead of the summation above gives a reliable and easier to remember
estimate:
-
2  ( c- n)(t-a)
~ ~a-02 In 2
Last, for every division, each of the two daughter cells can acquire the promotion mutation.
Therefore, the number of opportunities for promotion after (t - a) years is just twice the total
number of divisions:
2._(2 (cc - )(t- a)
In 2
as included in Equation 28.
3.5.5.4 Probability of death at age 't' given individual is at risk for cancer, POBS(h,t)
Combining the probability of initiation from Equation 25 with the probability of
promotion from Equation 28, one gets that the expected probability of death at age 't' for an
individual at risk is (m = 1 case illustrated):
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(Eq. 29)
(a - [)(t - a)
S 12 (2 1)(-rA )
t a-In 2 a
n rir rk  a-fan-Na d( - e 1c
POBs(h,t) = nt rr rk.. a d(t - a)
a 0
Obviously, an individual could develop more than one precancerous lesion within a lifetime. In
its simplest form, POBS(h.t) is then just the probability of a cell being initiated at any age 'a' and
having any one of its descendants promoted to a carcinoma at age 't', expressed as the
convolution of the probabilities of initiation and promotion.
3.5.5.5 Explicit determination of the growth rate of precancerous lesions
The growth rate of precancerous lesions can be estimated directly from the mortality
curves, derived as Equation 30 below. (Although illustrated for case n=2, m=l, the calculated
adenomatous growth rate is approximately the same for all other cases.)
For ages below Ah, OBS*(h,t) is approximately OBS*(h,t) = OBS(h,t) + [R(h,t) (1 -
S(h,t))] = Fb POBs(h,t), since most individuals at risk are not expected to have already died of
either the observed form of death or anyone of the connected forms of death. As a first
approximation, assume a constant number of cells in the target tissue. For clarity, parameters of
Equation 29 that do not vary with age have been grouped (e.g. Fh is included in C1):
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(a - 3)(t - a)
t
(',p4D tilt) =2:r-f,.d( - e
- C '(22
d(t - a)
-1)
)Ida
To help solve this integral, one can approximate ex = 1 + x when x is small. This yields:
OBS (h,t)= C1
t
Sd(l -
a
(a-0)(t-a)(1 - C2 • (2
d(t - a)
t "(a--)(t-a)
=C la[2 (a-0)
0
CIn2] da [2(a -) In2
(a-3)t
-t (a-o)In2 - 1]
combining the two constants, CIC 2 = C. Taking the derivative of OBS*(h,t):
d(OBS (h,t))
dt
(a-2)t
c [2 - 1] - C2
The log2 of dOBS*(h,t) + dt is therefore a function of 't' whose slope is the growth rate of the
precancerous lesion, a - 0:
(Eq. 30)
logd(OBS (h,t))
log2 dt
This approximation is valid only when 2(a - P)t >>
(a - 1)t + log2(C)
1, so when estimating the adenomatous growth
rate, one needs to be careful not to use data from the age groups below age 18.
%-/130 IL9L) 9/ % J j 9
1)) /i CIC2 d (2 - 1))d(t-a)
(a-3)t
t i .. ... ..I = k.- A - MIU
- (A
(oc-0)(t-a)
Im o -tmS a
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Fig. 41: Determination of (cx - 3) from the slope of log2 A(OBS*(h,t)) + At.
(Data is for colon cancer of EAM born in the 1920s, ages 17.5 to 57.5)
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If the increase in cell number during childhood were accounted for, the derivative of OBS*(h,t)
fort > 17.5:
d(OBS (h, t)) (-)t 2 165(a-) (a-)t
dt -16.5(a-) C 22-2 (1 + 16.5 ln2(a - P)
The log2 of this function plotted vs. t is indeed a straight line for ages for which the probability of
promotion is yet small (i.e. t < Ah), whose slope provides an estimate for the cell kinetic growth
rate of the precancerous lesions, (a - 1). As an example, Figure 41 shows an estimate for EAM
born in the 1920s. To evaluate the derivative of OBS*(h,t) from the mortality data, the
approximation A(OBS*(h,t)) + At = d(OBS*(h,t)) +dt is used.
3.5.5.6 Explicit Determination of the Product of Initiation Mutation Rates
The determination of the cell growth rate of a precancerous lesion, (a - 1), allows us to
calculate the product of the initiation mutation rates, (ri rj rk ... rn) using the previously derived
value of Kh in Equation 27. From this product, the geometric mean can be derived as (ri rj rk ...
r)(1/n)
3.5.5.7 Explicit Determination of the Promotion Mutation Rate for the Case of m = 1
Evaluation of the average promotion mutation rate can be expressed in terms of
previously defined values. The value Ah represented the average time between initiation and
promotion. The cumulative probability of promotion in a precancerous lesion is therefore
approximately one-half, Ah years after its initiation. Using Equation 28, this means:
(Eq. 31)
2•r _  1 _c" .(2 (-)Ah - 1)
1 
_rA FIn 2 ac
l=1-e2
However, the assumption that the cumulative probability is approximately one-half at the
average time between initiation and promotion is good only if the distribution for the probability
of promotion can be approximated by a normal distribution. As (a - 3) increases, deviation from
normality occurs. If this is the case, the exact solution is essential.
For a continuous random variable, i.e. the time between initiation and promotion, t - a,
can be defined as:
Ah = (t - a) P[t - a] d(t-a)
The expected time between initiation and promotion is then:
(Eq. 32)
rA  2 1 C (2-Xt-a)
rA K.-31 .n2 c c .*(2 (-X)
A O ' In 2 a
Ah = f(t-a) d(1 - e c d(t-a)
0 d(t-a)
A (a_ n2  2 1 c-c a 1 a-
-e _ 12 ln Ei[rA a -
A-e a- In 2 c
(a-P) In 2
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where Ei is the exponential integral function. A computational tool such as MathematicaTM
(ExplntegralEi function) or MatlabTM (expint function) can be used to evaluate the exponential
integral function.
The only unknown parameter is the promotion mutation rate, rA. Either of these equations
is sufficient to evaluate this last unknown parameter, thereby completing our explicit derivation
of all physiological parameters in the three-stage carcinogenesis model, ri, (a - 3) and rA.
3.5.5.8 Explicit Determination of the Promotion Mutation Rate for the Case of m > 1
If more than one genetic event were needed to convert a precancerous cell into a
cancerous one, m > 1, when a cell in the precancerous lesion acquires the first promotion
mutation, this cell has the potential to divide and become a distinct colony of cells now
containing one promotional mutation. A cell within this colony is a target for a second
promotional event, producing a new colony within the precancerous lesion, now made up of cells
with two promotional mutations. This process continues until a cell acquires all necessary 'm'
promotional mutations, thereby producing a carcinoma cell. As was the case for a newly initiated
cell, any cell that has acquired a new promotion mutation could undergo stochastic extinction
before developing a colony.
The precancerous lesion itself would thus appear to be a mix of colonies of cells
containing zero or more of the promotional events, and the delay in the rise of the mortality
curves, Ah, is now the sum of the average time between each promotional event.
Age 'a': initiated cell
Age 'tl': first promotional event
Age 't2 ': second promotional event
Age 'tm-t': (m-1)th promotional
event
Age 't': 'mth' promotional event
promoted cell
stochastic survival
growth rate (a1 - ni), mutation rate rA
stochastic survival
growth rate (a2 - 02), mutation rate rB
stochastic survival
growth rate (a3 - 03), mutation rate rc
stochastic survival
growth rate (am - pm), mutation rate rmth
stochastic survival
growth rate (a. - 3c)
NCER
The probability of promotion at age 't' simply follows as:
Probability of 1st promotion mutation by
Probability of 2 nd promotion mutation by
age (a < tl < t) x
age (ti < t2 < t) x
x
Probability of (m-l) h promotion mutation by age (tm- 2 < tm-I < t) x
Probability of mth promotion mutation at age t
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Explicitly, this is:
(acl-13)(t -a)
In 2 -1 ____aa
2 (a 2 - 2)(t 2 -t 1)
In 2
In 2
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d (t2 - t1)
0 .
2
-2r - ( m.1
m-1 a -p
m -1 m -1
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In 2
m
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(am -Bm)(t m-l-tm-2)
2 -1
In 2
d(t - tinl)
* ac-I3
a
C
where the first promotion mutation occurs at any age, tl, between initiation and death, the second
promotion mutation occurs at any age, t2, between the first mutation and death, the third
promotion mutation occurs at any age, t3, between the second mutation and death, and so forth
until the last promotion mutation which must occur at age t, death. As was the case for initiation,
there are 'm' target alleles for the first promotion event, (m - 1) for the second promotion event,
and so forth.
2(- 
1
I Pl-i
tS d(1 -e
a
t
Sd(1 -e
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d (t, - a)
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I
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Supposing that the acquisition of a new promotional event alters either the cell kinetic
rates, cx and ,x, or the promotion mutation rate, rx, for that cell, it is not possible to estimate each
cell kinetic rate and promotion mutation rate independently for each step. However, there exists
an average promotion mutation rate, rA, and an average cell kinetic growth rate, a - Othat
describes a similar process of 'm' promotional mutations such that the total delay of onset of the
disease is the same. The probability of promotion is now of the 'simpler' form:
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The estimate of the average promotion mutation rate can be written with respect to the
average interarrival time Ax between each promotional event. Using the approximation that the
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average time approximately corresponds to the time when the cumulative probability for that
promotion mutation is 0.5:
F 1
log2 1 + (m-1)rA a- [1n(2)]log2
1 + mrA a
c-f3
0 *
2-1
a • )2
lo2 1 + rA a-P 2
, Am =a-
The total expected delay between initiation
between each promotion mutation. For m>1:
(Eq. 33)
m A c 1
Slog2 1 + i rA-
i=2 [In(2)]2
Ah=
and promotion, Ah, is simply the sum of the delays
log2 1 + rA [ln(2)[In(2)]
+
assuming that the order the promotion mutations occur is inconsequential.
Supposing instead that each of the promotion mutations leads to either an elevated cell
growth rate or an elevated mutation rate per cell year, then there might exist a particular order for
the 'm' necessary promotion mutations that is most favorable for promotion of the tumor. If
these deleterious promotion mutations do not occur early in the order of the 'm' mutations, the
individual might not accumulate all of the necessary promotion mutations within their lifetime.
Am 1 =
A
.- LAP% - -
"-12
I
t
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Using the same logic as above, we can explicitly evaluate the delay between initiation and
promotion, if the 'm' mutations had to occur in a particular order:
(Eq. 34)
F_ 1\2 ac -D
1Z log2 1 +2(m -1) log2 1 + rA a •_ [ 2 1 +A L K [ln(2)]2  I
Lh- [ln(2)i)
Ah +
Equations 33 and 34 allow one to estimate the average promotion mutation rate for the
case where the 'm' promotion mutations occur in a completely unordered manner and the case
where the 'm' promotion mutations must follow in a particular order. Of course, it is possible
that only some of the promotion mutations must occur in order. For this case, where the 'm'
mutations are only partially ordered, these equations would describe the possible range for the
average promotion mutation rate.
In the process above, the average promotion mutation rate and the average growth rate of
the precancerous lesion refer to the average rate of only the precancerous cells that comprise the
direct lineage between the first precancerous cell and the first cancerous one.
3.6 COMPUTER APPLICATIONS
3.6.1 Calculating the Expected Mortality Rate Given a Set of Values for Fh, fh, ri, (a - 3), and
rA - MathematicaTM
The main advantage of the MathematicaTM software package is that allows a user to write
code for a mathematical model as is written in the derived Equations above. Included herein is
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the code for the case of 2 initiation mutations and 1 promotion mutation being necessary for
carcinogenesis. For demonstration, the parameters that have been plugged in to this program
are the maximum fit solution for the 1890 EAM lung cancer mortality data, assuming that there
is only one subpopulation at risk, the smokers. These are not the parameters listed in the
Results section which do correct for the fraction of individuals who died of lung cancer by
means other than smoking. Comments are enclosed in the code as (* COMMENT *):
(* Observed mortality data: Lung cancer 1890 a EAM (age,rate) ,)
DataOBS = ((32. 5, 0. 89), (37. 5. 2. 32). (42. 5. 6. 10), 47. 5, 16. 22), 52. 5,. 38. 08),
(57.5. 78.86), (62.5, 139.38),. 67.5, 212.90). {72.5, 283.78), {77.5. 345.98}.
(82.5. 370.73), (87.5. 371.51), (92.5. 329.36), (97.5, 264.36;):
(* Gender: 0 for females, I for males ,)
boys -= .;
(, Gender dependent growth rate of child between ages 0 and 1.5 years old *)
(* st term (--) checks for equality;
2nd term sets r = 1.23 if true; 3rd term sets r 1.17 if false *)
r =If[boys = = 0. 1. 23, 1. 17];
(, Gender dependent growth rate after age 1. 5 )
v = If [boys == 0, 0. 167. 0. 159];
(* Age at end of growth *)
puberty = If [boys == 0. 14. 5. 16. 5];
(* Number of cells at end of growth *)
Nmx = 2.4 10 ;
(e Number of cells at age 1.5 years old e)
nax
N1.5 = .2 (puberty- .5)
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(* Turnover rate of normal tissue *)
S = 5.7;
(* Rate of ist initiation mutation *)
ri = 0. 03910-s "
(* Rate of 2nd initiation mutation;
3 times as large as first *)
rj = 3 ri;
(* Division rate of precancerous cells *)
a = 12.7;
(*-Death rate of precancerous cells *)
S= a-0. 243:
(* Rate of promotion mutation *)
rj = 0. 0155 i10- s
(* Division rate of cancerous cells w)
-e = 42.2;
(* Death rate of cancerous cells w)
-= 28;
(* Fraction at risk *)
F = 0.9617;
(* Relative risk ,)
f = 0.0418;
(* Survival rates .)
(* This is the construct for a function named S, whose variable is t .)
S[tj : 0;
(. So that the program does not need to continuously calculate the derivative
term for the probability of promotion, [I-E a-t)2(4o )tn a.ion ,
it is advisable to have this precalculated as its own function .)
Promotion[tj :]
-1.2( •at) (a-) ) a2 r (ac -c)
( -)2
(a - P) ac
a2 Log[2] rj ( - )
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(, Function PS (t) = Pes (h.t) times (1I - S (h,t)) )
(. The extra PS[t]= term tells the computer to memorize the calculated
value for a given t once it has already being calculated;
this helps speed up integration of PS (t)in the next line; .)
(, The Clear command is so that whenever new parameters are used,
the computer will clear memory *)
(* The If statement is to account for the number of cells
at the age of initiation; the integrals (NIntegrate) are cut
into the three age periods of when initiation could occure)
Clear [PS]
PS[t_] :"=PS[t] =
2 2 ri rj Nawx
If[t si .5. NIntegrate[a !.s 2rý(_.) Promotion[t]. Ia. 0, 1.5)] .
nemx
If[t spubert ntegrateane a -(ot n1.)Promotion[t]t aa. 0. 1.51] +Nmx
NIntegrate[a 2? (a - puyer ty) Promotion[t]. Ia, i. 5. puberty)] +
Nlntegrate[a Promotion[t], a, puberty, t] ]]1 (1 - S[t]);
(C OBServed mortality rate per 100,000.)
OBS[t_] :=OBS[t] = S 10 5
i ](1 irtegr•te[Ps[uJ 4u.ot) 1(1-S[t])I+ (i - F)Ef
(w Calculates expected mortality
rate given set of parameters for ages 2.5,7.5,...,97.5 .)
Dataliodel =Table[(t. OBS[t])}, t, 2.5. 97.5, 5)];
(, Plots observed data as points; plots model results as line ,)
Show[ListPlot[DataOBS]. ListPlot [Dataliodel, PlotJoined -> True]]
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3.6.2 Calculating the expected mortality rate given a set of values for Fh, fh, ri, (a - 13), and rA
- MatlabTM
For each set of parameters, the MathematicaTM program takes approximately 30-45
seconds (Pentium III, 500 MHz) to calculate the expected mortality rate; the lengthy
calculation is primarily due to the fact that the integral term cannot be explicitly solved; as
such, numerical integration (NIntegrate) had been used. To maximize the fit of the solution
requires multiple iterations, such that implementation of the model would require a different
speedier software package. The above program is nonetheless indispensable so as to verify the
results of any other programs.
The MathematicaTM code was translated into MatlabTM. Comments now are shown as
% COMMENT. The code is included herein for documenting purposes.
%Observed mortality data: Lung cancer 1890s EAM
age = 32.5:5:97.5;
dataOBS = [0.89
2.32
6.10
16.22
38.08
78.86
139.38
212.90
283.78
345.98
370.73
371.51
329.36
264.361';
boys = 1;
% Gender: 0 for females, 1 for males
if boys == 0 % Rates for females (==) checks for equality
stopgrowth = 14.5; % Age at end of growth
zeta = 1.23; % Growth rate of child between ages 0 and 1.5
eta = 0.167; % Growth rate after age 1.5
else
stopgrowth = 16.5; % Rates for males
zeta = 1.17;
eta = 0.159;
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end
% Number of cells in adulthood
Nmax = 2.4*10^8;
% Number of cells at age 1.5 years old
Nchild = Nmax/2^(zeta*(stopgrowth-1.5));
% Turnover rate of normal tissue
tau = 5.7;
% Rate of 1st initiation mutation
ri = 0.039*10^(-5);
% Rate of 2nd initiation mutation; 3 times as large as first
rj = 3*ri;
% Division rate of precancerous cells
alpha = 12.7;
% Death rate of precancerous cells
beta = alpha - 0.243;
% Rate of promotion mutation
rA = 0.0155*10^(-5);
% Division rate of cancerous cells
alphac = 42.2;
% Death rate of cancerous cells
betac = 28;
% Fraction at risk
F = 0.9617;
% Relative risk
f = 0.0418;
% Survival rates for all ages 0.5,1.5,...,102.5
% in initializing an array, the '( ,1)' informs it only one column of values
S = zeros(103,1);
% Hazard function PS(t) = POBS(h,t) / (1 - S(h,t))
% Hazard function for cells initiated during the first 1.5 years of age
% have been excluded as they were verified to have negligible contribution
% when code in Mathematica program for these adenomas was removed
PS = zeros(103,1);
for t=2.5:102.5 % t - age at death
h=min(t,stopgrowth); % Contribution of lesions prior to
integx=[l.5:h] % reaching adulthood; for ages at death
integy=zeros(length(integx),l); % less than adulthood, we consider only
% lesions initiated prior to t (min)
for a=1.5:h % a - age at initiation
integy((a-1.5)+1)=2*tau^2*ri*rj*Nmax*(alpha-beta)/alpha*a*2^(eta*(a-
stopgrowth))*2^((alpha-beta)*(t-a))*exp(-rA*(alpha/(alpha-
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beta) ) ^ 2* (2 ^ ((alpha-beta) * (t-a)) -1) * (alphac-betac)/alphac) *alpha^2/(alpha-
beta)*rA*(alphac-betac)/alphac*log(2) * (-S(t+0.5));
end
% integy - calculates contribution of lesion initiated at age a to death
% at age t; for loop is used to calculate for all ages a. Note that it is
% the same calculation as Mathematica program prior to integration
PS(t+0.5) = PS(t+0.5)+trapz(integy);
% integration by trapezoids; similar to NIntegrate in Mathematica program
% Note, arrays can only take integers, so we add 0.5 to ages to
% correspond to array position
end
% same as previous loop, but now we consider only lesions initiated at ages
% between adulthood and death
for t=stopgrowth+1:102.5
integx=[stopgrowth:t];
integy=zeros(length(integx), );
for a=stopgrowth:t
integy((a-stopgrowth) +1)=2*tau^2*ri*rj*Nmax*(alpha-
beta)/alpha*a*2 ^ ((alpha-beta)*(t-a))*exp(-rA*(alpha/(alpha-
beta) ) ^ 2*(2 ^ ((alpha-beta) * (t-a)) -) * (alphac-betac)/alphac)*alpha2/(alpha-
beta)*rA*(alphac-betac)/alphac*log(2) * (-S(t+0.5));
end
PS(t+0.5) = PS(t+0.5)+trapz(integy);
end
% We now calculate the mortality rate, OBS(h,t) for ages 2.5, 7.5,..., 102.5
% There are 21 values; to convert from age to array position, we simply add
% 2.5 to the age and divide by 5 (i.e. (2.5+2.5)/5 = 1)
OBS=zeros (21,1) ;
for t=2.5:5:102.5
OBS((t+2.5/5)) = F*PS(t+0.5)/((1-S(t+0.5))*(F+(1-
F)*exp(trapz(PS(2.5+0.5:t+0.5))/f)))*10^5;
End
% plot observed as points; plot model as line
plot(age,dataOBS,'o',2.5:5:102.5,OBS)
Output:
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3.6.3 Calculating the expected mortality rate given a set of values for Fh, fh, ri, (a - P3), and rA
- Microsoft ExcelTM Template
Although faster than its MathematicaTM predecessor, the MatlabTM program could not
be effectively used for maximum likelihood routines. However, it does demonstrate that using
integration by trapezoids gives results that are comparable to the exact calculations made by
the MathematicaTM program.
Due to the existence of a built-in routine for maximum likelihood in Microsoft ExcelTM
and the limited loss in accuracy in integration by trapezoids, we finally opted to develop a
template in Microsoft ExcelTM which not only can calculate expected mortality rates for a
given set of parameters, but can also adjust these parameters until the expected mortality rates
match those observed. The template consists of two worksheets, one containing the Raw Data,
the other containing the formulas for calculating mortality rates and the Fitting routine.
Figure 42 illustrates the first worksheet (Raw Data) which contains the observed data
for the age-specific mortality rates for a birth decade cohort of interest corrected for
underreporting, OBSR(h,t). The column labeled Weight refers to how to weigh the fitting of
each point. The following are the weighing factors that can be used depending on which points
are to be best fit:
Population values/100,000 - Chi-square (favors early age points)
1 - Sum of the differences squared of observed versus
expected mortality rates, divided by the expected
mortality rate (favors points with lower mortality rates)
- Tells maximum likelihood roltine to irnnre noint
~V ~b~~VI·l rVIIIC
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Expected number of deaths - Sum of the differences squared of the number of
observed versus expected deaths (favors points with the
largest number of deaths)
Only this last method requires a formula (as shown in Figure 42). The formulae refer to cells in
column HG of the second worksheet (Fitting) corresponding to the expected mortality rates, as
shown in Figure 48. (We divide by 100,000 to get the true mortality since the observed
mortality data had been expressed as per 100,000).
Figures 43-51 illustrate the second worksheet (Fitting) that calculates expected
mortality rates for a given set of parameters. For instructional purposes, the template is shown
in duplicate form, with and without revealing formulas so that the user can distinguish which
terms must be input and which terms are calculated by the template. (To have ExcelTM exhibit
a formula instead of the values to the formula, go to the Tools Menu, and click on Options;
under the View panel, there is a click box to have the worksheets show formulae or not).
Instructions on how to use this template are included in the legend to the figures. 3
3 The construction of the template is by no means easy. Learning about the 'filling' feature in ExcelTM to speed the
construction is recommended, as this feature helps fill multiple formulae with similar patterns. Integration has
been approximated by trapezoids every 0.5 years. To improve upon the accuracy of the template, instead of
calculating the contribution of precancerous lesions initiated every 0.5 years, one could calculate contributions in
smaller time intervals. Given that the results, as shown in Figure 43, are similar to those of the MathematicaTM
program, we have not extended our template to do so.
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Fig. 42: MAXIMUM LIKELIHOOD TEMPLATE: Raw Data worksheet
Instructions:
1) Transcribe mortality data adjusted for underreporting, OBS R(h,t), into Column B, by
appropriate age category.
S2) If using Chi-Square or the least sum of errors of the number of deaths to fit mortality data,
include population values in Column D.
3) Type in which weighing factor to use for maximum likelihood. (Weighing factors are
described in Section 3.6.3) Illustrated is the case using the least sum of errors of the
number of deaths as the maximum likelihood method to fit the data; reference 'Fitting!HG'
is to the calculated expected mortality rate as shown in Figure 49). The number references
11, 20, 30,...,210 are the row number corresponding to the appropriate age groups (See
Figure 49).
4) If using Chi-Square to fit mortality data, the weighing factor is the population divided by
100,000:
i.e. for the age group of 3, cell C2 should read: =D2/10^5
D2 refers to the population parameter in cell D2, and since mortality data had been
expressed as per 100,000 we adjust this back to the true rate.
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Fig. 43: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Parameter section)
(Note that for the same parameters used in the MathematicaTM and MatlabTM programs, this
template calculates similar expected mortality rates).
Upper left section:
Columns A and C contain the name tags of the parameters used in the program. There are two
other parameters:
Cell B4 = 2 2 ri rj Nmax a log(2) rA (ac - 3c)/ac
Cell D8 = det = -rA (a/(a-P))2 (ac - Pc)/ac
used to facilitate the template, since these two parameters are used in multiple cells. The first
parameter is just the product of the constant term Kh and the constant terms after one takes the
derivative of the promotion term. The second parameter is just the constants inside the
exponential of the promotion term (a and t are variables):
Derivative of the promotion term 1 --E a- tac)
.,(-a • +t) (a-_) )L [ (2 -
2 (-a +0(a-P) o.43) 2 a2 Log [2] rA ( VIC
Lower left section:
Contains the calculated errors for each age point, and the sum of the errors.
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Nmax 2.40E+08
_ r 5.7 ri *10 =rj/3 3.90E-021
(ac- )/z 0.3365 Calculated A 48.17
2 i Age at Initiation (a)-*22 - r jNmax a log(2) rA (ac - )9c 3.27E-09 1.17 Age at death (t)
a 12.7 0.159 0
rA * 10 1.55E-02 stopgrowth 16.5i 0.5
S0.2434 N1 .5  i 459467401 1
F 0.9617 -rA (aa- a (c - 1 c .42E-04 1.5
f 0.0418 2
2.5400 -. .......
C 3
S350 3.5
J 300 -S250 -- Model I 4250 - 4.5
C200 Lo Data 5
S150 5.5
100 .
6.5
o 50,
7.5
0 20 40 60 80 100
Age (years) 8
i Error at aqge Sum of errors 9
#VALUE! i 3 13417.17662 9.5
#VALUE! 7.5 10
. . ................. ........................... -, ............. ... . ......... .. ......... . . .......... ........... ....................... ....... ......... ... ....... ............. ........................
#VALUE 12.5 10.5
#VALUE! 17.5 11
#VALUE! 27.5 12
24.56170544 32.5 12.5
352.8963361 37.5 13
1054.1 83287 47.5 14
99.65488053 52.5 14.5
956.9150598 57.5 15
800.909421 62.5 15.5
419.5035041 67.5 16
2876.2891 37 72.5 16.5
4507.014417 77.5 17
138.2997616 82.5 17.5
9121.5314265 87.5 18
- 69.1645084 - - 92.5 18.5
700.4714443 97.5
· #V A LL#V... ............. .........  .. .............. . .. ..  .........
9VALUEH 1 n.) .;
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Fig. 44: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Parameter section) w/
formulae
Instructions:
The following cells must be filled in,
Cell B 1: Number of cells in adult, Nmax
Cell B2: Stochastic survival probability of cancerous cell, (ac - Pc)/ac
Cell B3: Normal cell turnover rate, TC
Cell B5: Precancerous cell division rate, a
Cell B6: Promotion mutation rate, rA (multiplied by 100,000; ExcelTM's maximum
likelihood routine does not work well when changing cells with small values. rA is
one of the terms that the program will try to alter to maximize fit, so it has been
multiplied factor of 100,000. Note that any reference to this cell must take this
factor into account)
Cell B7: Growth rate of precancerous lesion, a - 3
Cell B8: Fraction at risk, F
Cell B9: Correction factor for connected forms of death, f
Cell D2: First initiation mutation rare ri; here assumed to be a third of the rate of the second
initiation mutation rate, rj (multiplied by 100,000; see explanation for Cell B6)
Cell D4: Growth rate of child age 0 to 1.5, ý
Cell D5: Growth rate of child age 1.5 through puberty, r1
Cell D6: Age at which child stops growing
All other cells contain formulae written in terms of the above defined cells. ExcelTM formulae
can refer to a cell by its column and row (letter, number); instead, we opted to use a feature of
ExcelTM that gives cells actual names. To do so, select cell (click on it), go to the Insert Menu,
click on Name:Define. This gives you the option to give the selected cell a name.
For example Cell D8:
=-rA/100000* (alpha/mu)A2*survc
refers to rA (Cell B6 divided back by 100,000 to get true value), alpha (Cell B5), mu (Cell B7),
and survc (Cell B2).
The error cells are references to the HJ column which is explained in Figures 49 and 51
.r,..
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Fig. 45: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Contribution to death at
age t, from lesion initiated at age a)
Due to limited space only
shown for ages t (0,0.5,1,1.5,....4.5)
shown for ages a (0,0.5,1,1.5,....19.5),
but are actually calculated up to age 102.5. Note that we do not calculate for a > t, since an
individual cannot die at age t, from a precancerous lesion that was initiated at a later age.
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Age at initiation (a]-*
Age at death (t] 4.
0 0
0 0 5 1 
1 5 2 2 5 
3 3 5 4 1 
4 5
ut 0 0.04254
1 0 0.04628 0.12763
1.5 0 0.05036 0.13886 0.28717
2 0 0.05479 0.15107. 0.31243 0.40458
.. . . ............. ...... 2 5 ............... - ..... .... .........   0 !0 -0 61 .. ... .. .. .0/ , 6 . ....03 2 .. .. ........ -..........  3 . ........ ..  ....... .. ..  .... ......... ...... ............. ............. .
2.5 0 0.05961 0.16436 0.33992 0.44018 0.53438
3 0 0.06485 0.17883' 036983 0.47891 0.58139 0.67758
35 0 0.07056 0.19456 0.40237 0.52104 0.63255 0.7372 0.83529
4 0 0.07676 0.21168 0.43777 0.56689 0.6882 0.80206 0.90879 1.0087
4.5 0 0.08352 0.2303 0.47628 0.61676 0.74875 0.87263 0.98875 1 .09745 1 .19908
5 0 0.09086 0.25056 0.51819 0.67102 0.81463 0.9494 1.07574 1.19401 1.30458
5,5 0 0.09886 0.2726 0.56377 0.73006 0.88629w 1.03293 1.17038 1.29907 1.41936
6 0 0.10755 029658 0.61337 0.79428 0.96427 1 .12381 1.27336 1.41336 1 .54424
6.5 0 0.11702: 0.32267 0.66733 0.86416 i 1.0491 1.22267 1.38538 1.53771 1.68011..............  .... ... ....  ..... ... ........ .... ... .70 i . . . .  . .... ... . .. ............      .    .. ...........  .. ......... .    2 10 2 941 8  1 1 3! 3 o4i
7 0 0.12731 0.35106 0.72603 0.94018 1.14139 1.33024 1.50727 1 .67299 1 .82792
75 0 013851 0.38194 07899i 1.02288 1.2418 1.44726 1.63987 1.82018 1.98874
8 0 0.15069 0.41553 0.85938 1.11286 1.35104 1.57458 1.784133 1.98031 2.1637
85 0O 0.16394 0.45208 0.93497 1 21075 1.46988 1.71309 1.94108 2.15452 2.35406
9 0 0.17836 049184 1.0172 1.31725 1.59918 1.86378 211183 2.34405 2.56115
95 0 0.19405, 0.53509 1.10667 1.4331 1 .73984 2.02773 2.2976 2.55025 2.78645
10 0' 0.21111 0.58215 1 .20399 1 .55915 1.89286 2.20608 2.4997 2.77459 3.03157..................... ..... . ............ .......... .... ..........  ... .3 3 ........' .59 4 .:2. .. . . 2 ......3 .. ..  •2 § 2 4 i
10.5 0 0.22967 0.63334 1 .30987 1 .69627 2.05934 2.40012 2.71957 3.01864 329824
.... . ..... ............. ..- ........... .    ....... .. ...  . ...... ..................  ............................      .     2 32 8 2 83.8 2 38 3....88 1 ..  11 0 0.24987 0.68904 1 .42506 1 .84544 2.24046 2.61121 2.95877 3.28416 3.58836
..... . . .. ..........   .....  .... ... .... .. .... ............ ...   . - . .  ...... ....  ....   ... .  ....... ..........  ..... .... .... 1 62 1 i 96 311.5 0 0.27183 0.74962 1.55037 2.00772 2.43749 2.84086 3.219 3.57302 3.9039912 957 .81553  68669 18427 65183 3.09 69 3.5021 .88727 4.24736
125 0' 0.32173 0.88722 1.83498 2.37632 2.88501 3.36248 3.81008 4.22914 4.62092
13 0 0.35001 0.96521 1.9963 2.58525 3.13868 3.65814 4.14513 4.60106 5.02732
135 0 0.38077 1.05005 2.17178 2.81252 3.41463 3.97979 4.50962 5.00566 546943
14 0 041423 1.14233' 2.36267 3.05975 3.71482 4.32969 4.90613 544582 59504
145 0 0.45063 1.24272 2.57032 3.32869 4.04137 4.71032 5.33747 5.92465 6.47363
...........15 0 0 .49022 1  35191 2.........79619 362124 4.......39659 512438 5..8067 6.44554 7..04283...............  ýý .4 : . 1 .79619: .6 i: 4.39659 i 5.12438: 5.8067: 6.44554; 7.042831
15.5 0 0.53328 1.47069 3.04188 3.93947 4.78299 5.57479 6.31713 7.01218 7.66203
16 0 0.58011 1.59987 3.30913 4.28562 5.20331 6.06475 6.87239 7.62858 8.33561
16.5 0 0.63106 1 .74039 3.59981 4.66213 5.6605 6.5977 7.47638 8.29911 9.06835
17 0 0.68646 1.89322 3.91597 5.07166 6.15781: 7.17742 8.13338 9.02849 9.86543
17.5 0 0.74672 2.05944 425985 5.51709 6.69872 7.80799 8.84804 9.82189 10.7325
18 0 0.81225, 2.24021 4.63385 6.00157 7.28706 8.49386 9.62538 10.6849 11 6756
18.5 0 0.88351 243681 5.04061 6.52849 7.92696 9.23986 10.4709 11.6236 12.7015
19 0 0.96101 2.65061 5.48297 7.10155 8.62292 10.0512 11.39051 12.6447 13.8174
19.5 0 1.04529 2.88311 5.96404 7.724781 937984 10.9337 12.3908 13.7552 15.0311
....... .. ........... ....... ....... ..  
f
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Fig. 46: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Contribution to death at
age t, from lesion initiated at age a) w/ formulae (a <= 1.5)
The formula here consist only of the terms inside the integration term of Poss(h,t). We have not
yet multiplied the constant of cell B4 (See Figure 43 legend for explanation of this constant)
because every cell must be multiplied by this term. Rather than use up memory to do so, we
wait until integration of these cells to do so. (Figure 49). The term det is defined as Cell D8
(See Figure 43 legend for explanation of this constant).
The G column shows the formulae for the lesions initiated at age 0.5. Reference G4 is for the
age 'a' at initiation; unlike other cells, we did not name G4 as this is a variable.
References E6, E7, E8, .... are for the age 't' at death. Likewise, we cannot name them as these
are variables.
(See the MathematicaTM for confirmation that these are indeed the correct formulas, Section
3.6.1)
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Age at Initiation (a --+
Age at death (t)] 0 0.5
3 0
0.5 i0 =G4*N1..5Nmax 2A(zeta*(G4-1.5))*2((E6-G4)*mu)*EXP((2((E6-G4)*mu)- )*det)
1 0 =G4 N1.5,Nmax*2•(zeta*(04-1.5))*2((E7-G4)*mu)*EXP((2A((E7-G4)*mu)-1)*det)
1.5 0 =G4*N1.5,Nmax*2A(zeta*(04-1.5))*2A((E8-G4)*mu)*EXP((2-((E8-G4)*mu)- )*det)
2 0 4 4*N1.5Jmax*2Tzeta(G4-1.5))•~2(E9-G:41*mu*EXPP(2(E9-G4 m•• u)-ljd )
3 2.5 0 =G4N15Nmax2C(zeta*( 4-15))((2jE1-G4*1muEXP(C2Ei :1-4*muŽ-1 .det
3.5 0 =04*N1 .5max2(zetaG4-1.5)2 1muEXP2mu d
0 ....... =G4 l.N m .... ... .. ......
5. 0 =G4NI G4-1)2 -G4-G4
.5 0 =0G4*NI.5Amax2• zeta*(G4-1.5)*2^(E1 3-G4)uEXP(2XCE1 -G4mu)-1)det)
.5 0 =04*N1 .5Nmax(z G4mu EXP( -G4 mu de)
7 .0 =G4*NI.5ENmax2Yzeta*(G4-1 .5),29((E7-G4*mu)EXP((2^XE17-G4m-0 u-*mudet)7.5 0 =04*N1 .5NMmax*2A(zeta.*.(G4.-1 ..5))* 2..((E2O... .- G.4)*fmu).EXP((2i((E20.G4)*rmu)-I.*d.) ................
7. 0 =G4*NI.5JNmax*2A(zeta*(.4-.5).2.(E194.uAEXP((2E1 4 u)det
8.5 __ _________ _ =G4*N1t.5/max*2(zetaA(G4-1.5))*2A(E22-G4)*mu)*EXP)(p^t((E21-.G4)*m)-det)
9 o =04*NI mx z 4-1 2
S. ...... ............ ...... .... .. ..... . ...90 .=G4*N1.5SNmax*2^(zetaG4-1 .5)*2i.E23-G4)mu)*EXPC( f23-G4*mu)1*det
10 2 '0 i=G4*N1.5,Nmax*2(zeta*G4-1 .5 )2(E29-G4'mu*EXP(2E2-G4)*mu)-1 )det)
105 0 =G4N15max2(a(G4G4 -1
11 0 =G4*N1 .5Mmax"2^zata" 4-.5)) 2)*E27 ~~-GmufX2 7-Gmu1detlr J
1145 0 =G4*N1.5,Nmax*2A(zeta*G4-1 .5).2E*28•3 4)muL)EXP(•A(2(E28-G4mu)-1¶det)
12.5 0 =G4*NI.5JG4-1.) 0-4 amu)EXP2IE30-G4N) mu) 1de
13 0 =G4*N1.5Nmax* 2A(ze taG4-1.5) 2(IE3-G4)*muX*EXP(2•(E31G4mu.-1)det)
13.5 - 0 -=G34N1 .5max 2.zea.(,g4-1.5.).2•(E32-G.4)mu).EXP((2^(E32-G4)..mU)1...d..
14.5 0 =;G4*N1.5JNmaxt2A(zeta*G4-1 2 3X 4*de)
16.5 .0 =G4 N1.5Nmax 2^.zeta¶.G4-1. 5)12^(•E3T-G4mu)EXP.((2,E38-G4)¶_mu)*det)
17 0 =4*NIN .5JNmax *23,-ze•(•4~ 2(E,.39-gi ,uEX( 39,-4.g) ....
16.8.5 s0 =G4*N1.5,4max2A(zetga 4-1 5),)*d4, mur XP_ 41 l et)
19 0 =.4*I N1.5Nmax t2'Yzeta(G4-1 .5W2 E(E43-G4)mu EXP((2E((E43-G04fmu-1elt
15 0 =G4*NI.5Nm2zaG4-1 E44-4
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Fig. 47: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Contribution to death at
age t, from lesion initiated at age a) w/ formulae (1.5 < a <= adulthood)
The formula here consist again only of the terms inside the integration term of PoBs(h,t). We
have not yet multiplied the constant from Cell B4 (Figure 43), because every cell must be
multiplied by this term. Rather than use up memory to do so, we wait until integration of these
cells to do so. (Figure 49). The term det is defined as Cell D8 (Figure 43).
The J column shows the formulae for the lesions initiated at age 2. Reference J4 is for the age
'a' at initiation; unlike other cells, we did not name J4 as this is a variable.
References E6, E7, E8, .... are for the age 't' at death. Likewise, we cannot name them as these
are variables.
(See the MathematicaTM for confirmation that these are indeed the correct formulas, Section
3.6.1)
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=J4*2"(eta(J4-stggrowth))*2o•02 -AJ4)mu) EXP(20((E -J4)mu)-1 det) =K4*2(6eta.K4-st
-=J4*2 Ae2-(otgrowht o i(! 2-JO pu *EXP(C(r2^El -JO 11Net9d = .. f..• a"(K4-sI
=J4*2(eta(J4-stopgrovwth))*2(E1 3-J4)*mu)*EXP((2P(E1 3-J4)mu)-1 )det) i=K4*2eta*(K4-st,
=J4*2A(J4etI stopgrowth)y2(514-J4)*mu EXP(2((E14-J4r)*mu)-Ide) =K4*22eta% K4-sts
=J4*2 *(J4-stopgrowth))*2(Ei0J4)*mu)(EXP(,(Ei2-J4)*muj).*det) =K4*2A aK.4-st-
..J4*aet(J4-stopgrowthl:J)tm2u)E16 EXP((21XE1 7J4)*mu)1)=)4*2A(^CK4-st&
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=J4*2•yet(J4-stgrowth))*2E24-J4)mu*-EXP((A3((4-mJ4)-retu de t) -A s
=J4*2eta*J4-stopgrowth))2~(E6-J4) mufEXP((2 E6-J4)*mu)-1 det) =K4*2 (eta•K4-st
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S=J=K t2Yetaý t-m de A j(K4-stc
=J4*2Aeta(etgJ4-st•growth))p2E32J4)mu)XP(2((E2J4mu)ydet) =K4*2.eta(K4-st
=J4*2/letagJ4-stopgrowth)*2t ((E 34-J4*mn uEXP•(2A^((E34-4Jmu-1i4f.d) =K4*2i(eta*K4-stb
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^J4*2Neta*(J4$stopg.rot))((E3J4)-J )*EX^((EA( (34)ujl )*det =K2(eta*K4-stc
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.4 )..de. =K4.2 .t. K4-stc.
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=JJ4 4-stopgrowth r2(E41-J4 ru)tEXP((2'\E43-J4 m fdet.=K4*2(eta*K4-st
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..... ......... .. .. ...
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Fig. 48: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Contribution to death at
age t, from lesion initiated at age a) w/ formulae (a > adulthood)
The formula here consist again only of the terms inside the integration term of Poss(h,t). We
have not yet multiplied the constant in Cell B4 (Figure 43), because every cell must be
multiplied by this term. Rather than use up memory to do so, we wait until integration of these
cells to do so. (Figure 49). The term det is defined as Cell D8 (Figure 43).
The AN column shows the formulas for the lesions initiated at age 17. Reference AN4 is for
the age 'a' at initiation; unlike other cells, we did not name AN4 as this is a variable.
References E6, E7, E8, .... are for the age 't' at death. Likewise, we cannot name them as these
are variables.
(See the MathematicaTM for confirmation that these are indeed the correct formulas, Section
3.6.1)
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Fig. 49: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Calculation of
OBS(h,t))
Instructions:
This part of the template contains the survival rates as a function of age which need to
be typed into Column HD. All other cells are formulas.
Calculated cells:
The template calculates POBS(h,t) (Column HF),
integrates the product of POBS(h,t) (1 - S(h,t)) (Column HH)
and then calculates OBS(h,t) (Column HG)
Column HI just refers back to the Raw Data worksheet to acquire the observed data.
Column HJ then calculates the error (given a weighing factor), comparing the model
(OBS(h,t)) to the raw data.
The plot of the observed and calculated mortality data of Figure 43 uses Columns HG, HI
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Fig. 50: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Calculation of
OBS(h,t)) w/ formulae
To calculate POBS(h,t) (Column HF), we must account for every single contribution to death at
age t by every lesion (since each column represents the age 'a' at initiation, we summed these
terms and divided by 2 as an approximation to the integral of POBS(h,t)). We now multiply by
the constant terms found in POBS(h,t) (Cell B4 as explained in Figure 43).
(We used SUMIF(cells, ">0") instead of the regular SUM(cells) command because certain sets
of parameters have been found to give errors (i.e. division by 0) which cannot be summed;
these errors typically occur when the maximum likelihood routine tries parameters which are
very small.)
To calculate the integral of POBS(h,t) (1 - S(h,t)) (Column HH), we used multiplication by
trapezoids. For a monotonically increasing function, this is simply:
t
£ [POBS(h,i) (1 - S(h,i)) + POBS(h,i - E) (1 - S(i,t - E))] x e / 2
i = E, intervals of ,
The limit of the above equation as E -- 0, is the exact integral. Since we have calculated
initiation every 0.5 years, we use E = 0.5. (The MatlabTM program had used E = 1).
The calculation of OBS(h,t) (Column HG) is straightforward (Equation 16, Section 3.5.2.2).
We multiply by 100,000 to express rates per 100,000.
(ExcelTM is not case sensitive, so we used 'F' for the fraction at risk (Cell B8), and 'ff for the
correction factor for connected diseases (Cell B9))
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Fig. 51: MAXIMUM LIKELIHOOD TEMPLATE: Fitting worksheet (Calculation of
differences - errors, between observed and calculated OBS(h,t)) w/ formulae
Column HI refers back to the Raw Data worksheet to acquire the observed data. We have used
the ISBLANK construct to detect age groups for which no data had been typed in. The reason
we do so is that in ExcelTM, a formula that refers to a blank cell, assumes a value of 0. What we
want is for this point to be ignored, so we turn the mortality rate to a space, " ". Any formula
that now uses this cell will give an error message instead. (Notice Cell HJ210 in Figure 49,
contains the error message of #VALUE! since no observed data had been typed in for age
102.5, Cell B22 in Figure 42). When the sum of the errors is calculated in C23 (Figure 44), this
error message is ignored because we used the SUMIF instead of the SUM command.
Column HJ then calculates the error (given a weighing factor, See Section 3.6.3), comparing
the calculated OBS(h,t) to the raw data.
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3.6.3.1 Determining Parameters for Best Fit by Maximum Likelihood
The template calculates mortality rates for a given set of parameters in fewer than 1
second, making this a potentially strong tool for maximum likelihood fits which use repeated
iterations. The built-in maximum likelihood function is called the Solver.
Instructions:
1) Click on Fitting worksheet of template file (Figure 43)
2) Go to the Tools Menu and click on Solver (this feature is sometimes not included when
ExcelTM was installed; to install, insert ExcelTM CD and select Custom Installation. This
will give the option to add features that were not originally installed. The Solver is
found under the Add-Ons section). The following window will come up.
jlW~
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3) To fit the data by maximum likelihood, the sum of the errors needs to be minimized, so
select Cell C24 (given the name Error - Figure 43) as our Target cell, and click on Min
(for minimize value). Set Changing Cells to the parameters of interest (to keep a
parameter constant, simply do not include it in this list).
4) The only necessary constraints are the ones shown above, (0.001 < F < 1), (0.001 < f <
1), and 0.01 > (a - 3) > a. Additionally, under the Options section, there is a checkbox
that constraints parameters to non-negative values.
5) Simply click on Solve to run the program.
The Solver will in time give a solution. Cells for the corresponding parameters will have been
changed within the template by the Solver.
3.6.3.2 Effect of a Change in Parameter on Cancer Mortality Rates
The template can also be useful for demonstrative purposes, by illustrating each
parameter's contribution to the carcinogenesis model, and how it affects the calculated
mortality rates. Figure 52 summarizes the results one parameter at a time: the parameter (ri rj),
divided by 2, 4, or 8; the parameter rA divided by 2, 4, or 8; the parameter (a - 13) multiplied
by 0.9, 0.8, or 0.7; the parameter F multiplied by 0.9, 0.8, or 0.7; and the parameter 'f
multiplied by 1.2, 0.8, or 0.4.
By decreasing the initiation mutation rates, the magnitude of the 'slope' of the mortality
curve decreases. The downwards trend in the slope of the curves is due to the slower
accumulation of cells containing the first initiation mutation (2 t ri Nmax a). If the number of
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these mutants decreases, there then is a smaller likelihood of initiation occurring at each age
such that the overall slope of the curve rises slower.
By decreasing the promotion mutation rates, the mortality curves shift rightwards. The
lower the rate of promotion, the smaller the expected number of cancerous cells at age t. Since
the probability of promotion is dependent on the expected number of cancerous cells, lowering
the promotion mutation rate has the net effect of delaying death.
Decreasing the growth rate of precancerous lesions has a similar effect to a decrease in
both promotion and initiation mutation rates, as the expected mortality curves are shifted both
rightwards and downwards. As was the case when lowering the rate of promotion, decreasing
the precancerous growth rate decreases the expected number of cancerous cells at age t (given
that there are fewer precancerous cells at age t). Since the probability of promotion is
dependent on the number of cancerous cells, lowering the growth rate has the net effect of
delaying death (shift rightwards). Additionally, a slower growing adenoma is more likely to
become extinct, where the probability of survival had been previously defined as
(Moolgavkar et al, 1990b). Since fewer lesions are surviving stochastic extinction, then the
mortality rates are consequently decreased as the production of new precancerous lesions with
age is decreased.
Decreasing the fraction at risk has the net effect of decreasing both the slope and area
of the mortality curves. The area is decreased, as quite logically, there are fewer individuals
who can die of the disease. By the same reasoning, since at each age there are fewer
individuals at risk, then there are fewer people at every age that actually die (observed
mortality rate is #dead/#alive) thereby decreasing the slope.
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Fig. 52 Effect of change in a parameter on cancer mortality rates.
Effect of change in one of the parameters ((ri rj), rA, (ca - 13), F, and f) on the cancer mortality
rates.
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To explain the effect of changing fh on cancer mortality curves requires a little more
explanation. This factor determines in part whether an individual at risk for the cancer of
interest is still alive. As a result, the factor fh primary plays a role in the elderly population, as
these individuals are more likely to have already died of a connected form of death. It has a
similar effect to changing the fraction at risk, Fh, in that it determines how many people
actually die of the cancer of interest; in other words, an individual cannot die of the cancer of
interest if they already have died of a connected form of death. Decreasing fh therefore
increases the relative risk of dying from a connected form of death instead, thereby decreasing
the area under the mortality curves for the cancer of interest. It however does not have an effect
on the slope of the mortality curves, because the majority of the individuals who are at risk for
dying of the cancer have not yet died of the cancer or any connected forms of death during
these ages. Changing fh has the net effect of determining when the mortality curve peaks.
3.6.4 Five Equations for Five Unknowns Fh, fh, ri, rA, and (a - 13) Template
Because of the complexity of the three-stage carcinogenesis model, maximum
likelihood techniques can give different final solutions (depending on initial parameter values).
To avoid this complication, Sections 3.5.4 and 3.5.5 formulated a methodology by which to
explicitly calculate the parameters for the three-stage carcinogenesis model without the need to
use maximum likelihood techniques. This section describes the construction of a template that
takes full advantage of this methodology to estimate the parameters of the carcinogenesis
model. (Figures 53-59)
Instructions on how to use this template are included in the legend to the figures.
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Fig. 53:5 EQUATIONS 5 UNKNOWNS TEMPLATE: Raw Data worksheet
Instructions:
1) Transcribe mortality data adjusted for underreporting, OBSR(h,t), into Column B, by
appropriate age category.
2) Transcribe survival data, S(h,t), into Column C, by appropriate age category.
3) The plots reveal the estimates for the values of Ah and (a - 3)
(plots are of the Determine A column versus Age column,
and the Determine (a - 13) column versus Age column respectively)
Formulae are shown in Figure 54
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Fig. 54: 5 EQUATIONS 5 UNKNOWNS TEMPLATE: Raw Data worksheet w/ formulae
Formulae:
Column D calculates OBS*(h,t) by dividing the values from Column B, OBS R (h,t) by the
values from Column C, (1 - S(h,t)). (See Figure 53)
Column E calculates the derivative of OBS*(h,t) approximating it as AOBS*(h,t) / At
(Mortality rates were expressed per 100,000 so column divides back 100,000 to calculate the
derivative)
INSTRUCTION: Transcribe the value for the maximum slope in Cell E24. In the case that
there are two similar slopes, take the average (as illustrated)
Column F calculates the log2 of the derivative of OBS*(h,t).
INSTRUCTION: Fill in all cells with the formula for all ages 17.5 to 57.5. This creates a line
with slope (cc - 3) as shown in plot (Figure 53). Remove the formula from any cell
corresponding to a point of this plot that does not lie on the line.
Column G helps calculate Ah.
INSTRUCTION: Fill in the formula only for the cells corresponding to the two age groups
that encompass the maximum slope. The x-intercept of a line drawn through these two points
estimates Ah.
Column H helps calculate Ah by taking the integral of the mortality data OBSR(h,t) in Column
B. Integral done by trapezoidal approximation.
INSTRUCTION: Fill in the formula only for the cells rio to the maximum. Note that the
maximum can occur between two points. In this mortality curve, the rates are similar for the
age groups 82.5 and 87.5 (Figure 53), so the maximum must occur between these two points.
This however calculates the area only up to the last cell with a formula. It is tempting to
assume that mortality curves are symmetrical, in which case we would multiply by 2, but to
verify this we would need a mortality curve that goes up to age 160 or possibly more.
Alternately, this template simply calculates expected mortality curves for ages up to 200, and
then determines the expected symmetry of the curve and the percentage of the area before and
after the maximum. Cell Il l multiplies the sum of the areas by this symmetry factor
(Reference Fitting!L4, See Figure 58) to estimate the actual area. Again this is divided by
100,000 since the mortality rates had been expressed per 100,000.
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Fig. 55: 5 EQUATIONS 5 UNKNOWNS TEMPLATE: Fitting worksheet (Parameter section)
Columns A and C contain the name tags of the parameters used in the program.
Worksheet contains the calculated errors for the slope estimate, the area estimate, and the
estimate of F.
This worksheet also contains a cell which converts the age to the row number of reference (i.e.
age 5.5 corresponds to row 17).
Given a value of (a - 13) and Ah, the Solver can be used to estimate the promotion mutation
rate. Go to the Tools Menu and click on Solver (this feature is sometimes not included when
ExcelTM was installed; to install, insert ExcelTM CD and select Custom Installation. This will
give you the option to
the Add-Ons section).
add features that were not originally installed. The Solver is found under
The following window will come up.
The Target Cell is the Calculated A (Cell D3). Select the value this cell should equal and select
rA as the parameter to change. Clicking on Solve will change rA until the calculated A equals
the value typed in.
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Fig. 56: 5 EQUATIONS 5 UNKNOWNS: Fitting worksheet (Parameter section) w/ formulae
Instructions:
The following cells must be filled in,
Cell B 1: Number of cells in adult, Nmax
Cell B2: Stochastic survival probability of cancerous cell, (cX - c)/ac
Cell B3: Normal cell turnover rate, T
Cell B5: Precancerous cell division rate, a
Cell B7: Growth rate of precancerous lesion, x -
Cell B8: Fraction at risk, F
Cell B9: Correction factor for connected forms of death, f
Formulae
Cell B4: Parameter equivalent to Kh
Error cells
Cell B 13: Absolute value of (observed area - expected area)/expected area
Observed area - as calculated in Cell 112 of Raw Data worksheet (Figure 54)
Expected area - Equation 23, Section 3.5.4.2
Cell B 14: Absolute value of (F - expected F)/F
Expected F - Equation 24, Section 3.5.4.2
Cell B 15: Absolute value of (observed maximum slope - expected maximum slope) /
expected maximum slope
Observed slope - as calculated in Cell E24 of Raw Data worksheet (Figure 54)
Expected maximum slope - F Kh
The maximum slope could be also described by evaluating the derivative of
OBS*(h,t) at t = age at which the slope is maximum. Section 3.5.4.2 describes how to
calculate this derivative. The resulting formula for this is shown in Cell B 15.
Instructions: Equation 24 (Section 3.5.4.2) has an exponential term for the integral of the
product of POBS(h,t) (1 - S(h,t)) evaluated at tmax. The column for this calculation is K (Figure
58). The row number varies by age; the appropriate row can be calculated by using the feature
as mentioned in Figure 55 to convert ages into row numbers. Put in proper row number in cell
B14.
If using the alternate maximum slope method, the integral POBS (ht) (1 - S(h,t)) evaluated at t
= age of maximum slope is needed. Put in proper row number in cell B 15.
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Fig. 57: 5 EQUATIONS 5 UNKNOWNS: Fitting worksheet - POBS(h,t) w/ formulae
Worksheet calculates POBS(h,t) (Column I) and POBS(h,t) (1 - S(h,t)) (Column J) based on the
modified Nordling model (Equation 19, Section 3.5.4)
PoBS(h,t) = Kh (t - Ah) (t > Ah)
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Fig. 58: 5 EQUATIONS 5 UNKNOWNS: Fitting worksheet - OBS(h,t) w/ formulae
Worksheet calculates the integral of POBS(h,t) (1 - S(h,t)) using integration by trapezoids, and
OBS(h,t) (Equation 16, Section 3.5.2.2)
OBS(h,t) =
F (1 - S(h,t)) R(h,t) P (h,t)h OBS
fP (ht) (1 - S(h,t)) dt
h OBS
F +(1-F )h e
h hi
There are two other cells with formulas here. They are used to help calculate the symmetry of
the mortality curve. It requires the age of the last observed point before the maximum of the
curve, and the other is the relative area under the curve after this point (Calculated as shown in
Figure 59). This factor was used to estimate the area under the curve in Cell I 11 (Figure 54).
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Fig. 59: 5 EQUATIONS 5 UNKNOWNS: Fitting worksheet - Area w/ formulae
Worksheet determines symmetry of the mortality curve by calculating area (integration by
trapezoids) of the area before the maximum, and finding what fraction of the total area it
comprises.
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3.6.4.1 Determining Parameters by 5 Equations 5 Unknowns
The 5 Equations 5 Unknowns template described in Section 3.6.4 can further calculate
Fh, fh, and ri by minimizing the error in the calculated area, calculated slope, and the
calculated F given a tmax.
Instructions:
1) Click on Fitting worksheet of template file (Figure 55)
2) Go to the Tools Menu and click on Solver (this feature is sometimes not included when
ExcelTM was installed; to install, insert ExcelTM CD and select Custom Installation. This
will give you the option to add features that were not originally installed. The Solver is
found under the Add-Ons section). The following window will come up.
klTfl -
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6) To fit the three remaining features of the curve (slope, area, and maximum), the sum of
the errors of these features needs to be minimized, so select Cell C 13 (given the name
Error - Figure 55) as our Target cell, and click on Min (for minimize value), or
alternately click on Value of 0. Set Changing Cells to the parameters of interest (to
keep a parameter constant, simply do not include it in this list).
7) The only necessary constraints are the ones shown above, (0.001 < F < 1) and (0.001 <
f < 1). Additionally, under the Options section, there is a checkbox that constraints
parameters to non-negative values.
8) Simply click on Solve to run the program.
The Solver will in time give a solution. Cells for the corresponding parameters will have been
changed within the template by the Solver.
3.6.4.2 Caveats of the 5 Equations 5 Unknowns Methodology
Because mortality rates have been calculated in 5-year age groups, there is no guarantee
that when selecting the age at which the mortality rate is maximum, and the age at which the
slope of the mortality rates is maximum, that the right ages have been selected. Technically
there is a 5-year window for these parameters based on observation alone.
Using the wrong ages along with the Solver in the 5 Equations 5 Unknowns template
(Section 3.6.4.1) will give results that do not fit the observed mortality data. Adjusting them
within their 5-year ranges and retrying the Solver will eventually give results that fit the data.
Experience has though shown that the results do not vary by more than 5% even if the
parameters chosen had been wrong.
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A further caveat is that if we select the alternate method for calculating the expected
maximum slope (See Figure 56 legend), then the observed estimate of Ah would be in error. As
shown in Figure 60, because of the curvature of the observed mortality rate function, the x-
intercept of the line going through the linear portion of OBS*(h,t) does not correspond with the
expected value of Ah. Experience using this application has shown that the expected Ah is less
than 5 years more than the observed Ah. When using the alternate method, we recommend first
trying Ah + 2.5 to get results that best fit the mortality data.
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Fig. 60: Difference in the observed Ah and the expected Ah
In the 5 equations 5 unknowns methodology, the approximation
OBS*(h,t) =
+ (1 -Fh)h
OBS*(h,t) 
- Fh Kh (t - Ah)
F - Kh h
1 f
1 h o
~h0
(t - A h)
S(t - Ah)(1-S(h,t)) dt
for t < tmax
was made.
However, the denominator is significant enough to create bending on the mortality
curve even prior to tmax. As illustrated this affects the estimation of Ah by a few years.
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4. RESULTS
4.1 Colon Cancer
4.1.1 Calculated Parameters for the Case of (n = 2 and m = 1)
Table 2 and Figures 61, 62 summarize the results for the n=2, m = 1 case, using the five
equations five unknown methodology. Initiation mutation rate ri values are reported assuming
that ri = rj/3. We base this approximation on observations by Grist et al (1992) of HLA-A point
mutations (ri) and LOH (rj) in presumptive T-cell stem cells in vivo and by de Nooij-van Dalen
et al (1998) who studied the pathways of LOH at this same locus in human cells in vitro.
Table 2: Summary of primary and secondary risk parameters, (n = 2, m = 1).
Birthyear Fh fh ri rA
EAM
1840s 0.30 0.11 4.4 x 10-8 8.4 x 10 --
1850s 0.35 0.13 4.6 x 10.8 8.8 x 10 --
1860s 0.38 0.15 5.6 x 108  8.0 x 108  --
1870s 0.41 0.15 5.7 x 108  8.2 x 108  --
1880s 0.40 0.21 5.9 x 10"  1.3 x 107  0.19
1890s 0.40 0.21 6.7 x 10' 8.6 x 10-8 0.20
1900s 0.39 0.24 7.0 x 10"  7.6 x 10"  0.21
1910s 0.45 -- 8.5 x 10"  8.1 x 108  0.19
1920s 0.43 -- 7.6 x 108 8.1 x 10"8 0.21
1930s 0.42 -- 7.4 x 10- 8.1 x 10"8 0.21
EAF
1840s 0.28 0.18 7.0 x 10"  1.6 x 107  --
1850s 0.33 0.18 7.0 x 108 1.5 x 107  --
1860s 0.41 0.15 7.2 x 10- 1.2 x 107  --
1870s 0.39 0.15 7.3 x 108  1.8 x 107  --
1880s 0.40 0.16 6.9 x 10"8  2.5 x 107  0.16
1890s 0.40 0.17 7.0 x 108  3.0 x 107  0.16
1900s 0.39 0.17 7.0 x 10- 2.6 x 107  0.17
1910s 0.39 -- 7.2 x 10- 2.4 x 107  0.17
1920s 0.39 -- 7.0 x 10 2.6 x 10-  0.17
1930s 0.39 -- 7.0 x 10-8 2.5 x 10-7 0.17
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Birthyear Fh fh cx-P
NEAM
1850s
1860s
1870s
1880s
1890s
1900s
1910s
1920s
1930s
0.31
0.35
0.36
0.43
0.45
0.43
0.43
0.43
0.45
0.06
0.08
0.11
0.13
0.17
0.21
m--
4.3
4.3
4.3
4.7
6.1
7.0
6.2
6.2
6.9
NEAF
1860s
1870s
1880s
1890s
1900s
1910s
1920s
1930s
0.41
0.45
0.45
0.44
0.45
0.41
0.42
0.42
0.08
0.11
0.13
0.14
0.14
4.8
4.4
4.6
6.2
6.4
5.9
5.8
6.1
10.8
10"8
10.8
10.8
10-8
10-8
10.8
10-8108-
10.8
10-8
10 -8
10-8
10-.
10.8
10.8
10-8
5.8x
5.8 x
7.1 x
8.5 x
7.4 x
8.1 x
6.8 x
5.6x
8.2 x
8.0
1.5
2.0
2.0
2.5
2.6
2.3
1.8
1 0-81010.8
10.8
10.8
10.810-.
10-8
10-8
10-8
10-8
10.7
10-8
10.7
10-7
10-7
10-7
10-71 o-7
10.8
.8
0.19
0.19
0.18
0.21
0.23
0.21
0.17
0.15
0.15
0.16
0.17
0.17
Comprehensive analysis of the data for birth year cohorts from 1910 onwards was not
possible. Estimation of fh was not possible for these birth year cohorts, as reasonable
knowledge of how the mortality rates decrease at extreme old age is required. (ca-) was still
observable for more recent birthyear cohorts permitting calculation of the promotion mutation
rate, rA. Fh and ri were approximated by noting that the slope of the colon cancer rates for the
later birth years did not show significant changes in their slope (Figures 31 and 32), suggesting
that the area under the mortality curves would be constant. If future data demonstrates that the
area actually changed, this will necessarily have been due to a result of a change in fh, but not
in Fh, as a change in Fh would have affected both the slope and area of the age-specific colon
cancer mortality rate function (Figure 52).
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Fig. 61: Historical trend in Fh and ri, for colon cancer
Historical trend in the calculated fraction at primary risk for colon cancer, Fh, and the
calculated initiation mutation rate, ri, for colon cancer.
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Fig. 62: Historical trend in rA and (a-3) for colon cancer
Historical trend in the calculated promotion mutation rate, rA, and the calculated growth rate of
a precancerous lesion, (xa-P).
246
0
.4,o
0S0
1840s 1860s 1880s 1900s 1920s
Birth Year Cohort
-- EAM -0--- EAF
-A-- NEAM -6-- NEAF
I I I I I
1900s
Birth
1920s
Year Cohort
1940s
30 -
20-
10-
0 - II I I
0
0
0
0.2 -
0.1 -
1880s
__ ·
- - · ·0
247
Similarly, (ca-13) could not be ascertained for birth years prior to 1880 since data for
the age interval 20-60 are needed for this purpose and data were available only from the
reporting year of 1930 forward. As this value appears invariant for each population cohort,
other parameters were estimated assuming that the adenomatous growth rate is a constant.
4.1.2 Calculated Parameters for the Case of (n = 2 and m > 1)
The hypothesis that m=1 is attractive because the observed value for the promotion
mutation rate was similar to the rate of LOH in T-cell precursors (Grist et al, 1992). This would
be consistent with the hypothesis that the necessary event for promotion was the loss of
heterozygosity of any of an undefined set of second gatekeeper genes, such that the fraction at
genetic risk could be defined as the fraction of the population heterozygous for at least one of
the second gatekeeper genes.
However, this hypothesis is inconsistent with the undisputed fact that colon tumors
display a very high fraction (on average 0.22) of LOH and LOI distributed over all
chromosomes (Vogelstein et al, 1988, 1989; Garcia-Patiflo et al, 1998; Resta et al, 1998;
Uhrhammer et al, 1999; Ragnarsson et al, 1999, Cui et al, 1998). There are about 9 x 63 = 567
lineal cell divisions between a first adenoma and first carcinoma cell in colon cancer (9 -
division rate, 63 years -Ah). The rate of LOH or LOI to achieve a fraction of 0.22 from events
in adenomatous growth alone would thus be 0.22/567 = 3.9 x 10-4 LOH or LOI events per
adenoma cell division.
This estimate can be considered in terms of the geometric means of the promotional
mutation rates for different values of m. Calculations are summarized in Table 3.
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Table 3. Calculated geometric mean of promotion mutation rates , m=1-5.
Data are for European-American females born in the 1860s.
(unordered = mutations can occur in any order,
ordered = mutations must occur in one particular order)
For the case of a required order of the promotion mutations, values of m = 3 and 4 yield
mutation rates bracketing the LOH/LOI rate of 3.9 x 10-4. If order were not required, the values
for m = 4 and 5 bracket this value. Such calculations can be of use in considering the number
of LOH plus LOI events that might be required in tumor promotion, but such considerations
should not lose sight of the fact that there is no present evidence that either LOH or LOI events
are required in promotion.
4.1.3 Robustness of the Model
In order to calculate the parameters of the three-stage carcinogenesis model for several
birth year cohorts, maximum likelihood techniques were avoided by making several
approximations. These approximations recognizably might have led to an inadequate
determination of the actual values.
Survival data were obtained by observations from a small, possibly unrepresentative
population (Eisenberg et al, 1968; NCI Monograph No. 6, 1961; Survival Report Number 5,
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1976; Ries et al, 1983; Beart et al, 1995; SEER, 1993, 1997, 1999). Table 4 shows the effects
of a 10% error in the estimate of the relative survival on the calculated parameters for one
cohort, European-American females born in the 1880s. It is clear by inspection that the
population risk parameters, Fh and fh, as well as the initiation mutation rate, ri, would not be
seriously affected by this range of errors. However, the terms for adenomatous growth rate and
mutation during promotion are more sensitive to this type of error.
Additionally, the reported survival data excluded diagnoses of colon cancer first
detected at autopsy. This primarily occurs in the elderly, and may lead to a larger error in the
estimated survival in the elderly. Table 3 shows the effects of a 10% error in the estimate of
survival for individuals older than 75. Again by inspection, the population risk parameters Fh
and fh would not be seriously affected by such an error.
Table 4. Percentage Change in Parameter Estimates Given Errors in Data Sets
(Data for European-American females born in the 1880s were used.)
Fh fh ri rA (a- 3)
+10% error in S(h,t) -0.9 +1.2 -1.5 -12.4 +4.0
-10% error in S(h,t) +0.1 -0.1 +1.8 +8.9 -4.0
+10% error in S(h,75+) -1.1 +1.5 +9.3 -19.8 0
-10% error in S(h,75+) +2.0 -2.6 -10.8 +29.1 0
+10% error in slope +11.1 -12.9 -4.7 0 0
-10% error in slope -5.5 +7.4 +2.6 0 0
+10% error in Ah -9.0 -2.8 +22.1 -48.8 0
-10% error in Ah +5.2 -11.2 -11.7 +95.7 0
+10% error in Ah +3.0 +6.0 +3.5 0 0
-10% error in Ah +0.8 -11.0 -5.5 0 0
+5 years intmax +10.9 -12.6 -17.0 0 0
-5 years in tmaýx +1.4 -1.7 +17.2 0 0
+10% error in a-5 0 0 -4.7 -38.0 0
-10% error in a-03 0 0 +5.4 +95.7 0
MLT model* +3.9 +3.9 -0.3 -21.8 +2.1 +2.0
*Maximum Likelihood Technique
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Robustness of the approach can also be tested for how much an error in any one of the
several observations derived from the raw mortality data by inspection would affect estimates
of the parameters (Table 4). They alert to the uncertainty of the estimate of the promotional
mutation rate, rA, while indicating a general robustness with regard to estimates of all other
derived parameters.
Of additional interest is that the solution that would have been derived by the maximum
likelihood routine (Table 4) showed no significant difference from that given by the five
equations five unknowns methodology (excluding rA once again), giving us the confidence
that the approximations used in this methodology are sufficient to define the parameters of the
three-stage carcinogenesis model.
4.1.4 5 Equations 5 Unknowns Methodology vs. Exact Solution (Moolgavkar and Luebeck,
1992)
Always of concern when using approximations in mathematical modeling is that in
doing so, the end results may deviate from the exact solution with statistical significance. To
verify that the approximation to the linear rising part of the hazard function, POBS(h,t), is not
significantly different from the exact solution, we plugged into our own model the results for
colon cancer incidence rates in Britain as given by the exact solution model of Moolgavkar and
Luebeck (1992). (The growth rate of precancerous lesions were reported as an exponential rate
which can be converted to a doubling rate for our purposes by dividing the estimates of cu and
1 by In 2).
Figure 63 plots the results for both methods on the same plot. The error between our
solution and the exact solution to the hazard function, POBS(h,t), is approximately less than
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4% (Figure 64) giving us reason to believe that our own methodology is sufficient. However,
as verified in Figure 63, the exact solution does indeed deviate from our solution, bending
over, but only at extremely high ages.
The linear estimate, as per Nordling (1953) for the case of two initiation mutations, is
the asymptote to the exact solution, with approximated slope 2 'r r i rj Nmax (c - j)/oc. Herrero
et al (2000) calculated the exact slope of the asymptote, considering the possibility, albeit
small, that a cell in a very small precancerous lesion, undergoes promotion, and then that
precancerous lesion becomes stochastically extinct. (Our approximation only allowed
promotion in precancerous lesions that have already survived stochastic extinction.)
Promotion in one of the cells of this to-be extinct lesion would only be of significance
if the rate of promotion were high. Results from Table 2 (Section 4.1.1) however suggest that
rates for the case of m = 1 are low. If more than one promotion mutation were required, we
recognize that one of these rare events must occur after each promotion mutation, as each
mutation gives rise to a new colony of cells that could become stochastically extinct.
Probability that a precancerous lesion survives
stochastic extinction
2 _rr
2 ri rj Nmax -
-(x + )+ ((x + P)2 - 4ap(1- rA c C2 4,2 T r r Nmax 1 +
2 (1- rA c c)C
Probability that a cell in the precancerous lesion
acquires the necessary promotion event (including a
cell in a colony that later becomes extinct)
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Fig. 63: POBS(h,t) - Comparison of exact solution to 5 Equations 5 Unknowns solution
Comparison of the exact solution of the hazard function POBS(h,t) Solution (Moolgavkar and
Luebeck, 1992) to the approximation as used in the five equations five unknowns methodology
(Sections 3.5.4 and 3.5.5).
We note that there is little deviation until ages t > 100,000 years of age given the estimated
parameters of Moolgavkar and Luebeck (1992).
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Fig. 64: Percentage error of the 5 Equations 5 Unknowns solution to POBS(h,t) versus exact
solution
The ages of interest, 70 < t < 110 which we use in the five equations five unknown
methodology to calculate the slope, have an error < 4%.
The turning over of the exact solution also does not appear to significantly occur before age
1000, as the error for ages 110 to 1000 is less than 0.1%.
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4.1.5 Turning Over of the Exact Solution to the Hazard Function, POBS(h,t)
As shown in Figure 63, the exact solution of the hazard function does not continue to
rise linearly at higher ages. At first glance, this would appear to not have been indicated by
expectation. Nordling (1953) had argued that if the carcinogenesis process required two events,
the hazard function, POBS(h,t), would rise linearly as a function of age, but recall that in the
case that only one event were required, the mortality would be constant for all ages.
Suppose then that two initiation mutations were indeed required. As an individual ages,
the percentage of cells that have not yet acquired the first initiation mutation decreases. In
other words, in an individual who is still alive after a very long time, it is expected that that
individual's organ would be primarily composed of cells containing the first of two initiation
mutations. Therefore, the hazard function should rise linearly for the younger ages, as most of
the cells have not yet mutated and follow a two-mutation process for initiation. Eventually, the
hazard function is expected to bend and appear constant, since as the individual ages,
eventually a majority of the cells would have the first mutation, and consequently the average
cell would more approximately follow a one-mutation process for initiation.
It is imperative to assess the turning over of the hazard function, because in our model
of the observed mortality curve, we have assumed that the curvature is due only to the
existence of a subpopulation at risk that dies off at a faster rate than the remaining population.
Any other form of curvature would lead to an underestimate of the fraction at risk.
Explored here is the rate at which the first initiation mutation must occur such that the
turning over of the hazard function, PoBs(h,t), is significant enough to create the condition that
a large percentage of cells in a surviving individual are carrying the first initiation mutation
during a normal lifetime.
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Assumptions:
Both the first and second initiation mutations may occur in either a stem or
transition cell.
No more initiation events can occur in a turnover unit where the stem cell has been
initiated.
There are Nstem stem cells and Nmax total cells.
There are Ntu cells per turnover unit.
X is the number of times the turnover unit has been renewed since birth
All cells except last layer of turnover unit divide once per renewal.
Divisions in turnover unit are synchronized.
The turnover unit structure is:
0
10 11
100 101 110 111
0
OOOO
where the stem cell is represented at the top, and each layer below represents the transition
cells. Transition cells during turnover give rise to the 2 cells directly below. The stem cell
gives rise to the stem cell and the first transition cell, while the last layer dies off during each
turnover.
Numbers to the left correspond to the cell position. The reason for using binary notation
is that the progenitor cell of a cell with number N1N2N3 ...NLayer is simply N1N2N3
...NLayer- 1. (The exception is that the stem cell (0) gives rise to (0) and (1), showing that this
division is asymmetric).
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We keep track of the state of the cell at each cell position in the turnover unit. The stages are:
State B(position #) - Normal (blank) cell
State I(position #)- Cell has first initiation mutation
State J(position #)- Cell is initiated
PB, PI, PJ represent the probabilities that the cell is in each corresponding state. There are
going to be a total of (3 x Ntu) differential equations per turnover unit. The differential
equations for ANY position are of the form:
aB,position
aX
I,position
aX
aPaPj,position
aX
2
= (1- ri ) PB,progenitor - PB,position
= 
2ri (1- ri )PB,progenitor + (1- rj )Pi,progenitor - PI,position
2
= ri PB,progenitor + rjPI,progenitor
The exact hazard function for initiation in the turnover unit for the last renewal of the turnover
unit is thus represented by:
aP~aPj,positionSdX
while our approximate hazard function for a turnover unit would have been:
2
2 "2 ri rj Ntu
With the following conditions (from Results in Table 2, Section 4.1.1):
j 8x1j8
ri = 8 x 10 rj = 3ri
259
and the sample case Ntu = 256 (real turnover unit size unknown), we can plot the resulting
exact and approximate hazard functions for the turnover unit up to the ages of interest (110
years):
. Ix10-
.2X10-
1X10-
8X10-
6xl103x10
2X10-
2X10-
50 100 150 200 250 300
x-axis is divisions (plotted up to 110 t)
This demonstrates that for mutation rates estimated in Table 2 (Section 4.1.1) for colon cancer,
the exact solution does not turn over significantly. Of course, the age at which the hazard
functions turns over is going to depend on both the size of the turn over unit and the initiation
mutation rates. We check for the following parameters:
Set 1 Set 2 Set 3 Set 4
Nt = 256
rj= x 110-7
rj = 3ri
Nt = 256
ri= 1 x 10 6
rj = 3ri
Nt = 256
ri= l x 10-5
rj = 3ri
"1T=
We suspect that mutation rates will not be higher than those of set. 3, since in vivo mutation
rates of T-cells at the hprt locus are 100 fold lower. (Bigbee, 1998; Branda, 1993; Davies,
Nt = 256
ri= x 10-4
rj = 3ri
,t=3
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1992; Finette, 1994; Henderson, 1986; Hirai, 1995; Hou, 1995; Huttner, 1995; Liu, et al, 1997;
McGinniss et al, 1990; Tates et al, 1991).
Set 1: Plot of exact and approximate hazard functions for the turnover unit on same graph
1 A•x10
1.2x10-
8X10-1 xlO0eXI 0-
6x10"
2X10O
2x1 0-
50 100 150 200 250 300
divisions (plotted up to 110 t)
The percentage difference between the exact and approximated solutions is
number of divisions (first five years)
101
6'
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There is a large error during the first year, since the exact solution accounts for the delay
between a stem cell acquiring the first initiation mutation and the time it takes to repopulate the
turnover unit; the graph above is similar for all 4 sets.
0o.
0.0
0.I
) 1IUU 150 2U00 250 3Uu
error is < 1% for all ages between 5 and 110
Set 2
Plot of exact and approximate hazard functions for the turnover unit on same graph
1.,X10-
1.2x10-
1X10-1 xl0-
8xlO0
6x10-
qx10-
2x1 0-
50 100 150 200 250 300
x-axis is divisions (plotted up to 110 t)
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The absolute percentage difference between the exact and approximated solutions is
0.6
0.2
0.2
50  1 0 0 150 200 250 300
error is < 1% for all ages between 5 and 110
Set 3
Plot of exact and approximate hazard functions for the turnover unit on same graph
50 100 150 200 250 300
x-axis is divisions (plotted up to 110 t)
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The absolute percentage difference between the exact and approximated solutions is
1.5
1.25
1
0.75
0.5
0.25
50 100 150 200 250 300
error is < 1.75% for all ages between 5 and 110
Set 4
Plot of exact and approximate hazard functions for the turnover unit on same graph
50 100 150 200 250 300
x-axis is divisions (plotted up to 110 t)
0.01 .
0.01:
0 . 0:
0. 00;
0.00'
0.00'
0.00:
I
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The absolute percentage difference between the exact and approximated solutions is
50 100 150 200 250 300
error for all ages between 5 and 110
-4
It would thus appear to be true that if mutation rates were less than I x 10-4 (Set 4) per cell
division, the approximation should be more than sufficient. The curvature caused by the
turning over from the depletion of stem cells not yet having acquired the first initiation
mutation should therefore not affect our calculation of the fraction at risk given real
physiological parameters.
4.2 Lung Cancer
4.2.1 Historical overview of lung cancer mortality in the American population.
To gain an overall historical perspective, one can first examine the lung cancer
mortality rates for specific age groups (i.e. 60-64-year olds, Figure 65). There are clear
differences expected from historical data regarding smoking prevalence between males and
females. For the 60-64 year old age cohort, male lung cancer death rates were minimal for birth
decades before 1860 but rose to a maximum value by the 1910-19 birth decade. For females,
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lung cancer death rates were minimal and constant up to the birth decade of 1890 and then rose
steadily not having reached a stable maximum by the birth decade of 1920. A clear historical
difference of about 25 years demarked this gender-specific difference. There are no major
historical differences between European American and African American populations. This
similarity between these American ethnic subpopulations extends to colon cancer but not to all
forms of cancer (Section 4.1.1).
The use of the entire U.S. population grouped into ten year birth year intervals assures a
very high number of observations in each age and birth decade category. They are, with the
exception of rates in children and the category 100+ years, which have little effect on
calculations, generally smaller than the symbols in our figures. (i.e. 35 deaths among 0-4 year
olds born in the 1980s, and 76 reported deaths among 100+ year olds born in the 1880s.) The
complete numerical data set is available for review and further research. (See end of
ABSTRACT for instructions).
4.2.2 Calculated parameters for the case of (n = 2 and m = 1) - Nonsmokers
Mortality rates among women born in the 1820s to the 1880s from lung cancer were
minimal and constant prior to cigarette adoption by each successive cohort. (Figure 65) These
earliest data create an age-specific lung cancer mortality function for the pre-cigarette smoking
female birth year cohorts. (Figure 66) Comparing these results to independently reported lung
cancer mortality rates from the American Cancer Society's second cancer prevention study
(CPS-II) of a much smaller group of one million Americans during the 1980s reveal no
significant differences. (Peto et al, 1988, 1992). (Studies by Enstrom et al (1980), Kahn (1966)
and Doll (1968) are also consistent with the data of Figure 66.
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Fig. 65: Historical trend in lung cancer mortality for 60-64 year olds
A clear historical difference of about 25 years in lung cancer mortality demarks the gender-
specific difference of smoking prevalence.
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Fig. 66: Lung cancer age-specific birthyear specific mortality rates for nonsmokers:
1) European American female nonsmokers (reconstructed from mortality rates for birth
decade cohorts prior to the 1880s)
2) American Cancer Society's second cancer prevention study - female nonsmokers (Peto
1988, 1992)
3) American Cancer Society's second cancer prevention study - male nonsmokers. (Peto
1998, 1992)
Data of (2) and (3) were smoothed by the authors; the raw data show a greater scatter as would
be expected for the smaller cohorts than that comprised in (1).
Peto et al (1988, 1992) also have an estimate for 85+, higher than our estimate of the mortality
using female nonsmokers born prior to the 1880s. However these results are not inconsistent,
since Peto et al's studies are more recent and less likely to be confounded by underreporting.
The effect of a decreased chance in underreporting on a mortality/incidence curve is predicted
by the three-stage carcinogenesis model to result in an increase in fh, thereby increasing
observed mortality rates only among the elderly. (as shown in Figure 52)
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The reconstruction used the data for all females in the U.S. population dying of lung
cancer born between approximately 1820 and 1890. The CPS-II populations of were lifetime
nonsmokers for which smoking status of the deceased was individually determined were born
between approximately 1900 and 1970. The degree of agreement between the reconstruction of
the nonsmoker age-specific lung cancer death rates and those of CPS-II and similar studies is
obvious by inspection. This agreement gives confidence to the estimates of mortality rates at
ages greater than 75 years, which are essential for calculation of risk parameters in the
quantitative carcinogenesis model.
An equivalent attempt for males is confounded by lack of data for birth years preceding
the general use of cigarettes by a significant fraction of American males. The estimates from
the American Cancer Society's second cancer prevention study (Peto et al 1988, 1992)
however suggest that lung cancer mortality rates among nonsmoking males were not different
from those among nonsmoking females. The female data set is therefore used to make first
order estimates of the parameters of lung carcinogenesis among nonsmoking men and women.
From the cross-sectional reconstruction of the age-specific lung cancer mortality for
European American females born prior to the 1880s, the estimated value of (Fh = FNs) is 0.1,
and of fh is 0.15.
The fraction of these obligatory nonsmokers to be at lifetime or essential risk of lung
cancer is about 10%. (The actual fraction of persons dying of lung cancer in these nonsmoking
birth cohorts was actually, as expected, much lower at about 0.7%.) Deaths from lung cancer
represented only about 15% of all deaths caused due to competing forms of death sharing the
identical inherited and environmental essential risk factors for lung cancer in nonsmokers. The
age-specific mortality data for mid 19t" century females in the United States and reported
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observations of these same rates among American nonsmokers of the present era as shown in
Figure 66 are remarkably similar. It appears that the fraction of nonsmokers at lifetime risk of
lung cancer has shown little if any historical variation. This is similar to the finding with
regard to an historically invariant fraction of the United States population at lifetime risk for
colon cancer (Section 4.1.1)
Assuming pro tempore that half of all lung cancer cases occur in the upper bronchi,
permits an estimate for the initiation parameter, 2 r2 ri rj, of 3.4 x 1011 in the tracheal
bronchial and 2.9 x 10-13 for the peripheral bronchiolar region of the lung. As may be noted in
Table 4, varying the fraction of tumors between these regions modifies these calculations to but
a small extent.
Figure 66 permits a straightforward estimate that (cC- 13) = 0.17 doublings per year in
hypothetically exponentially growing preneoplastic colonies in the lungs of nonsmokers at
lifetime risk of lung cancer. This value applies to all tumors of the lung regardless of
anatomical location and is approximately the same as previously calculated for the human
colon. (Section 4.1.1)
Given the values of the population and other physiological parameters it is possible to
estimate rate values for any theoretical biological model of promotion in nonsmokers. For the
case of a single required promotional event, m= 1, one estimates a rate of rA = 2.8 x 10-7 events
per cell division, a value again similar to that estimated for human colon. (Section 4.1.1)
4.2.3 Calculated parameters for the case of (n = 2 and m = 1) - Smokers
Initial analysis is done on the age-specific mortality data for a birth decade cohort for
which the predominant fraction of lung cancer deaths were among smokers and for which
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mortality data exists from early to late adulthood. The cohort of European American males
born 1910-1919 had a maximum smoking prevalence of 0.69. This cohort adopted the cigarette
habit at an average age of 18 and provided sufficient mortality data for analysis of all risk
parameters. (Harris, 1983) Using the estimations of population and physiological parameters
for this cohort as a starting point, analyses to all other cohorts was made, subject to certain
idiosyncratic restrictions due to inadequate data noted in the legend of Table 5. Key initial
approximations are that all members of the cohort began smoking at the average age for the
cohort and that the fraction of smokers for the cohort was the maximum fraction reported by
the cohort in health questionnaires as summarized by Harris (1983) and noted in Figure 33.
For the cohort of European American males of the 1910s, one can estimate the value of
(Fh = FNS U FS) to be 0.71, and of fh to be 0.17. This means that the estimated fraction of this
cohort to be at lifetime or essential risk of lung cancer is about equal to the fraction of smokers
in the cohort. Deaths from lung cancer represented only about 17% of all deaths sharing the
identical inherited and environmental essential risk factors for lung cancer. This lifetime risk
factor showed a clear historical increase among both males and females while the parameter
accounting for competing risks remained historically invariant. (Table 5)
Estimations of the rates of mutations putatively required for initiation are critically
dependent on the assumptions made about the number of required events, n, and the number of
cells, Na, which can give rise to preneoplastic colonies given the necessary event(s). For
smokers, the initiation parameter, 2& ri rj, was found to be about 3.1 x 1011 for the tracheal-
bronchial and 2.7 x 10-13 for the peripheral bronchiolar region. Varying assumptions regarding
anatomical distribution of tumors in the lung had but little effect on the primary observation
that the initiation parameter is much greater in the tracheal bronchial than the peripheral
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bronchiolar region. (Table 5) (A Connecticut cohort of men born in the 1930s was reported to
have somewhat more than 50% of all lung tumors in the upper bronchial tract so use of 50% of
tumors in the upper tract is consistent with these observations). (Zheng et al, 1994; Thun et al,
1997) All of these estimates were historically invariant and remarkably similar to estimates for
nonsmokers at lifetime risk of lung cancer. The value of the initiation parameter estimate for
the peripheral bronchiolar region is almost exactly equal to the previous estimate of initiation
rates in the colon. (Section 4.1.1)
Section 3.5.5.4 (Equation 30) demonstrates the calculation of the growth rate of
precancerous lesions directly from cancer mortality data without need for maximum likelihood
routines. For the colon, the growth rate of adenomas was constant throughout all the reported
birthyear cohorts. (Figure 67) Contrarily, this methodology applied to the lung cancer mortality
data set reveals that the calculated growth rate of precancerous lesions increases among
birthyear cohorts with higher smoking prevalence. (Figure 67)
To explain why the growth rate of precancerous lesions in smokers appears to increase
historically, one must first take into account the effect of having two potentially independent
groups at risk for lung cancer. The growth rates are calculated by simply taking the log2 of the
derivative of the observed mortality data, giving:
aOBS * (h, t) (a -f) tlog2 B( ) ~ log 2(C1 2 ) ~ log 2(C1) + (a - 13)t
at
where C t is a constant associated with the values for the fraction at risk, mutation rates, and the
adenomatous growth rate. This gives a line with slope (a - (3).
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Fig. 67: Graphical estimation of the growth rate of precancerous lesions of the colon and lung
Calculated as the slope of the log2 of the derivative of OBS*(h,t), the mortality rate adjusted
for survival and underreporting. (Equation 4, Section 3.2.6)
Smoking prevalence: EAF 1900s - 23%, EAF 1920s - 42%, EAM 1920s - 69%
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However, this equation is only true if there were only one group at risk. For lung
cancer, the population consists of the union of three groups at risk: (a) individuals who do not
smoke, but are still at risk for lung cancer from independent risk factors, (b) individuals who
smoke and are placed at risk only for cigarette-induced lung cancer, and (c) individuals who
smoke and are both at risk for cigarette-induced lung cancer and lung cancer due to
independent risk factors. Accounting for all groups at risk would affect the calculated slope of
the equation above. As a simplification, the effect of two groups is shown to be:
aOBS * (h,t) (a-P), t 22(a)2 (t-(A2-21))log2( ) ~ log2 (C12 + C2 2 )
at
where (A2 - A1) represents the difference in the expected time until promotion for the two
groups at risk (i.e. smoker's Ah vs non-smokers' Ah).
This function still behaves approximately linearly, with the overall slope now
dependent on the adenomatous growth rates of each group at risk (ca - 13)1,2 and the difference
in the expected time until promotion (A2 - A1), as demonstrated in Figure 68 using values of (ca
- 10) of 0.17 and 0.32 and setting for the example, C1 = C2 = 1. If the time until promotion for
the two cohorts were different, then the estimated value for the precancerous lesion growth rate
(a - 1) for a mixed cohort using the slope of the log2 of the derivative of OBS*(h,t), would be
an approximation of the growth rate for whichever group at risk had the shorter time until
promotion, Ah.
In practice, this means that for a birthyear cohort such as European American Females
born in the 1880s which began smoking at age 31 (Harris, 1983), since the lung cancer
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mortality peak associated with cigarette smoking occurs later than the lung cancer mortality
peak associated with other causes (Figure 27), the calculated value of (a - 13) for this cohort is
no longer representative of the growth rate of precancerous lesions of smokers in that cohort,
but rather that of the nonsmokers in that cohort..
As the age of initiation of cigarette smoking decreases as a historical function of the
birthyear cohorts, then our evaluation of (a - 03) would begin to more accurately estimate the
growth rate of precancerous lesions of smokers. The increasing trend in the values for the
growth rates suggested by Figure 67 is therefore representative of the fact that individuals from
each cohort are starting to smoke at an earlier age, as well as the fact that the fraction of
smokers to non-smokers has increased historically.
The growth rates of precancerous lesions of smokers is therefore best represented by
the estimates from the later birthyear cohorts, -(0.31-0.32).
To calculate promotion mutation rates in smokers, one must further the age when the
average smoker in a cohort began to smoke. As argued by Cook et al (1969), the x-intercept of
the linear portion of the mortality curves, A, is equal to the time between initiation and
promotion, Ab, plus the average age at which exposure to any necessary environmental risk
factor(s) commenced. Correcting for the age at which individuals began to smoke, one can
estimate the true value of Ah and rA among smokers. For the case of a single required
promotional event, m= 1, one can estimate a promotion mutation rate rA of 3.7 x 10-7 events per
cell division. The value of the promotion mutation rate estimate is similar to that calculated
above for nonsmokers as well as to the previous estimate in the colon. (Section 4.1.1)
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Fig. 68: Estimation of (a - 13) in a cohort with two subpopulations at risk for death
Effect of the difference in the expected time until promotion between two groups at risk, (A2 -
A1), on the estimated value of (a - 13) for a mixed cohort consisting of these two groups at risk.
In this example, the two cohorts are assumed to be identical, except for the growth rates of
their precancerous lesions, (a - 13). Values of 0.19 and 0.32 are used.
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Table 5. Summary of calculated parameters for lung cancer.
Lifetime Competing
risk fraction Death Fraction
Fh fh
Initiation Rate
2 T2 ri rj
(tracheal
bronchial)
Nmax - 2.4 x 10
Initiation Rate
22  ri rj
(peripheral
bronchiolar)
Nmax - 2.8 x 10
Promotion Preneoplastic
Rate Growth Rate
FEMALES
Nonsmokers
1880s
1890s
1900s
1910s
1920s
MALES
1870s
1880s
1890s
1900s
1910s
1920s
MALES 1920s
25% upper bronchi
75% upper bronchi
Females
Males
-11 -13 -7
0 0.10 0.15 3.4 x 10 2.9 x 10 2.8 x 10 0.17
-11 -13 -8t
0.03 0.17 0.13 3.8 x 10 3.3 x 10 1.8 x 10 0.31
-11 -13 -7
0.10 0.24 0.13 2.1 x 10 1.8 x 10 1.5 x 10 0.31
-11 -13 -7
0.23 0.31 0.11 2.5 x 10 2.1 x 10 4.2 x 10 0.31
-11 -13 -7
0.37 0.41 0.13 2.8 x 10 2.4 x 10 4.2 x 10 0.31
-11 -13 -7
0.42 0.44 0.13 2.7 x 10 2.3 x 10 7.5 x 10 0.31
-11 -13
- 0.27 0.14 2.5 x 10 2.2 x 10 tt 0.32
-1I -13 -7
0.34 0.37 0.28 2.4 x 10 2.1 x 10 3.0 x 10 0.32
-11 -13 -7
0.49 0.53 0.23 3.0 x 10 2.6 x 10 2.6 x 10 0.32
-11 -13 -7
0.61 0.61 0.22 3.6 x 10 3.1 x 10 2.7 x 10 0.32
-11 -13 -7
0.68 0.71 0.17 3.1 x 10 2.7x 10 3.1 x 10 0.32
-11 -13 -7
-11 -13 -7
0.69 0.70 0.17 1.6x 10 4.1 x 10 3.7 x 10 0.32
-11 -13 -7
0.69 0.70 0.17 4.8 x 10 1.4 x 10 3.7 x 10 0.32
Fcolon  2 r2 rj
10
Nmaxg 8.5 x 10
-13 -7
- 0.40 0.16 - 2.7x 10 2.0 x 10 0.17
-13 -8
- 0.41 0.21 2.3 x 10 8.0 x 10 0.20
t Lung cancer deaths in this cohort were predominantly due to nonsmoking risk factors (only
2-3% smoked) making evaluation of Ah for smokers particularly suspect, further affecting
evaluation of the promotion mutation rate for this cohort.
tt Age of smoking initiation unknown.
Smoking
prevalence
Eh,cigarette ((x -0)
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4.2.4 Calculated Parameters for the Case of (n = 2 and m > 1)
If the required events for promotion required loss of heterozygosity or imprinting, the
hypothesis that m=1 would be inconsistent with the undisputed fact that lung tumors display a
very high fraction (on average 0.6 for either allele) of LOH and LOI distributed over all
chromosomes studied (Wistuba et al 1997, 1999). The rate of LOH or LOI to achieve a fraction
of 0.6 from events in precancerous growth alone would be 0.6/(2x406.4) = 7.4 x 10-4 LOH or
LOI events per cell division.
This estimate can be considered in terms of the geometric means of the promotional
mutation rates for different values of 'm'. Calculations are summarized in Table 6.
Table 6. Calculated promotional event rates for m=l to 6 necessary events in smokers
independent of order of mutations
rA of smokers rA of smokers
-7 -4
m=1 3.0 x 10 m=4 4.9 x 10
-5 
-4
2 4.4 x 10 5 7.7 x 10
-4 -33 2.2 x 10 6 1.0 x 10
4.2.5 Historical Variation in the Histopathology of Lung Tumors.
The distribution of histopathologic types of all lung cancer cases has changed
throughout the past century as evidenced in Zheng et al's (1994) and Thun et al's (1997)
studies of Connecticut incidence data summarized in Figure 34. Use of these data to calculate
risk parameters for the tracheal bronchial and peripheral bronchiolar regions is impossible
without reasonable knowledge of the percentage of the anatomical location of these several
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forms of lung tumors. Since such data were unavailable, estimates were bracketed for the
initiation parameter by considering the cases wherein 25%, 50% or 75% of all lung cancer
cases arising in the tracheal bronchial epithelium. (Table 5, example 1920s birth decades,
European American males).
It has been argued that the historical decrease in the ratio of squamous cell to
adenocarcinomas is due to deeper inhalation of smoke from filtered cigarettes first introduced
in the 1950s. (Thun et al, 1997) On the other hand, the calculated parameter Kh for smokers
was found to be historically invariant (Table 5).
Kh = expected number of new initiated precancerous lesions per year
= Kh,squamous + Kh,adeno + Kh,other
= 2 T2 ri,squamous rj,squamous Nsquamous (CC - )squamous/(squamous +
2 2 ri.adeno rj,adeno Nadeno(Q - )adeno/CC adeno +
2 T2 ri,aother rj,other Nother(Q - •)other/t other
'other' refers to lung tumor types other than squamous cell and adenocarcinomas. This presents
a paradox: how can the total number of new initiated precancerous lesions per year remain
constant, while the age-specific risk for squamous cell carcinomas decreases relative to the risk
for adenocarcinomas?
Analysis of the Connecticut data is not possible with the model, since the data for ages
< 40 is needed to estimate the growth rate of precancerous lesions, but some logic can be used
to generate some hypotheses. The number of cells at risk for each tumor type is logically a
constant, so potential changes in either mutation or precancerous lesion growth rates must be
considered.
Scenario 1: Decrease in the mutation or precancerous cell growth rates of cells which can
potentially give rise to squamous cell carcinomas
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A means for Kh to remain historically invariant, while the ratio of squamous cell
carcinomas to adenocarcinomas decreases, is for a potential decrease in either the mutation rate
or the precancerous lesion growth rate for cells at risk for squamous lung cancers to be offset
by an increase in the mutation rate or the precancerous lesion growth rate for cells at risk for
adenocarcinomas. Thun et al (1997) however demonstrates no discernible change in Kh,squarnous,
as the historical changes in the slope of the incidence curves for squamous cell carcinomas, Fh
Kh,squamous, are proportional to the calculated changes in the fraction at risk for all lung cancers,
Fh, (Table 5). Mutation rates in cells which can potentially give rise to squamous cell
carcinomas have therefore remained historically constant. Furthermore, the estimate for Ah
among male cohorts in Thun et al (1997) does not change significantly. Since this parameter is
dependent on (a - 1), the growth rate of the precancerous lesions, this rate has also not changed
historically.
The differences in the incidence rate of squamous cell carcinomas between cohorts is
therefore solely dependent on the respective differences in smoking prevalence, such that no
discernible decrease is found in the rate of initiation of squamous cell carcinomas. This
scenario therefore cannot explain why the ratio of squamous cell carcinomas to
adenocarcinomas has decreased historically.
Scenario 2: The average age of onset of adenocarcinomas with respect to squamous cell
carcinomas has decreased historically
The age-specific ratio of squamous cell carcinomas to adenocarcinomas can decrease if
the age of onset for adenocarcinomas decreases with respect to the age of onset for squamous
cell carcinomas.
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Figure 69a illustrates this principle for two theoretical incidence curves, A and B, with
a difference in the age of onset of 6 years. Figure 69b shows their respective ratio. When curve
B is shifted left along the x-axis (equivalent to decreasing the average age of onset) this causes
the ratio of the incidence rate of A to the incidence rate of B to decrease.
Thun et al (1997) shows that Ah for squamous cell carcinomas has not varied
historically for men born in Connecticut, at about 50 years of age. On the other hand Ah for
adenocarcinomas has decreased from about 55 years for the male cohort born in the 1890s to
45 years for the male cohort born in the 1930s. Plotting the ratios of the male incidence rates
for squamous cell carcinomas to adenocarcinomas, the results resemble the expectation for two
diseases with a decreasing difference in the age of onset. (Figure 69) A change in the age of
onset of adenocarcinomas then likely explains the observed decrease in the decreasing ratio of
incidence rates of squamous cell carcinomas to adenocarcinomas.
Possible hypotheses to explain a decrease in the age of onset of adenocarcinomas
If smoking prevalence data for men born in the US were representative of smoking
prevalence in Connecticut, the observed change in Ah for adenocarcinomas is then not due to
differences in the age at which individuals began smoking. Men born in the 1890s began
smoking at an average age of 19 while men born in the 1930s began smoking at an average age
of 17. (Harris, 1983) The change in Ah for adenocarcinomas (Figure 34) is however larger.
Other possibilities are that the age of onset was decreased by either (a) an increase in
the promotion mutation rate of cells in the precursor lesion of adenocarcinomas, OR (b) an
increase in the growth rate of the precursor lesions of adenocarcinomas.
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Fig. 69: Effect of a change of onset of one form or death relative to another, on the ratio of
their rates.
a) Theoretical incidence curves A and B with a difference of age of onset, AB - AA, of +6;
b) Ratio of incidence rates A and B, as a function of the difference in the age of onset AB - AA.
c) Ratio of incidence rates for squamous cell carcinomas to adenocarcinomas as a function of
birthyear cohort. (Thun et al, 1997)
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For those cohorts for which few smokers consumed unfiltered cigarettes, exposure in
the lower sections of the lung would be rare. If promotion mutation rates were affected by
cigarette exposure, then incidence rates for adenocarcinomas would concurrently be low in
these individuals, because they primarily arise in lower regions of the lung than do squamous
cell carcinomas. The age of onset for adenocarcinomas would thereby be expectedly later in
life. For more recent cohorts which began to use filtered cigarettes, these lower sections of the
lung would receive higher exposures, theoretically driving up the promotion mutation rates.
This would result in a decrease in the age of onset, which concurrently drives up the age-
specific incidence of adenocarcinomas.
Wistuba et al (1997) have shown that about half of dysplastic colonies in smokers show
an elevated LOH rate, whereas no discernible LOH was seen in respective dysplastic colonies
in nonsmokers. If promotion of lung precancerous lesions were to consist of a series of LOH
events, then cigarette smoking would expectedly decrease the age of onset of adenocarcinomas
as it is inhaled more deeply with the advent of filtered cigarettes. Contrarily, the age of onset of
squamous cell carcinomas would not be affected as these primarily occur in upper sections that
were hypothetically already being exposed by cigarette smoke from unfiltered cigarettes. Thus,
an increase in promotion mutation rates of adenocarcinomas could explain why the ratio of
squamous cell carcinomas to adenocarcinomas has decreased, while the parameter Kh has
remained constant, since Kch is independent of the rate of promotion mutation.
Alternately, the age of onset of adenocarcinomas can be affected by a change in the
growth rate of precancerous lesions. Based on the results for individuals in the US (Table 5),
the primary effect of cigarette smoke was on the rate at which precancerous lesions grow.
These lesions were calculated to grow almost twice as fast in a smoker than in a nonsmoker.
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This effect may be more limited in the lungs of smokers of unfiltered cigarettes, such that the
precursor lesions of adenocarcinomas in these smokers grow more slowly due to limited
exposure. Those pre-adenocarcinoma lesions with high exposure (smokers of filtered
cigarettes) would grow at a faster rate than lesions with lower exposure (smokers of unfiltered
cigarettes).
Such a potential scenario would result in an earlier age of onset of adenocarcinomas
among smokers of filtered cigarettes compared to smokers of unfiltered cigarettes, which
concurrently would drive up the age-specific incidence of adenocarcinomas as filtered
cigarettes were introduced. Again, the age of onset of squamous cell carcinomas would not be
affected since the upper regions where these tumors primarily arise would have been exposed
by unfiltered cigarettes and filtered cigarettes alike. This would therefore explain the observed
historical decrease in the ratio of squamous cell carcinomas to adenocarcinomas.
In this case, we must however note that the parameter Kh is dependent on the rate at
which precancerous lesions grow. In order to maintain Kh constant while (a - 13)adeno increases
historically, the division rate of cells in the precursor lesion of the adenocarcinoma, aadeno,
must increase by the same proportion as the death rate of cells in the precursor lesion of the
adenocarcinoma, 13adeno. Increasing both division and death rates by the same proportion keeps
the term (c - 13)adeno/aadeno and thereby the number of expected new precancerous lesions per
year, Kh, constant even with a change in the growth rate of the precancerous lesions, (a -
13)adeno. In the analysis summarized in Table 5, calculations had been made assuming that ca was
the same for smokers and nonsmokers alike. To confirm this, it would be of interest for
research to be conducted to determine the difference, if any, in the division rate of cells in
precancerous lesions of smokers and nonsmokers.
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4.2.6 Comparison of the Fraction at Risk for Lung Cancer and Smoking Prevalence
Plotting the estimates of the lifetime fraction at risk for each birth decade, Fh, versus
Eh,cigarettes (Figure 70), reveals a simple linear relationship. Strikingly, the data include all birth
decade cohorts of European males and females as well as the estimate of lifetime lung cancer
death risk for nonsmokers. Solving the implied algebraic relationship, the calculated fraction of
smokers at lifetime risk of lung cancer is 0.94. However, the use of the maximum fraction of
smokers at any age for each birth decade cohort to initially define Eh,cigarettes must to some
degree include individuals of less than lifetime smoking habit and thus a lower lifetime risk.
Thus Eh,cigarettes must to this degree represent an overestimate of lifetime smoking prevalence.
Underreporting of cancer deaths in general and lung cancer in particular would, of course, lead
to an underestimate of Fh. and thereby an underestimate of the fraction of lifetime cigarette
smokers at lifetime risk of lung cancer death. It is clear, therefore, that at least 94% of smokers
are at lifetime lung cancer risk and a reasonable interpretation would include, and perhaps
favor, an estimate of 100%. Lower estimates are not in accord with these data. (Belogubova et
al, 2000).
4.2.7 Comparison of Age-Specific Lung Cancer Rates between Genders.
The idea that cigarette smoking women are at greater age-specific risk of lung cancer
than cigarette smoking males has been suggested both by a number of studies in which cohorts
consisting of female smokers with lung cancer were interrogated with regard to past smoking
levels and studies of differential production of DNA adducts in the lung. (Risch et al, 1993;
Ryberg et al, 1994; Kure et al, 1996; Tang et al, 1998)
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Fig. 70: Calculated fraction at risk for lung cancer vs. smoking prevalence
Fraction of the population at risk for lung cancer as a function of maximum smoking
prevalence for birth decade cohorts of European American males and females. (open circles -
females born in the 1880s to 1920s; closed circles - males born in the 1880s to 1920s)
0.80
0.60
Flung 0.40
0.20
0.00
Flung = 0.82 Ecigarettes+ 0.12
0 0.2 0.4
Ecigarettes
291
0.6 0.8
292
Such cohorts are perforce smaller than the entire female population, but this aspect of smoking
and cancer risk can be explored using a large cohort of males and females where the cohorts
had identical self-reported maximum smoking prevalence. The fraction of adults using
cigarettes was -35% among males born 1881-1890 and among females born 1911-1920.
(Harris, 1983). It is obvious by inspection that these populations showed near-identical age-
specific lung cancer mortality rates. (Figure 71) These values include all men and women
smokers in these birthyear cohorts, so that these data are perforce comparing the effect of
average smoking habits in females to average smoking habits in males. They do not permit
analyses of dose dependent effects of smoking levels or of other characteristics such as
inhalation habits which may differ between males and females of these birth decade cohorts.
4.2.8 The Age-Specific Appearance of Dysplastic Lesions
The model can also be used to predict the expected age specific appearance of
surviving initiated colonies. Figure 72 shows the predicted number of surviving preneoplastic
lesions in the upper bronchial tracts of smokers and nonsmokers as a function of age. These
expectations may be directly compared to the painstaking efforts reported by Wistuba et al
(1997) in which dysplastic lesions and carcinomas in situ were enumerated in dissected upper
airways of smokers and nonsnmokers of known age at death.
Wistuba et al (1997) reported zero moderate to severe dysplastic colonies or
carcinomas in situ in twenty-one nonsmokers of average age of 29. For nonsmokers of this age
the model predicts that fewer than 1 in 25 would carry a surviving preneoplastic lesion a
prediction consistent with observation. (Figure 72) Wistuba et al (1997) also reported
observations of 27 potentially preneoplastic colonies among 18 smokers born in the 1930s.
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Fig. 71: Effect of gender on lung cancer mortality rates
Given equivalent maximum cigarette use
Males (1880s) and females (1910s).
- Males born in the 1880s
o Females born in the 1910s
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Fig. 72: Expected number of preneoplastic lesions as a function of age
For these calculations it was assumed that 50% of preneoplastic colonies arise in the upper
bronchial tree, that 10% of nonsmokers and 100% of smokers are at risk of developing
preneoplastic colonies and that the growth rate in smokers is 0.32 and in nonsmokers 0.17,
with identical initiation rates in smokers and nonsmokers, as recorded in Table 5. Shown as a
filled circle is the number of carcinomas in situ per smoker (7/18) reported by Wistuba et al
(1997) in a group of 18 male smokers of average age 60 yrs. Wistuba et al (1997) also
reported a total number of moderate to severe dysplastic lesions of 1.1 per person (20/18) in
this same group.
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averaging 60 years of age. Of these, 7 were carcinomas in situ and 20 were moderately to
severely dysplastic lesions. The predicted number of preneoplastic lesions in male smokers at
age 60 is obviously consistent with the reported number of carcinomas in situ and significantly
less than the number of other dysplastic lesions.
4.2.9 Prediction of Lung Cancer Mortality Rates Among Former Smokers
Peto et al (2000) published a large retrospective study of lung cancer in former
smokers. They presented their data as the cumulative age-specific risk for cohorts of British
males who smoked from mid teens or later to age 30, 40, 50, and 60. The cumulative age-
specific risk is calculated as (1 - exp(-integral of POBS(h,t))) from birth to the age of interest.
This provides a secondary test of the interpretation that the only two parameters affected by
cigarette smoking were the fraction at lifetime risk, Fh , and the growth rate of preneoplastic
lesions, (ca-13).
The approach is to calculate the size and distribution of preneoplastic lesions in
smokers starting at the age of smoking initiation and ceasing to smoke at exactly ages 30, 40,
50 and 60 to accord as closely as possible with the conditions defined by Peto et al (2000). In
physiological terms, existing preneoplastic colonies were assumed to continue to grow with a
net growth rate of 0.17 doublings per year after smoking cessation, and that 10% of former
smokers remained at lifetime risk of developing new lesions as was calculated for nonsmokers.
(Table 5) This would intuitively have the effect of delaying the appearance of a tumor from a
pre-existing preneoplastic lesion and would drop the number of expected subsequent surviving
preneoplastic lesions to that expected in the average nonsmoker.
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These predictions are presented along with the observations of Peto et al (2000) in
Figure 73. The distributions of ages of smoking adoption and cessation among the several
cohorts were not precisely known. Incidence among lifetime smokers best fit if the average age
of smoking adoption was 22.5 years, which was applied to all other cohorts. The age smoking
cessation had been defined as "around 60,50,40 and 30 years of age" leaving some uncertainty
as to the actual length of smoking experience especially for those who ceased smoking at
"around 30," but it was assumed that cessation occurred at exactly those ages. Since the
epithelium of former smokers undergoes significant histologic changes back to that of normal
epithelium of nonsmokers by five years after cessation, a relaxation time of two years to return
to nonsmoker parameters is assumed. (Auerbach et al, 1962).
Figure 73 shows that the hypothesis that cigarette smoking affects growth rates of
precancerous lesions is wholly consistent with Peto et al's (2000) data for cumulative risk of
lung cancer among former smokers.
This is consistent with the analysis of the U.S. lung cancer mortality data which had
suggested that growth rates of precancerous lesions in smokers were greater than in
nonsmokers. Not having known these previous results, one may be tempted to test the alternate
hypothesis, that cigarette smoke has a direct mutagenic effect on mutation rates of lung
epithelial cells. Figure 73 predicts the effect that a decrease in mutation rates (both initiation
and promotion) would have had on incidence among former smokers. The results conclusively
agree better with the hypothesis that growth rates and not mutation rates are altered by cigarette
smoke, but the possibility that there might be a small effect on mutation rates within smaller
subpopulations of smokers (i.e. heavy smokers) could not be dismissed with the analysis alone
of Peto et al's (2000) lung cancer incidence data among former smokers.
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4.3 Caveat
Calculations based on the actual public health records and the assumptions outlined
herein have one very important characteristic when it comes to thinking about mutation rates,
cell kinetics and cancer. They are derived from observations of persons who died of cancer.
They provide absolutely no information about mutation rates and cell kinetics in persons who
are not at risk.
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Fig. 73: Age-specific cumulative risk of developing lung cancer among former smokers
Markers represent data from Peto et al (2000) and lines represent the cumulative risks
predicted by model. Numbers on the right hand side represent approximate age at which
smoking cessation occurred.
a) Predictions assume that preneoplastic lesions of current smokers grow at a doubling rate of
0.32, preexisting precancerous lesions in former smokers continue to grow at a doubling rate of
0.17 two years after smoking cessation, and only 10% of former smokers develop new
precancerous lesions after smoking cessation, as calculated for nonsmokers (Table 5).
b) Predictions assume that preneoplastic lesions of smokers and nonsmokers grow at the same
doubling rate of 0.32. Two years after cessation, initiation and promotion mutation rates were
decreased 6-fold (best fit).
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5. DISCUSSION
5.1 General Conclusions
Use of the data for survival probabilities as a function of age and history has extended
and confirmed the earlier interpretation based on mortality data alone that there is a true
maximum in the age-specific colon cancer mortality rate for males and females in both
European- and African-American subpopulations. This interpretation is essential for the
development of a means to calculate the fraction at risk of cancer for each birth year cohort.
Using an extended Knudson-Moolgavkar model for initiation and promotion, in which
'n' rare events are required for initiation and 'm' for promotion, and the approximation of
Equation 14 (Section 3.5.2.2) to account for competing forms of death sharing environmental
and/or genetic risk factors with cancer, permits calculation of birth year cohort-specific values
for the fraction at primary risk, the product of initiation mutation rates, the product of promotion
mutation rates, and the average growth rate of the precancerous intermediate colony.
Since these parameters have been calculated for each birth year cohort, their historical
changes may be observed. These in turn may be considered in terms of historical changes in
human habits and their environment. These parameters may be compared between the two large
demographic cohorts for which data are available. Similarly, the parameters for males and
females may be compared.
In particular, the robustness of the estimates for each parameter calculated relative to
uncertainties in the accuracy of the recorded data has been determined. The effects of +/- 10%
errors in the estimates of the slopes of the ascending age-specific mortality data or the intercepts
of these data extrapolated to an age intercept were examined on estimates of the calculated
parameters. These uncertainties were found to result in errors of less than +/- 25% for estimates
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of initiation mutation rates and growth rates of preneoplastic lesions. However, errors in the
estimates of the rates of promotion events were far less robust leading us to place little reliance
on what might otherwise have been interpreted in historical shifts in this parameter. In short,
estimates derived from the data set by this mode of analysis are no better but no worse than the
public record and the accuracy of the three-stage hypothesis of carcinogenesis that underlies our
mathematical model.
In one important area, the use of estimates of mortality rates at ages above 80 years, the
degree of accuracy trespasses on the widely held belief that such data are grossly inaccurate and
unusable for quantitative analyses. Recent records are bolstered by the prevailing
Medicaid/Medicare system of reporting the care and causes of death in the very aged and are in
general agreement with earlier records of death rates at ages > 80 yrs. Furthermore, mortality
rates among the elderly in Malmo, Sweden, where autopsies were once required after every
death, also decreased among the elderly. (Prof. Thilly, personal communication)
Even so only the accuracy of but one parameter, fh, would be seriously affected by the
supposed underreporting of death rates among the extremely aged for any specific cancer type.
Such underestimates would lead to overestimation of fh, the fraction of the lifetime population at
risk that is expected to die of the particular cancer given only multiple competing forms of
mortality. (Figure 52)
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5.2 Colon Cancer
5.2.1 Historical Changes in the Fraction at Primary Lifetime Risk, Fh.
Implicit in the assumption that an individual is or is not at lifetime risk of any particular
form of cancer is the existence of inherited and/or environmental factors that create a condition
essential for the incidence of cancer during a maximum human life span. An inherited factor
necessary for initiation or promotion that is not carried by all members of the population is an
essential factor if persons without this inherited factor would not experience the specific cancer
type in a maximum human life span. An environmental factor could take the place of an
inherited factor in terms of physiological effect or it could interact in an essential manner with an
inherited essential risk factor.
The fraction at primary risk of colon cancer has remained essentially constant for the
birth year cohorts of the 1860s to the 1940s (Figure 61). This is true for males and females of
both European or African heritage. This fraction is about 0.4. It is possible that this fraction at
risk was increasing from 0.3 for the birth cohort for the 1840s to 0.4 for the 1870s.
The constancy of this fraction during a period of marked changes in American life in
nutrition, smoking habits, level of exercise, industrialization and urbanization is striking. These
data suggest that none of these known environmental changes had any effect on the fraction at
risk. It might be imagined that there have been offsetting environmental changes but such
arguments, absent data, violate the "law of parsimony". It should be noted that this result does
not indicate that there are no environmental factors affecting age-specific colon cancer rates.
Subpopulations with conditions varying significantly from the population average might have
higher or lower rates depending on their circumstances.
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A large fraction at risk of 0.4 may seem surprising, given that less than 5% of all deaths
result from colon cancer. This result, however, emphasizes the importance and necessity of
accounting for all other connected forms of death in calculating the primary risk fraction for any
mortal disease, as well as taking into consideration that an individual dying of an independent
form of death (i.e. accident) could have potentially died of colon cancer had they not prematurely
died.
The estimate of 0.4 represents a minimum value for the fraction at primary genetic risk.
If all persons were at environmental risk (i.e. no environmental risk factor necessary), then the
fraction at primary genetic risk would be 0.4.
Case I: Genetic risk is conferred by a dominant mutation non-deleterious for reproductive
fitness
In this case, homozygous recessives (wild type) would not be at genetic risk, but
heterozygotes and homozygous dominants would be at equal risk. If risk were monogenic and
the dominant and recessive alleles have reached Hardy-Weinberg equilibrium in the population,
2
then the sum of heterozygous and homozygous dominant fractions would be 0.4 = 2pq + q . "p"
is the allele frequency of recessive and "q" of dominant alleles such that p + q = 1. Solving this
quadratic equation, q= 0.23.
For the case of a dominant monogenic primary genetic risk factor, the sum of inherited
alleles coding for risk would thus be 0.23. For multigenic risk the average value of q would be
equal to (0.23 / number of genes), and for polygenic risk the average value of q would be equal
to 0.23 1/number of genes (i.e. 0.5 for 2 genes).
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These estimates are in the realm of possibility if there were no physiological effect on
reproductive fitness for homozygous or heterozygous states. The physiological effect would be
limited to a risk of death by colon cancer at advanced age. Since the average rate of gene
mutations leading to gene loss is about 3x1 0-5 per human generation and there have been about
104 human generations, the accumulated mutant fraction of about 0.3 would be expected for the
sum of a set of neutral alleles for a single gene.
A hypothesis that primary genetic risk for colon cancer is defined by any of a set of non-
deleterious dominant mutations in one or several genes is thus not inconsistent with the
calculated primary risk fraction of 0.4. The physiological effect of such a dominant mutation
could affect initiation, promotion or progression, there being no way to differentiate among these
possibilities with the existing data or understanding of carcinogenesis.
Case II: Genetic risk is conferred by homozygosity for a recessive mutation non-deleterious
for reproductive fitness.
In the case where primary genetic risk for colon cancer requires inheritance of two
recessive alleles of the same gene, neither of which affect reproductive fitness, the fraction of
2
recessive homozygotes would be q = 0.4, or q = 0.63 for a monogenic disorder.
Since these recessive alleles in homozygous or heterozygous form would have by
definition no effect on reproductive fitness, they might have reached so high a fraction in present
day populations if the mutation rate for a single gene were about twice the average for all gene
inactivating mutations (See Case I) or if the risk were distributed over several different genes. As
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in Case I, one could not logically deduce which stage of carcinogenesis might be affected by the
recessive homozygous state.
Case III: Genetic risk is conferred by a recessive mutation deleterious for reproductive fitness.
A third possibility is that risk is conferred by a set of alleles in one or more genes in
which homozygosity for such mutations is lethal in embryos or at least prevents reproduction.
Assuming again that these alleles are in Hardy-Weinberg equilibrium and that mutations leading
-5
to gene loss, average about 3x10-5 per generation, the average expected sum of mutant allele
fractions for heterozygotes in any one gene would be 0.013 in the population. The actual value
for any gene would depend on gene size and the presence of particularly marked mutational
hotspots. For these to sum to 0.4, a multigenic model is obviously required. Forty separate genes
each at the Hardy-Weinberg equilibrium value of about 1% would be a hypothesis consistent
with these calculations.
In colon cancer, it would appear that any required event involving loss of heterozygosity
would occur during promotion since the events of initiation are accounted as loss of two wild
type APC alleles, and events in progression would not be rate-limiting. An inherited condition of
heterozygosity in one of these 40 genes would therefore be sufficient to account for primary risk
since the need for only a single LOH/LOI event for promotion would presumably place these
individuals at equal risk.
A model considering a polygenic combination of deleterious recessive alleles would have
to consider a very large number of genes (>1000). This consideration leads to the conclusion that
a combination of LOH events during promotion involving two or more genes carrying alleles
deleterious for fitness is an unlikely scenario.
308
In summary, a primary genetic risk fraction of 0.4 or higher could be conferred by mutant
alleles of one or a few genes if reproductive fitness were not affected. On the other hand, 40 or
so genes would seem to be required to create so high a primary genetic risk fraction if
homozygosity for the mutant alleles did prevent reproduction. In the former case, the original
alleles occurring as hotspot mutations would have arisen and been fixed multiple times
throughout human history. In the latter case, selection against ancient deleterious mutations
would leave only relatively recent mutations. In large present day populations, such as those of
Asia, Africa and Europe, these would be expected to be distributed over very large numbers of
families.
5.2.2 Historical Changes in the factor Accounting for Connected Risks, fh.
As may be seen in Table 1 (Section 4.1.1), fh increases markedly in historical time for
three of the four cohorts and has a maximum value of 0.24 in the most recent European-
American male cohort for which fh may be calculated. Values for males are generally higher
than for females.
This factor accounts for both underdiagnoses, underreporting, and deaths of persons at
risk of colon cancer by other diseases which share the genetic and/or environmental risk
factor(s). Underdiagnoses and underreporting should have decreased from 1930 to 1992. The
increasing value of fh is probably in part accounted for by this trend. On the other hand, the low
value of fh derived from the populations born in this century suggests that the genetic and/ or
environmental risk factors for colon cancer are responsible for a significant fraction of other
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deaths. Given that colon cancer accounts for somewhat less than 5% of all deaths and that the
value of fh is about 0.2, one must consider that risks for colon cancer are associated with as
much as (5% / 0.2) = 25% of all deaths. So large a fraction could comprise all cancer deaths;
alternately, the genetic or environmental risk factors for colon cancer could contribute to a large
fraction of vascular disease.
As noted in Section 3.5.2.2, fh is an approximation forced by ignorance of any forms of
death sharing risks with colon cancer. It is the shakiest part of this modeling effort and represents
an area in which more theoretical work is needed.
5.2.3 Historical Changes in Initiation Mutation Rates, ri rj.
Estimates of the rate of the first initiation mutation for the condition n=2 varied from 4 to
-8
8 x 10 over all four gender and ethnic cohorts for the birth year cohorts from the 1840s to
1940s. Based on Grist et al (1992) the ratio of the loss of an active gene by primary mutation was
approximately one third the rate of allelic loss by LOH. Thus, rj = 3 ri has been used to calculate
ri after the product rirj was calculated. These values are remarkably similar to observed rates of
spontaneous mutations for gene inactivation in human cell cultures of about 10 per cell
division. They are almost identical to an estimate of about 0.7 
x 10
per stem cell division
derived from the age dependent hprt mutant fractions in human peripheral T cells assuming three
stem cell divisions per year. (Figure 8) (Bigbee et al, 1998; Branda et al, 1993; Davies et al,
1992; Finette et al, 1994; Henderson et al, 1986; Hirai et al, 1935; Hou et al, 1995; Hutner et al,
" ~ ' - - --
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1995; Liu et al, 1997; McGuniss et al, 1990; Tates et al, 1991). These values are consistent with
a model of loss of the first APC allele in colonic stem cells at a rate of about
cell division and a rate of LOH for the second allele at a rate o 0
8
7 x 10- :per stem
per stem or
transition cell division. So close are these calculated values to observed human in vivo mutation
and LOH rates that n = 2 is established for colon cancer initiation until contradictory evidence is
discovered.
fIhe mutation rate tor European-American Females is essentially invariant at 7 x 10
with historical time, but the data suggest a significant increase in mutation rates in both male
-8 -8
cohorts from a steady value of 4 x 10 from the 1840s through 1880s to over 6 x 10 from the
1880s through the 1940s. African-American Females appear to show a steady increase from 4 x
-8 -810 in the 1840s to the 1900s when it reaches the rate of 7 x 10 seen in European-American
Females.
Considering each birth year cohort as an independent trial, one could agree that the
differences are statistically significant. However the accuracy of primary data for OBS(h,t),
S(h,t) and R(h,t) cannot be ascertained, nor can the accuracy of the approximation represented by
fh. The apparent differences might arise from unknown biases.
Another uncertainty is that the studies of Fuller et al (1990) and Jass et al (1992) provide
estimates for the rates of colon stem cell LOH of about 7 x 10-6 LOH events per colonic stem
cell division, 30 times higher than LOH rates derived from observations in T cells. If these LOH
rates for colonic stem cells are accurate and apply to transition cell divisions, then the estimate of
- I- --- ~ - -~ -
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the loss of the first APC allele by point mutation or deletion must be reduced to about 2 x 10-9
per stem cell division. There are no data available to exclude this possibility.
5.2.4 Historical changes in Promotion Mutation Rates, rA.
The number of genetic changes required for promotion in colon cancer is unknown.
Values for the geometric mean of the mutation rates for m= 1, 2, 3 .... as an estimate of rA must
be considered.
These genetic changes could be gene "activation" missense mutations, gene inactivation
events, LOH for an inherited heterozygous state, or loss of imprinting of a gene by other
mechanisms (LOI). These processes could involve point mutations, recombination, chromosomal
and or chromosomal segment loss. As noted above (Section 5.1.1), on the basis of population
genetics, there could be one and only one promotional LOH event in the case of an inherited
recessive allele deleterious for fitness in the inherited homozygous state.
-7For the case m=l, the estimated value of rA is about 2x10 per cell division for females
-8
and 8 x 10 in males, a value which is approximated by LOH in human T cells in vivo or gene
inactivation of a somewhat larger than average gene. It is however much lower than the colonic
-6
stem cell LOH rate of 7 x 10 derived from Fuller et al (1990) and Jass et al (1994). If any of
multiple genes were involved, then activation of any of several proto-oncogenes might also be
considered a numerically reasonable hypothesis.
It is clear that if m= 1 no increase in promotional mutation rates above those seen in
normal human T cells need be invoked to account for the age-specific colon cancer rates in
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humans. Curiously, the historical estimate of this promotion mutation assuming m = 1 is
8
remarkably constant for both European and African-American males at about 8 x 10 . For both
European-American and African-American females it appears to have risen significantly from
-7
the mid-ninetieth century to a constant level of about 2.5 x 10 since the 1890s.
The differences between the genders and similarities between the ethnic groups may give
some reason to place confidence in these results, leading to the question of what environmental
changes may have affected all women beginning in the 1860s that was completed by the 1890s
which might conceivably have affected promotional mutation rates. On the other hand, the
differences, while apparent, may have arisen by the action of unknown biases in reporting or
diagnosis which were in some way gender specific. Given the economic differences of the ethnic
groups, however, one would have expected such biases to effect comparison between ethnic
groups. Such differences do not appear at all.
5.2.5 Historical Changes in the Growth Rate of Precancerous Lesions, (aX- 3).
These values are extraordinarily constant at about 0.2 for males and 0.17 for females over
the entire historical period analyzed. The gender specific differences appear to be real and
constant over a century of birth year cohorts. There appear to be no differences between the two
ethnic groups. It would appear that the many environmental changes during the century observed
have had no effect on the net growth rate of colon adenomas.
It is worth noting that these net growth rates of 0.2 and 0.17 doublings per year are
remarkably similar to the net growth rates of children which are about 0.16 (Figures 35 a,b). Net
r
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colon carcinoma growth rates are about 20 doublings per year which may be compared to the net
growth rate of the human fetus of some 54 doublings per year.
These similarities give a quantitative basis for the idea that the genetic steps of.
carcinogenesis recreate the conditions of fetal and postnatal growth in reverse. In this scenario,
the mutations permitting adenomatous growth take the cell back to the growth rates of children
while the additional change(s) creating a carcinoma cell permit the more rapid growth rate of
fetal life.
It is necessary to note that the observations of a, 13 and t were made in adult colons. It
would be interesting to know if t changes in neonatal and childhood growth.
5.2.6 High LOH and LOI Levels in Human Colon Carcinomas.
The fraction of loci showing LOH or LOI is on average about 0.22. This high fraction
would not be produced in adenomatous growth at the LOH rate observed in human T cells of
.7
about 2 x 107 mutations per cell division. The rate of LOH/LOI necessary to achieve such a
-4
fraction was calculated out to be about 4 x 10-4 per cell division. A comment on a common error
in this matter of high LOH/LOI levels in tumors is in order. Some cancer researchers have used
only the number of net doublings in adenomatous growth to account for an LOH/LOI fraction of
0.22. This would be the log2 of the cell number of an average adenoma at promotion, which is
log2 2 (a-O)Ah, or about 17. However one requires the total niumber of linear divisions
between the first adenoma and first carcinoma cell for this calculation. This number is about aAh
= 567.
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This represents an estimated 2000 fold greater rate than observed in normal human
lymphoid cells in vivo and in vitro and about 60 fold higher than estimated for normal colon stem
cell LOH rates. So high a rate would however accommodate a value of m = 4 LOH/LOI events
required for promotion (Table 3) in initiated cells.
Even if this high LOH and LOI rate occurred in colon adenomas, it would not necessitate
the conclusion that the number of promotional events were 3 or 4 or that LOH or LOI were
-4
involved in promotion. Even if the LOH/LOI rates increased to 4 x 10-4 in adenoma cells, the
necessary promotion event might still be a single point mutation occurring at a rate of 2 x 10-7
per cell division.
5.2.7 Conclusions
From public records from the 1930s to the present day, the three-stage carcinogenesis
model predicted that the fraction of the population at primary risk for colon cancer risk was
historically invariant at about 42% for the birth year cohorts from 1860 through 1930. This was
true for each of the four demographical groups examined (European- and African-Americans of
each gender). Additionally, the data indicate an historical increase in the initiation mutation rates
for the male cohorts and the promotion mutation rates for the female cohorts. Interestingly, the
calculated rates for initiation mutations are in accord with mutation rates derived from
observations of mutations in peripheral blood cells drawn from persons of different ages.
Adenoma growth rates differed significantly between genders but were essentially historically
invariant.
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A historically variant calculated fraction at risk would have insinuated that there had been
a historical change in either the extent or types of environmental exposures that place an
individual at risk for cancer. On the other hand, the observation of a historically constant
calculated fraction at risk for colon cancer insinuates that genetic risk factors alone predispose an
individual to colon cancer, but does not exclude the possibility that environmental risk factors
still play a role in accelerating the time of occurrence of colon cancer within smaller
subpopulations within the fraction at risk.
Brindha Muniappan's (unpublished) study of the induced in vitro mutational spectrum of
the APC gene by replication with DNA polymerase 13, has shown that 3 of the 6 so far
characterized, induced mutational hotspots are concordant with the mutational hotspots found in
the APC gene of cells taken from colon tumor samples. As the loss of function of the APC gene
has been shown to be necessary, but not yet shown to be explicitly sufficient, in the initiation of
at least 80% of all colon tumors (Powell, 1982), Brindha Muniappan's results are consistent with
the hypothesis that primary risk factors for colon cancer are endogenous.
Furthermore, the three-stage carcinogenesis model predicted a potential two-fold increase
in the calculated initiation mutation rates of colonic cells in males (Table 1) during the last
century, insinuating that environmental risk factors, presumably changes in the diet of the
average male, may play some role in accelerating the occurrence.of colon cancer. However,
these calculations were made assuming that the turnover rate of normal colonic tissue has been
constant throughout this same period. Our calculations can in fact not distinguish between these
two phenomena; only the product of the turnover rate T and the mutation rate ri could be
estimated. As such, Kinzler and Vogelstein's (1996) hypothesis that dietary factors may play a
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role in carcinogenesis by acting as irritants that accelerate tissue regeneration, is consistent with
the results of the three-stage carcinogenesis model.
Likewise, the three-stage carcinogenesis model predicted a potential two-fold increase in
the calculated promotion mutation rate of colonic cells in females (Table 2) during the last
century. However, the robustness of the model (Section 4.1.6) demonstrates that the uncertainty
in the calculated parameter of the promotion mutation rate, rA, alone could explain this
calculated result. Possible unknown biases in the primary data sets of mortality, survival, and
underreporting could explain the calculated changes in promotion mutation rates.
Lastly, the three-stage carcinogenesis model predicted a historical change in fh, the ratio
of the number of deaths attributed to colon cancer to the number of all deaths sharing the risk
factors of colon cancer. If either treatment for the connected diseases, which share the same risk
factors as colon cancer, had improved more rapidly than treatment for colon cancer during the
last century, or the number of underdiagnosed colon cancer deaths had decreased historically, the
increased risk of dying and actually being correctly reported of dying of colon cancer within the
elderly population would explain the calculated increase in fh.
Together, these calculations and observations suggest that the observed changes in colon
cancer mortality rates are predominantly explained by the increase in the lifespan of the
American population. New environmental exposures during the last century did not appear to
place more individuals at risk. Instead, environmental risk factors may potentially have a
secondary role accelerating the occurrence of cancer at initiation, by either increasing the rate of
normal tissue turnover or by increasing the rate of mutation by means other than through a direct
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mutagenic effect (i.e. impairment of the mechanisms by which mispaired bases in the DNA are
repaired).
5.3 Lung Cancer
5.3.1 Historical Changes in the Fraction at Primary Lifetime Risk, Fh.
The argument that there exist genetic and/or environmental factors that create a condition
essential for the incidence of cancer during a maximum human life span has been anticipated by
others who previously noted a maximum age-specific rate for several cancer sites. (Cook et al,
1969; Smith, 1996). Smith (1996), for instance, noted a decrease in mortality rates among the
elderly for lung cancer and commented, "If most smokers die between ages 65-70, lung cancer
mortality rates would expectedly decrease as the subpopulation at risk is killed off at a faster rate
than the remaining non-smoking population."
The derived estimate of the fraction of lifetime nonsmokers at risk is -10%. The fraction
of nonsmoking persons at risk does not appear to have changed since the mid-1800s to the
present day as may be concluded by inspection of Figure 66. This resembles the finding that Fh
was unchanged for colon cancer in the American population since the birth years of the 1860s.
Given that inherited risk has not significantly changed in the human population in so short a span
of years, the many environmental changes between the mid 1800s and mid 1900s are concluded
to have had little if any net effect on lifetime lung cancer risk in nonsmokers. The data however
do not provide any indication as to the nature of the environmental and/or inherited essential
lifetime lung cancer risk factors in nonsmokers.
In the case of lung cancer for cohorts of mixed populations of smokers and nonsmokers,
there is an unambiguous linear relationship (Figure 70) between smoking prevalence and the
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fraction of the total population calculated to be at lifetime risk, Fh. Data for males and females of
Americans of predominantly European descent fall on this same straight line. This quantitative
relationship is evidence that cigarette use is an environmental factor essential for lifetime risk
lung cancers in smokers. Were cigarette smoking to affect age-specific mortality rates solely by
accelerating either initiation and/or promotion by inducing higher rates of required genetic
changes, then lifetime risk fractions Fh, would be the same for smokers and nonsmokers and
would also be historically invariant, as was the case for colon cancer.
The linearity of the relationship permits the inference that cigarette use alone is sufficient
to account for lung cancer primary risk in male and female smokers. The hypothesis that some
other essential environmental factor for lung cancer in smokers, e.g. air pollution, rose
simultaneously with cigarette use is not supported by the marked linearity of the relationship.
Data from men and women born many decades apart would not yield the same value for Fhl
given the same prevalence of cigarette use if such were the case. (Figure 71)
The fraction at risk was calculated assuming zero survival for lung cancer, and that the
maximum smoking prevalence throughout the lifetime of a cohort was representative of the
smoking experience of that cohort. An underestimate in the true survival rate for lung cancer or
an overestimate of the true average smoking experience have the net effect of causing an
underestimate in the lifetime risk fraction, so a reasonable estimate of the fraction of lifetime
smokers at lifetime risk of lung cancer is ~100%. This suggests that there are probably no
lifetime smokers who would escape death by lung cancer if they did not die by some other cause
i.e. there is no inherited lifetime resistance to cigarette induced lung cancer. Interestingly, the
historical changes in the histopathological nature and anatomical location of lung tumors in
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smokers, Figure 34, has had no effect on the value of Fh for smokers, meaning that a smoker
would be at risk for all forms of lethal lung cancer.
Although some lifetime smokers do reach extreme old age without lung cancer, this is not
inconsistent with the finding that all smokers are at lifetime risk for lung cancer. Initiation and
promotion rates could be similar among all smokers but stochastically distributed such that some
smokers die of lung cancer earlier than others. Surviving smokers have simply not lost yet in a
game ruled by chance, or die by chance from another form of death before developing lung
cancer.
5.3.2 Historical Changes in the Factor Accounting for Connected Risks, fh
Introduction of the parameter fh was required by the seemingly obvious fact that persons
at lifetime risk of lung cancer would frequently die of some other disease for which cigarette
smoking was also a risk factor. Basically fh is the fraction of persons at lifetime risk of lung
cancer who would die of lung cancer if deaths were caused only by those factors essential for
lung cancer, i.e. not including deaths by accident, infectious disease, etc. Its use in a
mathematical model of age-specific cancer mortality is essential. The persons at risk of lung
cancer would have higher age-specific death rates than those not at risk not only because of lung
cancer deaths but also because of deaths caused by diseases having the same essential risk
factors as lung cancer.
fh for nonsmokers was 0.15 (Table 5). This indicates that the essential inherited and/or
environmental factors required for lung cancer in nonsmokers are capable of killing by other
forms of mortality in a manner quantitatively similar to smokers as noted below. Since
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nonsmokers' deaths by lung cancer account for about 0.7% of deaths of a birth year cohort, the
fraction of all deaths attributable to the essential factors for lung cancer in nonsmokers may be
estimated to be 4.7%. This is hardly an insignificant fraction of a birth year cohort and further
analyses to seek these essential risk factors in nonsmokers would seem to be important.
Doll and Peto (1976) and Kahn (1966) studied cohorts of smokers and nonsmokers and
measured the effects of cigarette smoking on multiple forms of mortality. Ischaemic heart
disease risk, a common form of death among nonsmokers, was in fact increased twice as much as
lung cancer risk in smokers. Of the excess total deaths due to cigarette smoking, only 15-17%
was attributable to lung cancer. (Doll and Peto, 1976; Kahn, 1966) The estimate that 15-17% of
excess deaths among smokers are due to lung cancer would be a reasonable approximation to fh
in the sense employed.
Calculated values for fh range from 0.11 to 0.13 for female smokers and from 0.14 to
0.28 for male smokers (Table 5). The average value of fh for all female cohorts analyzed
(1880s-1920s) is 0.13 and for males (1870s-1920s), 0.20. The average for both genders and all
cohorts is 0.165. These numbers are thus in reasonable agreement with the epidemiological
estimates based on British males born in the 1900s (Doll and Peto, 1976) and U.S. males born in
the 1910s. (Kahn, 1966)
5.3.3 Historical Changes in Initiation Mutation Rates, ri rj.
For the purposes of simplification and by analogy with colon cancer, calculation of
initiation mutations rates was made for the case of n = 2 necessary initiation mutations as
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recorded in Table 5. Recognizably, however, there is no experimental data suggesting n = 2 for
lung cancer in smokers or nonsmokers.
Since the upper bronchial tree has but 2.4 x 108 cells and the lower bronchiolar region
about 2.8 x 1010 cells, these anatomical regions were treated separately as depicted in Table 5. So
as to bracket the historical experience of an initially high but declining fraction of tumors
classified as squamous cell carcinomas of the upper bronchial tree calculations of initiation
mutation rates used the limiting assumptions that 25, 50 or 75% of lethal tumors occurred in the
upper tree. Assuming 25% of lethal tumors occur in the tracheal bronchial region increases this
estimate by 1.3 fold, and assuming 75% decreases the estimate by 0.8 fold. As these assumptions
had a relatively small effect on estimates of a first initiation mutation rate, estimates of 50%
lethal tumors should be sufficient for the purposes of discerning any historical shift.
2
As may be seen in Table 5, the initiation parameter 2 T2 r i rj was essentially identical for
female nonsmokers, female smokers and male smokers for all birth decade cohorts analyzed.
-11 -11 2 2The average value is 2.9 x 10 with a range of 2.1 to 3.6 x 10 11 mutations /yr2. Using a
turnover rate estimate of r = 5.7 divisions per year and assuming pro tempore that the first and
second initiation events have approximately the same rate, ri = rj, the rate of the first step of
initiation, ri, would be about 7 x 10-7 events (mutations) per stem cell division, ten times higher
than derived by observation of hprt mutations in peripheral T-cells of people from 0 to 75 years
of age (Bigbee et al, 1998; Branda et al, 1993; Davies et al, 1992; Finette et al, 1994; Henderson
et al, 1986; Hirai et al, 1995; Hou et af, 1995; Huttner et al, 1995; Liu et al, 1997; McGinniss et
al, 1990; Tates et al, 1991) and ten times higher than the estimated first initiation step calculated
for colon cancer (Table 5).
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More importantly, if the necessary number of steps for initiation in the tracheal bronchial
tree were the same for both smokers and nonsmokers, the hypothesis that cigarette smoke causes
lung cancer by increasing initiation rates, either by increasing mutation rates or turnover rates, is
untenable. Likewise, the possibility that smoking increases nuclear mutation rates but also
creates an environment in which one less initiation mutation is required in smokers than in
nonsmokers is excluded by the observation that the overall initiation parameters are identical. As
'n' decreases for a fixed initiation parameter, so would the geometric mean of the rate of the 'n'
required initiation events, such that if fewer events were required in a smoker, initiation mutation
rates in the smoker would be calculated to be less than in the nonsmoker. However, the converse
possibility that smoking could increase the initiation mutation rate such that an initiation
pathway in which one more event is required than in nonsmokers could now occur during a
smoker's lifetime, is not excluded. The values of the geometric means of initiation mutation rates
for the cases n= 1, 2, 3 or 4 do not create values outside the realm of information about lung cell
mutation rates.
As seen in Table 5, initiation parameters in the peripheral bronchiolar region of the lung,
2
2 T ri rj, was essentially identical for female nonsmokers, female smokers and male smokers for
all birth decade cohorts analyzed. The average value is 2.5 x 1013 with a range of 1.8 to 3.6 x
-13 2 210 13 mutations2/yr about two orders of magnitude less than that estimated above for the cells
of the tracheal bronchial epithelium. This rate is essentially identical to that calculated for the
colon.
If as these calculations suggest, the background rate of mutation is some ten times higher
in the upper tracheal bronchial epithelium than in the lower bronchiolar epithelium, the
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biological basis for this difference is unknown. A tenfold higher level of initiation mutation rate
might nonetheless explain to some degree the observation known as "field cancerization," that
multiple independent colonies of P53 mutants are found scattered in the head and neck, upper
digestive tract, and tracheal bronchial areas (Chung et al, 1993; Tian et al, 1998; Sozzi et al,
1995).
The possibility of n=1 must also be considered. For this case the initiation parameter is r
ri and for the case of all cells in a turnover unit at risk results in an estimated value of ri = 5.6 x
10 12 . If however only mutant stem cells could give rise to preneoplastic colonies, then this
estimate would increase by a multiplicative factor equal to the number of cells in a turnover unit.
Preliminary evidence (Li-Sucholeiki et al, unpublished; Coller et al, unpublished) suggests there
are 32 cells in the turnover units of the human tracheal bronchial epithelium leading to an
estimation that under the stem-cell-only assumption ri = 1.8 x 10-10. A rate of this magnitude
might be imagined for a process in which a single very rare event, such as a particular single
missense point mutation, would be required for initiation, e.g. activation of a proto-oncogene.
5.3.4 Historical Changes in Promotion Mutation Rates, rA.
For neither colon, lung nor any other form of mammalian cancer has any genetic event
been found that is required for promotion of a preneoplastic cell into a cancerous cell. For
simplicity then, promotion mutation rates for the case m = 1 required promotional events were
calculated. No significant differences were found for average values of rA among female
nonsmokers (2.9 x 107), female smokers (4.4 x 10 ) and male smokers (3.0 x 107). A similar
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value for rA for the case m= 1 (2.0 x 10 7), had previously been estimated for colon cancer. The
three-stage carcinogenesis model does not predict an effect of cigarette smoking on promotion
mutation rates.
5.3.5 Historical Changes in the Growth Rate of Precancerous Lesions, (a- ).
Precancerous lesions of the lung were found to have a growth rate of (xa-P) = 0.17 for
female nonsmokers born in the mid 19 th century. This same value would be obtained for
nonsmoking males as shown in Figure 66. Net growth rates of precancerous lesions of
nonsmokers are similar to those calculated for the colon and observed for the total mass of
children (0.16) between the ages of 1.5 through puberty, suggesting the possibility that mutations
permitting proliferative growth take the cell back to the growth rates of children.
Contrarily, (a-P) = 0.31 for female smokers and 0.32 for male smokers. Almost doubling
(x-0) has a major impact on the age-specific cancer rate in a population of persons at risk (Figure
52). The inverse of this parameter is the doubling time of the preneoplastic lesion in the two
stage cancer model, so this change has the effect of changing the doubling time in nonsmokers of
about 6 yrs to about 3 yrs in smokers. If promotional event rates were unaffected by smoking
(Section 5.3.4) the smoking effect of doubling preneoplastic colony growth rates would be to
reduce the period between initiation and promotion by about 40%, a difference of about twenty
years.
5.3.6 High LOH and LOI levels in Human Lung Cancer
Considering (Table 6) the possibilities of m>l perforce raise the estimated rates for rA.
Obviously, as the number of events is increased, the mean geometric mutation rate must
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increase. Because tumors show a very high fraction of loci with loss of heterozygosity or
genomic imprinting, it is clear that the rates of these processes while low in normal tissues must
be high in preneoplastic colonies.
Average LOH levels of all loci lung tumors of 0.6 (Wistuba, 1997, 1999), an estimated
average time of 32 years between initiation and promotion for smokers (Ah - age of smoking
adoption), and a division rate of preneoplastic lesions of 12.7 per year, lead to estimates of LOH
rates (single outcome) in preneoplastic lesions to be approximately 7.4 x 10-4 events per year.
Comparing this rate to the calculations of Table 6 leads to the observation that about 5 events at
this rate could be accommodated in a promotional hypothesis involving independent losses of
heterozygosity or genetic imprinting.
High rates of genomic instability have been noted from the time of Theodor Boveri
(1914) as a characteristic of solid tumors and dysplastic lesions. It appears to be generally
assumed that such genomic instability is a phenotypic requirement for neoplasia that is acquired
after initiation, although no reported test of these assumptions exist.
Further speculation along these lines is not yet justified. Promotion may not involve
genetic changes or even rare events of any kind. As noted above there are no known genes
associated with tumor promotion in humans. An alternative mechanism is that individual cells in
a growing preneoplastic colony become more isolated from normal cells by virtue of diminished
intercellular electrochemical communication, as proposed by Bronk (1970). Here the idea is that
intercellular communication in a tissue is essential for maintaining the order and balance
represented by zero net growth during maintenance turnover in adult tissues. If initiation permits
slow exponential growth by altering intracellular communication, then a natural consequence of
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colony expansion would be isolation of cells from external signals. In this scenario, a cell
embedded in a preneoplastic colony becomes electrochemically remote from normal cells of the
tissue. In such a state it can either fail to receive important growth suppressing signals from afar
or fail to disperse autocrine growth factors that it may make from time to time.
In this condition, m=0, and the principal term defining the expected number of promoted
cells in a growing preneoplastic colony becomes W(c-13) (cc-Ic)/ac 2(a -2 )(t-a) This has a value
of approximately 75,000 cells when half of all preneoplastic lesions would be expected to have
developed at least one surviving promoted cell at (t - a) = Ah. Since potentially preneoplastic
colonies such as "severely dysplastic lesions" or carcinoma in situ appear to attain such
dimensions, Bronk's (1970) concept is encouraged by these calculations.
5.3.7 Conclusions
The assumption that cigarettes cause lung cancer by inducing genetic changes in normal
cells, or that environmental factors affect cancer rates in other organs, must be recognized as an
untested but critical hypothesis that drives a large fraction of public investment in environmental
cancer research. As is the case for lung cancer and cigarettes, the clear record of environmental
effects on cancer rates is generally assumed to be accounted by exposure of humans to
environmental mutagens. Denissenko (1996) has found that the mutational spectrum of the TP53
gene created by benzo[a]pyrene, a putative carcinogen found in cigarette smoke, is the same as
the mutational spectrum of the TP53 gene of cells taken from lung cancer samples, thereby
suggesting a direct etiological link between cigarette smoke and lung cancer. Rodin and Rodin
(2000) have however since found that the mutational spectrum of the TP53 gene in smokers' and
nonsmokers' cells from lung cancer samples are not dissimilar.
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Consistent with Rodin and Rodin's (2000) conclusions, Coller et al (1998) found that
mitochondrial DNA mutant hotspots of a 100bp sequence in smokers' samples of normal
bronchial tissue were not different from the mitochondrial DNA mutant hotspots found in
nonsmokers' normal bronchial tissue samples. Elevated mutant fraction among smokers were
also not observed. (Coller et al, 1998). Preliminary results have also revealed no significant
differences in the mutant frequency of normal bronchial cells of three smokers and two
nonsmokers of similar age for the mutant hotspots at base pair 746 and base pair 747 mutations
of the TP53 gene. (Li-Sucholeiki et al, unpublished.)
The three-stage carcinogenesis model further predicts that:
1. All cigarette smokers are at lifetime risk of lung cancer risk, (Fh - 1.0) but that only 0.1 of
all nonsmokers are at lifetime risk.
1. The estimated net growth rate of preneoplastic lesions, (a-0), is ~0.32 for smokers and 0.17
for nonsmokers.
1. Estimates of initiation and promotion mutation rates are unaffected by smoking status.
These data form a new hypothesis: cigarettes cause lung cancer by creating a condition in
all smokers by which certain undefined but naturally occurring preneoplastic lesions grow at a
rate nearly twice that observed for preneoplastic lesions in nonsmokers. The quantitative
differences observed for (ax-0), growth rate of preneoplastic lesions, and Fh, fraction of the
population at lifetime risk, are sufficient to account for all of the differences between the age-
specific lung cancer mortality rates between smokers and nonsmokers.
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The hypothesis that smoking causes lung cancer by inducing genetic changes appears to
be in error. Instead, one must consider the possibility that cigarette smoking selects for cells
already carrying the necessary initiation mutations.
As a hypothetical example, the conditions for initiation in nonsmokers could involve
mutational losses of both alleles of unknown gene X and in smokers, loss of both alleles of
unknown gene Y. As the rates of loss of alleles for genes X and Y are similar and unaffected by
smoking, the rate of creation of newly initiated cells is the same in smokers and nonsmokers.
However, in nonsmokers the loss of gene Y creates a preneoplastic colony with net growth rate
of 0.17 doublings per year and in smokers the loss of gene X a preneoplastic colony with net
growth rate of 0.32. This parameter, (a-j3), effects both the survival chances of a newly initiated
cell and the growth rate of any surviving preneoplastic lesion.
A simplification of this model is X = Y wherein smoking provides directly or indirectly
a growth stimulus for cells lacking functional gene X/Y. Indirect effects of external stimuli must
be considered seriously. As previously reported, induction of mammary tumors in rats treated
with methylnitrosourea selected previously occurring mutants in the H-ras gene rather than
inducing the specific G--A transition as had been assumed. (Cha et al, 1994) The effect on the
growth rates of initiated cells in the lung might occur as a result of chemical contact with the
affected cells. It might also result from a more general effect on all cells of the lung epithelium
as was subsequently found for methylnitrosourea on mammary cells. Even a systemic effect such
as responses to central nervous system stimulation by nicotine cannot be eliminated by present
evidence.
Genes now known to be involved in human initiation such as the APC gene in human
colonic epithelium are involved in intercellular communication. It seems reasonable to propose
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that the histological changes in the epithelium of smokers' lungs may also change the nature of
intercellular communication. Changes in gene expression induced by cigarette smoking have also
been reported relevant to DNA damage. (Willey et al, 1997; Crawford et al, 1998). These
changes in turn may be permissive for preneoplasia if loss of unknown genes by normal
mutational processes creates an initiated cell growing at the rate calculated for smokers'
preneoplastic colonies.
As shown in Figure 72 the expected number of preneoplastic lesions in the upper
bronchial tract at age 60 was about 0.39 so that 18 such persons would have been expected to
display about 7 dysplastic lesions and carcinomas in situ if these were indeed all preneoplastic
lesions. Wistuba et al (1997) reported 27 such lesions which is significantly greater than
predicted by the model. They also reported that 7 of these 27 lesions were denominated as
carcinoma in situ, a number similar to the predicted value of 7 for preneoplastic lesions.
Interestingly only 35% of the male heavy smokers in Wistuba et al's (1997) study exhibited
dysplasia in their upper bronchi [personal communication, Dr. Adi F. Gazdar]. Our model
predicts that some 32% of smokers would carry such lesions based on an expected number of
0.39 per smoker (Figure 72) and a Poisson distribution of the number of expected lesions among
smokers. Thus it is possible that the predicted values for preneoplastic lesions are consistent with
those observed in smokers of age 60.
However, the apparent non-Poisson distribution of total moderate-severe dysplastic
lesions plus carcinomas in situ is not anticipated by any version of the three-stage model of
carcinogenesis. The model may be wrong, many lesions classified as dysplastic may not in fact
be preneoplastic lesions, or dysplastic lesions may create multiple microcolonies in lungs as they
grow. Finally, it may be that what are identified by pulmonary pathologists as carcinomas in situ.
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are in fact the only true preneoplastic lesions among a set of lesions identified as "dysplastic".
Prediction and observation with regard to the number of preneoplastic lesions in the tracheal
bronchial tracts of smokers may not be in disagreement.
Figure 73 compares the age-specific cumulative risk of developing lung cancer among
smokers and former smokers reported by Peto et al (2000) to that predicted by the model
assuming that population and physiologic risk parameters returned to those in a nonsmoking
population soon after smoking cessation. The agreement between the observations and the
prediction was satisfactory, assuming only that preneoplastic lesions of smokers grew at a
doubling rate of 0.32, preexisting precancerous lesions in former smokers grew at a doubling rate
of 0.17 soon after cessation, and that 10% of smokers after cessation were still at risk for new
surviving preneoplastic lesions could arise.
When the alternative hypothesis that cigarette smoking might affect the rate of initiation
(both initiation and promotion) was tested, the results were inconsistent with Peto et al's (2000)
incidence data among former smokers.
Lastly, of great interest to lung pathologists has been the absolute rise of
adenocarcinomas and small cell carcinomas as a function of history relative to the absolute
number of squamous cell carcinomas (Figure 34). The three-stage carcinogenesis model predicts
that the rise of adenocarcinomas is due to a decrease in the age of onset of the disease. However,
as data was unavailable for ages <40 years of age, the analysis could not distinguish whether this
effect was due to an increase in promotion mutation rates in cells of the precursor lesions to
adenocarcinomas, or alternately due to an increase in the growth rates of these precancerous
lesions.
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The prediction that cigarette smoking will be found to be without influence on the rates
of nuclear genetic or other events required for initiation can be tested only by direct
measurements in the upper and lower tracts of human lungs. The prediction that tracheal
bronchial initiation (mutation) rates will be found to be considerably higher than peripheral
bronchiolar rates when expressed as events per cell year requires similar studies in humans. Of
additional interest is that there are no reports of point mutations induced in bacteria or human
cells by cigarette smoke condensate or extracts in the literature of mutation research.
5.4 Alternate Hypotheses for the Observed Curvature of Age-Specific Mortality Rates
Recognition that the mortality/incidence curves by cancer reach a maximum and then
decline, created the rationale for describing a subpopulation within each birthyear cohort that
was at risk for that cancer. Necessarily, this construct also creates a subpopulation not at lifetime
risk for cancer, such that mortality rates expectedly reach a maximum and decrease as a function
of age since the subpoulation at risk dies off at a faster rate than the remaining population. As
Cook et al (1969) have suggested, the possible existence of subpopulations at risk does not
preclude other reasons that could likewise create the observed curvature of mortality data.
5.4.1 Assumption of Homogeneity in the Population for Secondary Risk Parameters ri, rA, (a -
For simplification, the development of the mathematical models had assumed
homogeneity among all the individuals who died of cancer such that stochastic distribution alone
determined the age at which each individual died. Reasonably, inherited genetic and/or
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environmental risk factors would affect the age of onset of cancer, such that the assumption of
homogeneity in the population for cancer risk factors is not based on expectation.
Hemminki and Vaittinen (1998) have reported the elevated risk for breast cancer among
Swedish mothers whose daughters have breast cancer (Figure 74). The relative risk of breast
cancer for this set of mothers versus all mothers is constant at a value of 1.6 for all ages greater
than 40 years.
The fact that the relative risk was a value greater than one and is constant for ages 42.5 to
92.5 suggests that the elevated risk of developing breast cancer among mothers whose daughters
have breast cancer is due to a primary risk factor. If the primary risk factor were genetic, then a
daughter with breast cancer is an obligatory carrier, such that the probability that her mother also
carries the genetic risk factors is relatively higher than for a mother of a daughter who may not
be a carrier of the genetic primary risk factor. (Since mothers and daughters likely share similar
environments, the possibility that the primary risk factor is environmental cannot be excluded).
Primary risk factors do not affect the age at which the mother is expected to develop breast
cancer, such that the relative risk is expectedly constant.
Individuals inheriting a secondary risk factor (or exposed to an environmental secondary
risk factor) are predisposed to get cancer at an earlier age, such that the relative risk would
appear to decrease as a function of age based on probabilistic distribution. As the mother ages,
the fact that she has not yet developed breast cancer, even though her daughter did, decreases the
likelihood that she herself had inherited a secondary risk factor, such that the relative risk would
appear to decrease as a function of age. Hemminki and Vaittinen's (1998) familial breast cancer
data does reveal that for ages 27.5 to 42.5 there is an age-dependent decrease in the elevated risk
of a mother, whose daughter has breast cancer, herself developing breast cancer. This suggests
333
that there may exist a secondary risk factor associated with early onset breast cancer. As the last
of these mothers develop breast cancer, the remaining mothers who have inherited only the
primary genetic risk factor are all at about the same risk of developing breast cancer, such that
the calculated relative risk reaches a constant value. (Note that the daughters in this study had not
yet reached age 60 so perforce some daughters who do have a secondary risk factor have not yet
developed breast cancer. This limitation determines the age at which the relative risk is observed
to reach a constant level; the decrease in relative risk may in fact extend to ages higher than 42.5,
still decreasing to a level of 1.6, but more gradually).
The observation of a decreasing relative risk does reveal that there exists heterogeneity in
the population at risk (breast cancer, Figure 74). Other cancers reveal similar results. Relative
risk for colorectal cancer among parents whose children have colon cancer (data supplied by
Prof. Hemminki, Karolinska Institute, Figure 74) reveals once again a constant relative risk
among the elderly consistent with the hypothesis of a primary risk fraction for colon cancer. For
the earlier age groups there is an elevated relative risk, consistent with a subpopulation having
inherited genetic or sharing enviromental secondary risk factors.
For the earliest ages, the relative risk is even higher consistent with the existence of FAP
and HNPCC families for which familial inheritance of one of the two APC initiation mutations
or a mutation in a mismatch repair gene respectively, elevates risk of developing colorectal
cancer at an early age.
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Fig. 74: Elevated risk of parent developing cancer given that a child has cancer
a) Relative risk of mothers, whose daughters have breast cancer, themselves developing breast
cancer versus all mothers with daughters as a function of age
b) Relative risk of parents, who have a child with colorectal cancer, themselves developing
colorectal cancer versus all parents as a function of age
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5.4.2 Effect of heterogeneity in the population for secondary risk parameters ri, rA, (a - ), on
the curvature of mortality data (n = 2)
In the two initiation mutation carcinogenesis model, the hazard function rises
approximately linearly for physiologically observed rates of mutation (< 10-5 per year). The
slope of the linear rise is dependent on the mutation rate. Individuals who have inherited or due
to environmental exposures have higher mutations rates expectedly would develop and die of
cancer at an earlier age than individuals without these accelerating risk factors. The average
mutation rate ri of individuals who have not yet died would expectedly decrease as a function of
age.
As a result, the slope of the hazard function would concurrently decrease thereby creating
curvature on the observed mortality data. However, this would not actually cause the observed
mortality curves to reach a maximum and then decrease unless the distribution of mutation rates
were binodal, with distinct populations having high or low mutation rates. The only available
data set for the distribution of mutation rates in humans is the mutant frequency distribution
compiled by Dr. Aoy Tomita-Mitchell for the hprt locus of peripheral T-cells (Figure 8).
Converting to mutation rates (Figure 75), the distribution is revealed to be approximately log-
normal. Such a distribution would not create a condition by which the observed mortality would
reach a maximum and decrease, if two initiation mutations were required. The slope of the
mortality curve would decrease but the overall mortality curve would keep increasing, albeit at a
gradually smaller rate.
Heterogeneity for the other two accelerating risk parameters, rA and (a - 03) would have
similar effects if their distributions among all individual were like Figure 75. There is yet no
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available data to determine actual distributions for these two parameters. However, in the case of
(a - P), recall that distinct growth rates for smokers and nonsmokers were estimated (Table 5).
Therefore the distribution of lung precancerous growth rates in a mixed population of smokers
and nonsmokers based on these results would not resemble that of Figure 75 for mutation rates,
but would rather be binodal with peaks at about 0.17 (nonsmokers) and 0.32 (smokers).
The three-stage carcinogenesis model had suggested that each cohort is comprised of
three subpopulations: smokers all at risk for lung cancer, 10% of all individuals at risk for lung
cancer by means other than smoking, and 90% of nonsmokers who were not at risk for lung
cancer within a normal lifespan. This created a condition in which the mortality curves for
cohorts of mixed populations of smokers and nonsmokers would reach a maximum and decrease,
as the smoking population was depleted. The maximum in lung cancer mortality rates is
observed due to the marked differences in the calculated growth rates of precancerous lesions
between smokers and nonsmokers.
By the same reasoning that there is a decrease in the overall lung cancer mortality data
after the smoking population is depleted due to their higher growth rate of precancerous lesions,
it may be that the lung cancer mortality data for nonsmokers (Figure 66) also decreases if the
10% of nonsmokers found to be at risk for lung cancer are depleted more rapidly than the
remaining nonsmokers (i.e. the other 90% of nonsmokers have a markedly lower precancerous
growth rate). In this case, theoretically every individual would be at risk for developing cancer;
the curvature was caused alone by a distribution of precancerous growth rates with three distinct
populations: 0.32 (smokers), 0.17 (10% nonsmokers), and theoretically <0.08 (other 90%
nonsmokers). However, this is mere speculation until the distribution of growth rates among all
individuals is determined.
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Fig. 75: Distribution of mutation rates of the hprt locus of peripheral T-cells
Mean mutation rate is 2.1 x 10-7 per cell year
Compiled by Dr. Aoy Tomita- Mitchell
(Bigbee, 1998; Branda, 1993; Davies, 1992; Finette, 1994; Henderson, 1986; Hirai, 1995; Hou,
1995; Huttner, 1995; Liu, et al, 1997; McGinniss et al, 1990; Tates et al, 1991)
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Heterogeneity of the three accelerating risk parameters (ri, rA, a - 13) could therefore
create the observed maximum mortality data if and only if the distribution in these parameters
showed subpopulations with distinct rates. This permits the possibility that all rather than some
individuals are at risk for cancer. However, the data from Hemminki and Vaittinen (1998) does
still show the existence of a distinct population at primary risk. (Section 5.4.1)
Evidently, both heterogeneity for secondary risk factors and the existence of a primary
fraction at risk create curvature in the mortality data. Since the mortality data was initially
analyzed assuming homogeneity, the observation of curvature was attributed entirely to the
fraction at risk or to the factor, fh, correcting for death by connected forms of death. Correcting
for the curvature caused by heterogenity predicts that our initial calculations may have
underestimated the fraction at risk or the correction factor, fh. It is left for future research to
answer this question.
5.4.3 Effect of heterogeneity in the population for secondary risk parameters ri, rA, (a- 13), on
the curvature of mortality data (n = 1)
Assuming homogeneity, the one initiation mutation carcinogenesis model predicts that
the hazard function rises rapidly, plateaus and remains constant throughout the ages of a normal
lifetime (assuming physiologically observed rates of mutation of < 10- 5 per year). The
magnitude of this constant is directly proportional to the mutation rate. Again, individuals who
have inherited or due to environmental exposures have higher mutations rates would develop and
die of cancer at an earlier age than individuals without these accelerating risk factors. The
average mutation rate ri of individuals who have not yet died would expectedly decrease as a
function of age.
In the one initiation mutation model, since once the hazard function has 'plateaued'
mortality is directly proportional to the mutation rate, the hazard function would concurrently
decrease thereby creating not only curvature on the observed mortality data, but actually create
the condition that observed mortality rates reach a maximum and decrease. Heterogeneity in the
case of the one initiation mutation model could alone explain the observed maximum of
mortality rates, and would make calculation of the fraction at risk not feasible.
The peaking of the observed mortality curve in the one initiation mutation model could
also be predicted if exposure to a necessary environmental risk factor occurred only during part
of life. This would create the condition in which the individuals who were exposed in this way
would die at the elevated rate due to the environmental exposure. Once this fraction is killed off,
the mortality rate would come down towards the level of unexposed individuals. Variability in
the duration of exposure among all individuals would create a function that never plateaus, but
rather reaches a maximum for the individuals exposed for the longest period and then continues
to decrease thereafter.
We must however remember that as of yet no form of sporadic cancer has been shown to
require but one initiation event, such that these hypothetical situations that would also create a
mortality curve that peaks without regard of a fraction at risk may be of no consequence.
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6. CONCLUSIONS
COLON CANCER:
42% of the population in the U.S. was calculated to be at risk for developing colon cancer within
their lifetime, independent of gender or race.
No significant historical change in the calculated fraction at risk was found, suggesting that the
primary risk factors for colon cancer are not environmental.
The calculated rate for the first initiation mutation in the colon was similar to the mutation rate
observed for the hprt locus in human peripheral T-cells (~2.1 x 10-7 per cell year) and the
spontaneous mutation rate of the hprt locus of human B-cells in culture.
Mutation rates were not found to increase significantly from the birthyear cohort of 1860 to the
birthyear cohort of 1940. Environmental risk factors may play a secondary risk in colon cancer,
albeit small, possibly by just increasing tissue renewal.
The calculated doubling rate of these lesions (-0.17-0.21) was found to be similar to the growth
rate of children, suggesting that the required initiation events may have the net effect of
reactivating pathways involved in child development.
The observed changes in colon cancer mortality rates can be explained alone by the increase in
the lifespan of the American population during this century.
LUNG CANCER:
10% of nonsmokers and at least 94% of smokers were estimated to be at lifetime (primary) risk
of death by lung cancer. The fraction at lifetime risk for all birthyear cohorts, consisting of mixed
populations of smokers and nonsmokers, was found to be a simple linear function of reported
cigarette use, independent of gender or race.
Growth rates of preneoplastic colonies of both genders and ethnic groups were found to be 0.17
and 0.32 doublings per year for nonsmokers and smokers respectively.
Rates of events such as genetic alterations necessary for initiation or promotion showed no
differences among smokers and nonsmokers of either gender or ethnic group.
Incidence of lung cancer among former smokers can be predicted by a decrease in the growth
rate of precancerous lesions of 0.32 doublings per year to 0.17 after smoking cessation.
Smoking causes lung cancer not by increasing the rate of genetic change in human lung
epithelial cells, but by stimulating the growth of independently induced preneoplastic lesions in
all smokers.
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7. SUGGESTIONS FOR FUTURE RESEARCH
7.1 Verification of Conclusions
Mathematical models such as the one used herein are valuable in helping only to develop
hypotheses, or to potentially disprove hypotheses. As such, mathematical models depend on
actual in vivo or even in vitro experimentation to verify or prove any suggested hypotheses.
The conclusion that individuals are not placed at risk for colon cancer by exogenous
exposures suggests that replication errors or endogenous damage are the leading causes of colon
cancer.
Brindha Muniappan's work on the determination of the mutational spectrum of APC
induced by DNA polymerase 03 should be extended to other potential endogenous processes
(other replication pathways or repair mechanisms) and to other known tumor suppressor genes.
Even if an exogenous agent could induce a mutational spectrum similar to that in a tumor
suppressor gene of cells taken from cancer patients, it is imperative to have first discovered the
background mutational hotspots so that one can distinguish between direct mutagenicity and
selection for preeexisting mutants. The pathway by which an exogenous agent increases
carcinogenicity would be of importance in directing potential research in therapies.
Dr. Li-Sucholeiki et al's work in determining mutant fraction of mutational hotspots of
the TP53 gene should be continued so as to guarantee strong statistical significance for the
current observation that smoking plays little, if any, role in the direct mutagenicity of lung
epithelial cells. In the event that the tumor suppressor gene for lung cancer were to be
discovered, of course the work should shift towards that gene. Even if work with further lungs
were to show a somewhat elevated mutation rate in smokers' lungs, this observation would
require the further verification that tissue renewal had not been accelerated in a smoker's lung.
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For that purpose, Dr. Elena Gostjeva's work in determining mitotic rates in bronchial epithelia
should be broadened to consider smokers and nonsmokers independently, not only of normal
epithelia, but also of precancerous lesions.
Additionally, the increase in incidence of adenocarcinomas versus other forms of lung
cancer is theoretically due to an increase in the growth rate of these lesions concurrently with a
proportional increase in the mitotic rate (thereby keeping the term Kh constant as predicted by
our model). This would be confirmed if mitotic rates were indeed different between smokers and
nonsmokers.
Laslty, the current lung research has been conducted in the upper bronchial region.
However, the models predict that mutation rates in the lower epithelia are 10 times lower, the
same as calculated in the colon and in peripheral T-cells. This difference may be due to
differential turnover rates or differential mutation rates. Alternately, the number of necessary
initiation mutations is different for lung peripheral versus bronchial cells, such that the difference
in calculated mutation rates may not be factual. For this purpose, the lung work should be
extended to the lower peripheral portions.
7.2 Application of Model to Other Cancers
It would be of particular interest to determine whether or not the model predicts the
association of cigarette smoke with other forms of cancer than lung. Peculiarly, no other cancer
exhibits the 20-30 gender-dependent lag in the increase in occurence of cancer associated with
the 20-30 year lag in females picking up the smoking habit. Paradoxically, there are many
reports which show an elevated risk of other cancers among smokers (Doll and Hill, 1952;
Hammond and Horn, 1958; Kahn, 1966).
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Preliminary work in the analysis of pancreatic cancer, for which a 2-3 fold relative risk is
reported among smokers, revealed that cigarettes were not a primary risk factor. However, the
age of onset of pancreatic cancer has decreased in a similar way as. have adenocarcinomas of the
lung. Further analysis of this data should be done to determine whether or not smoking is a
secondary risk factor for pancreatic cancer instead.
Of course, eventually every single form of cancer for which data exists should undergo
similar analysis as has been done for colon and lung cancer.
7.3 Theoretical extension of carcinogenesis model - Effect of heterogeneity on estimated
parameters
As explained in Section 5.4.2, heterogeneity in the population for secondary risk
parameters creates curvature which had previously been wholly attributed to the potential
existence of a primary fraction at risk. Excluding the existence of heterogeneity for secondary
risk parameters would have the net effect of underestimating either the fraction at risk or the
parameter correcting for the risk for connected forms of death. It would be recommended to
ascertain the exact effect of this heterogeneity on the calculated population parameters.
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